Compliance and regulatory

Standardized Infection Ratio (SIR)

The Standardized Infection Ratio (SIR) is an NHSN risk-adjusted summary measure calculated as the number of healthcare-associated infections observed at a facility or unit divided by the number statistically predicted for that same population, using a risk-adjustment model fit against a national NHSN baseline. SIR = 1.0 means observed infections matched the risk-adjusted prediction; SIR > 1.0 means more infections were observed than predicted; SIR < 1.0 means fewer were observed than predicted. NHSN reports a 95% confidence interval alongside the point estimate because small device-day or procedure denominators make the SIR statistically unstable at the unit level.

Beyond-Use Date (BUD)

A beyond-use date (BUD) is the date, or date and hour, established by a compounding pharmacist after which a compounded preparation must not be used, stored, or transported. It is set at the time of compounding and is distinct from a manufacturer's expiration date, which applies only to the original, unopened, commercially manufactured product. Under USP General Chapter 797 (sterile preparations, current since November 1, 2023), the BUD is determined primarily by the CSP Category the preparation was compounded under (Category 1, 2, or 3, reflecting the degree of verified environmental control), together with the storage condition (controlled room temperature, refrigerated, or frozen), the dosage form, and any supporting sterility or stability testing or applicable stability data. Under USP General Chapter 795 (nonsterile preparations, also current since November 1, 2023), the BUD is determined primarily by whether the formulation is aqueous or nonaqueous, the dosage form and packaging, the storage condition, and whether supporting stability data exists — the chapter provides conservative default periods to use when no such data is available. In both chapters, the current chapter text and the USP Compounding Compendium contain the exact, category-specific and formulation-specific tables a compounder should use to assign a BUD to a given preparation; a value copied from a pre-2023 reference will not reflect the current framework.

EU AI Act

Regulation (EU) 2024/1689, the European Union's law regulating AI systems and general-purpose AI (GPAI) models placed on or used in the EU market. It classifies AI systems into four risk tiers (unacceptable, high, limited, minimal) with obligations scaling to risk, applies a separate GPAI-model regime, and phases in on a multi-year timeline set by Article 113 and later revised by the 2026 'Digital Omnibus' amendment.

AI Literacy (EU AI Act Article 4)

Under Article 4 of the EU AI Act, AI literacy is the obligation on providers and deployers of AI systems to take measures ensuring, to their best extent, a sufficient level of AI literacy among staff and other persons who operate or use AI systems on their behalf -- accounting for those individuals' technical knowledge, experience, education, and training, and the context and population the AI system is used on or for. The obligation entered into force on 2 February 2025 under Article 113(a), ahead of the Act's later staged compliance deadlines for high-risk and GPAI provisions.

Fundamental Rights Impact Assessment (FRIA)

A Fundamental Rights Impact Assessment (FRIA) is the pre-deployment assessment that Article 27 of the EU AI Act requires certain deployers of high-risk AI systems -- public bodies, private entities providing public services, and deployers of the Annex III(5)(b)/(c) credit-scoring and life/health-insurance risk-assessment use cases -- to complete before first use. It must describe the intended deployment process, the categories of people likely affected, the specific risks of harm to their fundamental rights, the human-oversight arrangements, and the mitigation measures in place, using a template the European AI Office is required to provide.

European AI Office

The European AI Office is the body established within the European Commission -- by Commission Decision of 24 January 2024, effective 21 February 2024 -- to oversee implementation and enforcement of the EU AI Act. It has exclusive enforcement authority over the general-purpose AI (GPAI) model obligations in Chapter V, develops codes of practice and evaluation methodologies for GPAI, coordinates enforcement with Member States' national market surveillance authorities, monitors AI market and technology developments, and publishes standard templates -- including the Fundamental Rights Impact Assessment template.

WHO International Clinical Trials Registry Platform (ICTRP)

The WHO International Clinical Trials Registry Platform (ICTRP), initiated in 2000 and operated by the World Health Organization, is a search portal and aggregation platform over a network of independently operated national and regional 'primary registries' -- it is not itself a registry that a trial registers with directly. Each primary registry (ClinicalTrials.gov, the EU's CTIS, ISRCTN, ANZCTR, CTRI, ChiCTR, DRKS, JPRN, and others) independently meets WHO's registry-quality criteria and sends regular data feeds to ICTRP, which pools records into a single global, searchable database. A trial is registered once, with one primary registry, and becomes automatically discoverable through ICTRP's search portal.

Sale-Leaseback (Equipment)

An equipment sale-leaseback is a two-part transaction, executed together, in which an institution that already owns a piece of equipment (1) sells it to a buyer-lessor at fair market value and (2) immediately leases the same equipment back for continued operational use. It qualifies as a distinct instance of this concept only when both legs occur as part of the same arrangement and the seller retains uninterrupted physical use of the asset; a disposal followed by acquiring different, replacement equipment is not a sale-leaseback, and a loan collateralized by owned equipment (with no transfer of title) is not a sale-leaseback either.

Ancillary Materials in Cell Therapy Manufacturing

A raw material used during the manufacture of a cell, gene, or tissue-engineered product that contacts the cells or construct during processing but is not intended to remain in the final product administered to the patient (e.g., growth factors, cytokines, enzymes, selection reagents, culture media additives) -- as distinct from a 'component,' which is a raw material deliberately carried through into the finished product. Qualification rigor is risk-tiered per USP General Chapter <1043>, based on the material's existing quality pedigree (cGMP manufacturing history, prior regulatory approval) versus weaker documentation such as research-use-only labeling.

Temperature Monitoring Alarm

A temperature monitoring alarm is the notification component of a temperature monitoring system: the function that detects a monitored storage condition moving outside its defined safe range and actively alerts a responsible person, rather than simply recording the excursion for later review. A monitoring setup only has a functioning alarm -- as distinct from a data logger that merely stores readings -- when three things are true together: (1) a defined threshold (high, low, or both, and often a duration threshold to filter brief door-opening events from real excursions) triggers the notification automatically, without a person having to check a screen or download a log; (2) the notification reaches a specific accountable person or on-call rotation through a channel independent of a single point of failure, typically an escalation sequence -- local audible/visual alarm, then app push or email, then SMS or automated phone call, then a secondary contact or central monitoring station if the first contact does not acknowledge within a defined window; and (3) the alarm's own function (power supply, connectivity, and trigger logic) is itself periodically tested and that testing is documented, since an alarm that has never been verified to actually fire is not meaningfully different from having no alarm.

21 CFR Part 11 Temperature Monitoring

A temperature-monitoring system (freezer, refrigerator, incubator, or cold-room monitor) is accurately called "21 CFR Part 11 compliant" only when its electronic records -- and any electronic signatures applied to them -- meet 21 CFR Part 11 Subpart B/C requirements as actually configured, validated, and used at a specific site: a secure audit trail, unique attributable user accounts, documented system validation (IQ/OQ/PQ), retrievable retention, access controls, and (if used) compliant electronic signatures. It is a property of site-level configuration and validation, not a certificate a vendor sells.

Scientific Data Management System (SDMS)

A scientific data management system (SDMS) is laboratory software that automatically captures, indexes, and archives electronic data files generated by lab instruments (chromatography, spectroscopy, balances, plate readers, raw instrument logs) in their original native format, and makes that archive centrally searchable, version-controlled, and audit-trail-protected. It is distinguished operationally from a shared drive or manual file store by automated unattended capture direct from the instrument, metadata extraction that makes files findable without opening each one, and a tamper-evident audit trail logging every access, export, or modification attempt. An SDMS is the raw-data archive layer beneath a LIMS (sample/workflow/results management) and an ELN (experimental narrative record), and typically integrates with one or both rather than replacing either.

Veterinary Cytology

Veterinary cytology is the diagnostic technique of collecting, preparing, staining, and microscopically examining individual cells (rather than intact tissue architecture, as in histopathology) obtained from an animal by fine-needle aspiration, impression smear, scraping, swab, or body-fluid sampling, in order to characterize a lesion, mass, effusion, or organ as inflammatory, infectious, hyperplastic, or neoplastic — and, for neoplastic samples, to assess features consistent with malignancy. A sample or workflow counts as veterinary cytology, in the operational sense used here, when it involves: (1) a minimally invasive collection method that disaggregates or exfoliates cells rather than removing an intact tissue block; (2) a rapid stain (commonly a Romanowsky-type stain such as Diff-Quik, Wright-Giemsa, or new methylene blue for fluids) applied to an air-dried or fixed smear; and (3) microscopic interpretation — performed in-house by a trained veterinarian or veterinary technician, or referred to a board-certified veterinary clinical pathologist (Diplomate, American College of Veterinary Pathologists, ACVP-Clinical Pathology) — that produces a cytologic diagnosis or descriptive report distinct from a surgical histopathology report.Procurement and lab-management decisions in this category generally split into two connected questions: what in-house capability (microscope, stains, slide-prep supplies, staff training) a practice or diagnostic lab maintains for first-pass or triage interpretation, and which reference laboratory or telecytology service it uses for definitive, board-certified review — most practices use both, routing straightforward or urgent cases in-house and referring diagnostically challenging, potentially malignant, or medicolegally significant samples out.

ELAP Certification (Environmental Laboratory Accreditation Program)

A laboratory holds ELAP certification when California's State Water Resources Control Board (Division of Drinking Water) has accredited it for specific matrix/analyte/method combinations, called "fields of accreditation," allowing it to perform environmental testing whose results can be used to satisfy California regulatory compliance reporting. Certification is field-specific rather than a single blanket credential, and it requires ongoing proficiency testing participation plus a documented quality management system consistent with the TNI Standard.

What Is A2LA? American Association for Laboratory Accreditation Explained

A2LA (American Association for Laboratory Accreditation) is a US-based, nonprofit, third-party accreditation body, founded in 1978, that formally recognizes a testing/calibration laboratory, medical laboratory, inspection body, biobank, or certification body meets the requirements of a specific ISO/IEC conformity-assessment standard (e.g. ISO/IEC 17025 for testing and calibration labs, ISO 15189 for medical labs, ISO 20387 for biobanks). A2LA does not itself test or certify products; it audits and accredits the bodies that do, and is a signatory to the ILAC and IAF international mutual-recognition arrangements.

Tier II Reporting Software

Tier II reporting software is compliance software purpose-built to compile a facility's hazardous chemical inventory into the data fields, threshold calculations, and submission format required under EPCRA Section 312 (40 CFR Part 370), and to generate or submit the annual Emergency and Hazardous Chemical Inventory ("Tier II") report to the State Emergency Response Commission (SERC), Local Emergency Planning Committee (LEPC), and local fire department. To qualify, a tool must apply EPCRA's threshold-planning-quantity logic (not just list inventory) and output in a format the recipient agency accepts, such as EPA's Tier2 Submit schema or a state's electronic portal.

Colilert

Colilert is a defined-substrate technology (DST) reagent, manufactured by IDEXX Laboratories, used to simultaneously detect and enumerate total coliform bacteria and Escherichia coli (E. coli) in a single water sample. A test is correctly described as 'Colilert' only when it uses IDEXX's proprietary ONPG/MUG nutrient-indicator reagent, incubated per the manufacturer's protocol (24 hours for Colilert, 18 hours for the Colilert-18 variant) and read for color change (yellow indicates total coliform presence) and fluorescence under 365 nm UV light (indicates E. coli presence). Quantification requires pairing the reagent with IDEXX's Quanti-Tray or Quanti-Tray/2000 sealing system to produce a Most Probable Number (MPN) result per 100 mL. The method is standardized as Standard Methods 9223B (Enzyme Substrate Coliform Test) and is included on the U.S. EPA's list of approved analytical methods for Safe Drinking Water Act compliance monitoring under 40 CFR Part 141.

TRAC Lease (Terminal Rental Adjustment Clause)

A TRAC lease is a motor-vehicle lease governed by IRC Section 7701(h)'s terminal rental adjustment clause exception: the lessee guarantees the vehicle's end-of-term residual value and pays (or is credited) the difference between that guaranteed figure and the vehicle's actual value when the lease ends, while the lease still qualifies as a true lease for tax purposes rather than being recharacterized as a financed purchase. It applies specifically to motor vehicles and trailers, not general lab or clinical equipment, and sits alongside fair market value (FMV) leases and dollar buyout leases as one of the standard vehicle-lease structures procurement and fleet teams compare.

Scale vs Balance

A scale is a general-purpose weighing instrument (commonly strain-gauge based) optimized for capacity and ruggedness with coarser readability, while a balance is a precision weighing instrument (traditionally comparative, now typically electromagnetic force restoration) optimized for fine resolution -- down to 0.1 mg or better -- under controlled, draft-free conditions; procurement should be driven by the required readability/minimum sample weight, applicable regulatory framework (NTEP/Handbook 44 for legal-for-trade, OIML R76 accuracy class, USP <41> for pharmacopeial work), and calibration traceability, not by marketing language alone.

What Is ANAB? ANSI National Accreditation Board Explained

ANAB (the ANSI National Accreditation Board) is a US laboratory and certification-body accreditation organization, operated as a subsidiary of ANSI, that formally recognizes a testing/calibration laboratory, medical laboratory, inspection body, biobank, or certification body meets the requirements of a specific ISO/IEC conformity-assessment standard (e.g. ISO/IEC 17025 for testing and calibration labs, ISO 15189 for medical labs, ISO 20387 for biobanks). ANAB does not itself test or certify products; it audits and accredits the bodies that do, and is a signatory to the ILAC and IAF international mutual-recognition arrangements.

Xeno-Free Media

Xeno-free (XF) media is cell-culture medium formulated to contain no components derived from a species other than the one being cultured, used to eliminate the risk of xenogeneic contamination (viral, prion, and immunogenic non-human antigens) that comes with animal-derived supplements like fetal bovine serum. A product qualifies as xeno-free specifically when every raw material's species of origin has been checked against the cell type being grown -- human-derived components (e.g., human platelet lysate, human serum albumin) are permitted in xeno-free media intended for human cell culture, which is what distinguishes it from the stricter 'animal-component-free' (ACF) or 'animal-origin-free' (AOF) designation, where no animal-derived material of any species, including human, is used at all.

SEFA 8 (Laboratory Fume Hoods Recommended Practice)

SEFA 8 is the Laboratory Fume Hoods Recommended Practice published by the Scientific Equipment and Furniture Association (SEFA), setting construction requirements and tracer-gas containment/face-velocity test protocols (As-Manufactured, As-Installed, As-Used) that laboratory fume hood procurement specifications cite to verify vendor performance claims.

Single-Use Assemblies (SUAs)

A single-use assembly (SUA) is a pre-fabricated, pre-sterilized fluid-path component -- typically some combination of flexible tubing, bags, connectors, filters, and sensors -- manufactured, irradiated, and supplied ready to install into a bioprocess for exactly one production run before being discarded rather than cleaned and reused. What separates an SUA from ordinary disposable plasticware is that it is qualified as a controlled process component: it comes with sterilization-validation and, for GMP or GMP-adjacent use, extractables-and-leachables documentation, rather than being purchased as a generic consumable on a certificate of conformance alone.

Chemically Defined Media (CDM)

Chemically defined media (CDM) is a cell-culture growth medium in which every component -- salts, amino acids, vitamins, lipids, and any protein supplements -- is a known, individually specified chemical entity added at a documented concentration, with no undefined biological components such as serum, hydrolysates, or tissue extracts. A formulation qualifies as CDM only when its full composition is disclosed and quantified, protein supplements (if present) are purified/recombinant and identified by expression source, and no ingredient is an undefined animal- or plant-derived mixture -- a medium that is merely 'serum-free' does not automatically meet this bar if it still contains an undefined hydrolysate or extract.

Chemical Safety Software

Chemical safety software is a category of purchased or subscribed platforms that help a lab, facility, or manufacturer manage the compliance obligations that come with owning, using, or producing hazardous chemicals. In procurement terms, a product qualifies as chemical safety software if it automates at least one of these core workflows: safety data sheet (SDS) management (collecting, indexing, and making supplier SDSs searchable at the point of use), GHS-compliant labeling (generating secondary-container and workplace labels with the correct pictograms, signal words, and hazard statements under 29 CFR 1910.1200 or the EU CLP Regulation), chemical inventory tracking (quantities, locations, and container-level data tied to a chemical's CAS number), exposure and risk assessment (flagging incompatible storage, threshold quantities, or reactive combinations), and regulatory reporting (EPA EPCRA Tier II / Form R, state fire-code chemical inventories, or waste manifests). A single-purpose spreadsheet or a manual paper SDS binder does not meet this definition even though it stores some of the same information — the defining feature of the category is automated compliance workflow, not just data storage.Buyers evaluating this category should distinguish it from two narrower, adjacent purchases it often gets bundled or confused with: a <a href='/guides/choosing-a-chemical-inventory-management-system/'>chemical inventory management system</a>, which focuses specifically on tracking what chemicals exist, in what quantity, and where; and <a href='/guides/sds-authoring-software-buyers-guide/'>SDS authoring software</a>, which generates new, regulator-compliant SDSs for chemicals an organization manufactures or reformulates under its own label, rather than managing SDSs received from suppliers. Many commercial chemical safety platforms bundle inventory tracking, SDS management, and labeling into one subscription; others are sold as separate modules. Neither is inherently the correct scope — the right purchase depends on which specific compliance obligations (OSHA HazCom, EPCRA reporting, fire-code inventory limits, internal EHS audit requirements) a facility actually has to meet.

Glove Compatibility Chart

A glove compatibility chart is a reference table, published by a glove manufacturer, distributor, or standards body, rating a specific glove product's resistance to specific named chemicals, typically as a breakthrough-time-based class (ANSI/ISEA 105's 0-6 scale, or an EN ISO 374 Type A/B/C letter code) derived from ASTM F739 or EN 16523-1 permeation testing. A table only qualifies as compatibility-grade data if it ties a named test method to a specific product, a specific chemical (not a category), and a time-based rating rather than a plain yes/no label; procurement and EHS teams use it, alongside Section 8 of the relevant Safety Data Sheet, as the documented basis for specifying which glove is fit for a given task.

NELAC (National Environmental Laboratory Accreditation Conference)

NELAC (National Environmental Laboratory Accreditation Conference) was the multi-state, EPA-supported effort that created the original national standard for accrediting environmental testing laboratories, replacing separate state-by-state certification schemes. The standard is now governed by The NELAC Institute (TNI) and implemented through the National Environmental Laboratory Accreditation Program (NELAP), under which recognized state and other Accreditation Bodies grant scoped accreditation -- specific to matrix, analyte, and test method -- to individual labs. In field usage, 'NELAC accreditation' commonly means current NELAP accreditation to the TNI Standard.

Fetal Bovine Serum (FBS)

Fetal bovine serum (FBS), also called fetal calf serum (FCS), is the liquid fraction of blood collected from bovine fetuses at slaughter, clarified and filtered for use as a growth-supporting supplement added to basal cell-culture media (typically 5-10% of final volume). It qualifies as FBS specifically when the source animal is a bovine fetus, distinguishing it from newborn calf serum (collected postnatally) and adult bovine serum (collected from mature cattle) -- both related but compositionally and functionally distinct products.

Eyewash Station

An eyewash station is emergency safety equipment that delivers a controlled, hands-free stream of flushing fluid to a person's eyes (or eyes and face) to remove a hazardous substance following an accidental exposure. In U.S. laboratory and facility procurement, "eyewash station" means specifically equipment designed and installed to meet ANSI/ISEA Z358.1, the voluntary consensus standard OSHA cites as the benchmark for the general duty created by 29 CFR 1910.151(c) to provide "suitable facilities for quick drenching or flushing of the eyes and body." A device only counts as an eyewash station in this operational sense if it can deliver flushing fluid to both eyes simultaneously, hands-free, for a continuous 15-minute minimum, at a minimum flow rate of 0.4 gallons per minute (eyewash-only) or 3.0 gpm (eye/face wash) in the tepid 60-100°F (16-38°C) range Z358.1 specifies — a first-aid-kit eye-flush bottle or a sink does not meet this definition even though it can rinse an eye.

Nitrile Glove Sizing: Chart, Fit, and Facility Size-Mix

Nitrile glove sizing is the mapping between a glove's dimensional designation (XS through XXL) and hand-circumference measurements, used both to fit an individual wearer and, for institutional buyers, to translate a facility's hand-size distribution into a purchase-order size split. Because ASTM D6319 and its counterpart exam-glove standards set performance requirements rather than a mandatory dimensional band per size label, the same size letter can differ measurably between manufacturers.

Nitrile Glove Thickness (Mil)

Nitrile glove thickness in mils measures the gauge of the glove material -- one mil equals 0.001 inch (0.0254 mm) -- and is reported per point on the glove (fingertip, palm, cuff) because dipped-glove manufacturing, the standard nitrile exam-glove process under ASTM D6319, produces uneven thickness across a single glove. Within a given material, higher mil thickness generally increases puncture resistance and permeation breakthrough time, and decreases tactile sensitivity and increases hand fatigue. It is a secondary variable within a material choice, not a stand-alone chemical-protection rating: material compatibility with the specific chemical in use governs whether a glove protects against it at all.

Procurement Card (P-Card)

A procurement card (P-card, used interchangeably with 'purchasing card') is a commercial charge or credit card an institution issues to a named individual for direct, point-of-sale purchases within defined transaction and monthly limits, reconciled centrally against the institution's own accounts after the fact rather than approved through a purchase order beforehand. To qualify: the card must be tied to the institution's own commercial card program (not personal credit used for later reimbursement); the purchase must occur directly at point of sale, not via a purchase order or punchout catalog; and institutional limits plus post-purchase reconciliation, not pre-purchase approval, are the control mechanism.

Central Stores

A centralized institutional department -- part of a university's or hospital's supply chain, procurement, or facilities organization -- that receives, inspects, warehouses, and internally distributes commonly used supplies, chemicals, and equipment to the labs and departments it serves, instead of each unit receiving and stocking its own shipments independently. Central stores sits downstream of purchasing: it governs how an already-ordered item physically arrives and gets stocked/distributed, not which vendor or price it was bought at.

Simplified Acquisition Threshold (SAT)

The simplified acquisition threshold (SAT) is the dollar ceiling, set in FAR 2.101 and cross-referenced by 2 CFR 200.1 for federal grant recipients, up to which a buyer may use streamlined, informal purchasing procedures instead of formal sealed bidding or a competitive request-for-proposals process. A purchase counts as falling under the SAT when its total anticipated value -- not a single invoice or line item, but the full requirement, since the FAR and 2 CFR 200 both prohibit splitting a purchase into smaller pieces to stay under a threshold -- is above the micro-purchase threshold but at or below the current SAT figure. Cross the SAT and the buyer must switch to formal procurement methods (sealed bidding under FAR Part 14, or competitive proposals under FAR Part 15 for direct federal contracts; sealed bids or competitive proposals under 2 CFR 200.320(b) for non-federal entities spending federal award funds), plus additional documentation obligations such as an independent cost estimate and, for construction, bonding.

GPO Administrative Fee

A GPO administrative fee is the percentage-based payment a vendor makes to a group purchasing organization (GPO), tied to the volume of purchases its member institutions make under that vendor's GPO contract, which the GPO retains to fund its own contracting and member-services operations rather than billing members a direct fee. The payment runs vendor-to-GPO, not buyer-to-GPO, and is what distinguishes this arrangement, for Anti-Kickback Statute purposes, from a direct vendor discount to a buyer.

What Is a DICOM Conformance Statement?

A DICOM conformance statement is a vendor-published document, structured per DICOM PS3.2 (Conformance), that specifies exactly which SOP (Service-Object Pair) classes a medical-imaging device or software supports and in which network role (SCU or SCP), which transfer syntaxes it can send or receive, which network and media-storage services it offers, and any vendor-specific extensions or restrictions. A document counts as a real conformance statement only if it specifies this level of protocol detail; a marketing claim of 'DICOM compliant' with no published SOP-class/transfer-syntax detail does not meet the bar, because it gives a buyer no way to verify whether two specific devices will actually interoperate.

CGA Pamphlet P-1

CGA Pamphlet P-1 (Safe Handling of Compressed Gases in Containers) is the Compressed Gas Association's industry consensus standard covering the in-plant handling, storage, and use of compressed gas cylinders, portable tanks, and similar containers. It is incorporated by reference into US federal law at 29 CFR 1910.101(b), OSHA's general industry rule for compressed gases, which states that 'the in-plant handling, storage, and utilization of all compressed gases in cylinders, portable tanks, rail tankcars, or motor vehicle cargo tanks shall be in accordance with Compressed Gas Association Pamphlet P-1-1965.' A lab, hospital, or industrial site is operating 'under CGA P-1' whenever its cylinder-securing, storage-segregation, and handling practices trace back to this pamphlet's requirements, whether an EHS policy cites the pamphlet by name or simply cites the OSHA regulation that incorporates it. Because OSHA's text still names the 1965 edition specifically, facilities should treat that citation as the enforceable floor and CGA's more recent revisions (the association updates its pamphlets periodically, as it does across its full P-, C-, V-, and S-series) as current good-practice guidance layered on top.

CGA Fittings

A CGA fitting is the standardized valve outlet/regulator inlet connection, identified by a CGA (Compressed Gas Association) three-digit number under CGA V-1 / ANSI B57.1, that is matched to a specific gas or group of compatible gases so that a regulator built for one gas cannot readily be connected to an incompatible one. It answers 'will this regulator connect to this cylinder,' a separate question from the gas identity or the cylinder size.

USP Class VI Certification

USP Class VI certification is a designation that a specific plastic material or component has passed the most stringent tier of biological reactivity testing under United States Pharmacopeia (USP) General Chapter <88>, "Biological Reactivity Tests, In Vivo." Chapter <88> defines six plastic classes (I through VI) based on which combination of three in-vivo bioassays -- systemic (acute) toxicity injection, intracutaneous reactivity, and implantation -- a material passes, and at what extraction rigor. A material reaches Class VI, the highest of the six classes, only when it passes all three bioassays using extracts prepared at the most demanding temperature/duration condition the material can withstand without degrading. Certification is specific to a tested formulation and manufacturing process, not a general property of a polymer family: it is not automatically inherited by variants, colorants, regrind blends, or downstream-sterilized versions of the same base resin, and passing Class VI does not by itself satisfy the broader ISO 10993 biocompatibility program most finished medical devices require.

Type I Borosilicate Glass

Type I borosilicate glass is a pharmaceutical primary-packaging glass classified under USP General Chapter <660>, Containers—Glass, as meeting the highest hydrolytic-resistance category through borosilicate composition and a passing result on the chapter's powdered glass test. A glass lot or container qualifies for the 'USP Type I' designation only once tested and documented under this method — borosilicate composition is necessary but not sufficient on its own; the designation follows from a specific tested result, not from raw material alone. It is distinct from the general-purpose term 'borosilicate glass' used for laboratory apparatus under ASTM E438, a different standard that covers non-pharmaceutical labware such as beakers and flasks.

cGMP Facility

A cGMP facility is a drug, biologic, device, or API manufacturing site that meets FDA's current Good Manufacturing Practice regulations (21 CFR Parts 210/211 for drugs; Part 600-series provisions for biologics; Part 820/QMSR for devices; ICH Q7 for APIs) through qualified facilities and equipment (IQ/OQ/PQ), an independent quality unit, documented and followed procedures, trained personnel, and demonstrated process validation. cGMP status is verified through FDA registration, listing, and inspection — FDA does not issue a one-time 'cGMP certificate.'

ANSI/AIHA Z9.5 (Laboratory Ventilation)

ANSI/AIHA Z9.5 ("Laboratory Ventilation") is the American National Standards Institute-approved consensus standard, developed and maintained by AIHA (the American Industrial Hygiene Association), that specifies engineering and performance criteria for laboratory ventilation systems, including general room air-change rates, fume hood design and containment performance, and the recurring testing needed to verify a hood or ventilation system still performs as designed. It is periodically revised by an AIHA-accredited standards committee, with the most recent edition dated 2022; the core testing benchmarks below have held stable across recent revisions. A laboratory or ventilation system is operating "to Z9.5" when it meets both the initial design/commissioning criteria in the standard and the ongoing routine-testing schedule it sets out.

GMP Facility

A GMP facility is a manufacturing, packaging, testing, storage, or distribution site that is designed, qualified, and operated to meet Good Manufacturing Practice requirements applicable to its product type (21 CFR Part 211 for finished drugs, ICH Q7 for APIs, 21 CFR Part 820/QMSR for devices, or equivalent EU/international GMP regulation) -- demonstrated through a documented quality system (qualified premises via IQ/OQ/PQ, environmental controls, batch records, CAPA, calibrated equipment, trained personnel) that a regulatory authority can inspect and hold the site to, rather than a self-declared or purely physical description of the space.

Compressed Gas Cylinder Sizes

A compressed gas cylinder size designation is the alphanumeric code (for example lecture bottle, size 150, size 200, size 300, or letter codes such as D, K, Q, and T) that gas suppliers use to describe a cylinder's physical dimensions (diameter and height), water capacity, and the resulting volume of gas it delivers at a given fill pressure. Labs use the designation, not the raw dimensions, to specify what to order because it determines storage footprint, how it fits in a gas cabinet or cylinder rack, how often it needs to be swapped or refilled at a given consumption rate, and which regulator and CGA fitting it takes.

CLIA-Waived Test

A CLIA-waived test is a laboratory test the FDA has determined is simple and accurate enough to perform under a CLIA Certificate of Waiver -- 42 CFR 493.15's criteria are that the methodology is "so simple and accurate as to render the likelihood of erroneous results negligible" and poses no reasonable risk of harm if performed incorrectly. Waived status attaches to a specific FDA-cleared test system, not to a facility or a general category of testing; a facility can hold waived and non-waived tests side by side depending on which certificate(s) it holds.

Purchasing Cooperative

A purchasing cooperative is a membership-based arrangement in which two or more independent organizations — typically public entities such as states, municipalities, school districts, public universities, or hospital systems — pool their buying volume and jointly use a single, competitively solicited contract, so that any member can purchase against it directly instead of running its own bid or RFP for the same goods or services. Membership is usually formal (a signed participation or membership agreement) and the lead contract is awarded through one member's or one cooperative's own competitive solicitation process, which is what lets other members 'piggyback' on it and still satisfy their own competitive-procurement requirements.

Specific Pathogen-Free (SPF) Mice

A colony or shipment of mice qualifies as specific pathogen-free (SPF) when it is bred and housed in a barrier facility and is documented, through a formal, periodic health-monitoring program, to be free of a defined list of excluded microorganisms and parasites (the 'exclusion list' or 'agent panel'). SPF is a relative, list-bound status, not a claim of total sterility: two colonies can both be validly called SPF while being screened against different panels, so the operative question for procurement and research use is always 'SPF with respect to which agent list, tested how recently, and by whom' rather than a single universal standard.

Biosafety Cabinet (BSC)

A biosafety cabinet (BSC) is a ventilated enclosure that uses HEPA filtration (removing at least 99.97% of particles 0.3 microns in diameter) combined with directional, certified airflow to contain biological aerosols generated during laboratory procedures. A device only counts as a biosafety cabinet, in the operational sense used across biosafety programs, if it (1) HEPA-filters air before it reaches the work surface, the exhaust, or both; (2) maintains inward airflow at its front opening (Class I and most Class II) or is fully gas-tight and glove-operated (Class III), so aerosols generated inside cannot reach the operator uncontrolled; and (3) has been performance-tested and field-certified — typically against NSF/ANSI 49 in the U.S. — rather than simply having a fan and a filter installed. Class I protects the worker and environment only; Class II protects the worker, product, and environment together and is the most common type in research and clinical microbiology labs; Class III is a gas-tight glovebox providing the highest level of containment, used for BSL-4 work. A biosafety cabinet is not a chemical fume hood (no certified chemical vapor containment unless specifically a Class II Type B cabinet) and is not a laminar flow "clean bench" (which protects only the sample and provides no worker protection at all).

Universal waste disposal requirements

A waste item is subject to universal waste disposal requirements — rather than full hazardous-waste rules — only if it falls into one of the categories EPA designates under 40 CFR Part 273 (batteries, pesticides, mercury-containing equipment, lamps, and, since 2019, aerosol cans, plus any categories a state adds) and the generator meets that rule's labeling, containment, and one-year accumulation-time-limit conditions. Items outside those designated categories remain fully regulated hazardous waste regardless of volume or apparent low risk.

Fume Hood

A fume hood (also called a chemical fume hood) is a ventilated enclosure that captures, contains, and exhausts airborne hazardous vapors, gases, dust, and fumes generated by chemical work, drawing room air in through an open front (the sash) and expelling it — usually after passing through ductwork, and sometimes through filtration — outside the building or to a treatment system. It protects the worker, not the material inside it: contaminated room air is pulled away from the user's breathing zone rather than the hood creating a sterile or particle-free zone around the work. A device only counts as a fume hood, in the operational sense used across lab-safety programs, if it (1) has continuous mechanical exhaust ventilation drawing air inward through a face opening, (2) is tested and certified to maintain a minimum face velocity (commonly cited around 80–120 feet per minute under ANSI/AIHA Z9.5, the U.S. consensus standard for laboratory ventilation) rather than simply having a fan running, and (3) is used specifically to control chemical exposure — not biological aerosols and not sample contamination, which are the jobs of a biosafety cabinet and a laminar flow hood respectively.

ANSI/AAMI ST79

ANSI/AAMI ST79 is the ANSI-approved consensus standard, developed by AAMI (Association for the Advancement of Medical Instrumentation), titled "Comprehensive guide to steam sterilization and sterility assurance in health care facilities." A sterile processing program is operating to ST79 when it documents, for every steam sterilizer and load type: (1) installation, operational, and performance qualification (IQ/OQ/PQ) testing at commissioning and after major repair or relocation; (2) routine physical monitoring (time, temperature, pressure) on every cycle; (3) a chemical indicator inside every package and a Bowie-Dick air-removal test on each dynamic-air-removal (pre-vacuum) sterilizer, run daily before the first processed load; (4) a biological indicator (BI) in at least one load per sterilizer per day and in every load containing an implantable device, with the implant load held until a negative BI result returns; and (5) written procedures for immediate-use steam sterilization (IUSS), wet-pack investigation, and load recall when a monitoring result fails. The current edition is ST79:2017, the consolidated base text plus amendments issued through 2020; AAMI has not published a full replacement edition since 2017, so "ANSI/AAMI ST79 2020" and "ANSI/AAMI ST79 latest version" both refer to this same amended 2017 text rather than a separate edition. ST79 is a voluntary consensus standard rather than a federal regulation in its own right, but it is the document nearly universally treated as the baseline standard of care for hospital-based steam sterilization in the United States, and many state health department licensing rules and hospital accreditation surveys reference it directly.

Second-Party Audit

A second-party audit is an audit an organization conducts, or commissions, against one of its own suppliers, contractors, or external providers — using the customer's own criteria (a contract, quality agreement, or specification) — to decide whether to qualify, continue, or remove that supplier, as distinct from a first-party (internal self-audit) or a third-party (independent certification/regulatory) audit.

HS Code for Chemicals

An HS code for chemicals is the numeric classification assigned to a chemical substance or product under the World Customs Organization's (WCO) Harmonized System (HS) nomenclature, used by customs authorities to determine import duty rates, admissibility requirements, and statistical reporting for a shipment. It is not the same as the chemical's CAS Registry Number, its UN transport hazard number, or its Export Control Classification Number (ECCN) -- those identify what the substance is or how it must be shipped/exported, while the HS code determines how it is classified and taxed at the customs border. In the United States, HS codes are implemented as 10-digit Harmonized Tariff Schedule (HTSUS) codes for imports, maintained by the U.S. International Trade Commission (USITC) and enforced by U.S. Customs and Border Protection (CBP); exports use the related but separate Schedule B code maintained by the U.S. Census Bureau.

DEA Form 161

DEA Form 161, officially the 'Application for Permit to Export Controlled Substances,' is the permit application a DEA registrant with export authority must file with the DEA Diversion Control Division before shipping a Schedule I-V controlled substance out of the United States. It is transaction-specific -- filed for a defined substance and schedule, quantity, destination country, and consignee -- and it is not itself a registration: holding a DEA registration whose authorized business activity includes exporting is a precondition for filing Form 161, not a consequence of filing it. A DEA 'Researcher' registration, which authorizes possession and use of controlled substances for research, does not by itself authorize export.

DEA Form 357

DEA Form 357 ("Application for Permit to Import Controlled Substances") is the application a DEA registrant -- typically a research or analytical lab that is not registered as a DEA Importer -- files with DEA's Diversion Control Division to obtain a shipment-specific permit to bring a controlled substance into the United States for a scientific, research, or analytical purpose, under 21 CFR Part 1312.

Class 9 Dangerous Goods

Class 9 (Miscellaneous Dangerous Goods) is the transport hazard classification, under the UN Model Regulations, the IATA Dangerous Goods Regulations (DGR), the US DOT Hazardous Materials Regulations (49 CFR Parts 171-180), and the IMDG Code for ocean freight, that captures any substance or article presenting a hazard during transport that isn't already covered by Classes 1 through 8. It functions as a catch-all class. In a research lab, the two shipments that trigger Class 9 most often are dry ice (UN1845, solid carbon dioxide, used as a coolant for biological and temperature-sensitive materials) and lithium batteries (UN3480/UN3481 lithium-ion, UN3090/UN3091 lithium metal) packed in or with instruments, sensors, and data loggers.

IMDG Code Classes (Ocean Freight Dangerous Goods)

The IMDG Code (International Maritime Dangerous Goods Code) is the International Maritime Organization's (IMO) mandatory code for classifying, packing, marking, labeling, and documenting dangerous goods carried by sea in packaged form, given legal force under SOLAS Chapter VII. A material is governed by the IMDG Code's class system whenever it is offered for carriage on a vessel and meets one of the same nine UN hazard-class definitions used across every transport mode — the classes themselves come from the UN Recommendations on the Transport of Dangerous Goods (the 'Orange Book'), so a chemical's or biological substance's UN number, proper shipping name, hazard class, and packing group (I, II, or III) do not change between air, road, and sea. What changes for ocean freight is the layer of sea-specific requirements the IMDG Code adds on top of that shared classification: Emergency Schedules (EmS) codes for firefighting and spillage response, a separate 'Marine Pollutant' designation and marking driven by aquatic-toxicity criteria (which can apply on top of a substance's primary class), 18 segregation groups controlling which dangerous goods cannot be stowed near each other, and lettered stowage categories describing where on or below deck a package may be carried relative to accommodation and machinery spaces. The Code is amended on a two-year cycle by IMO's Maritime Safety Committee, drawing on the same biennial UN Model Regulations updates that also feed the IATA Dangerous Goods Regulations and (in the US) 49 CFR.

Packing Group I, II & III (Hazmat)

A packing group is the DOT/UN three-tier severity classification (I = great danger, II = medium danger, III = minor danger) assigned to a hazardous material within its hazard class, using class-specific criteria under 49 CFR 173.121-173.137, that determines the required UN-specification packaging performance level, maximum shipping quantities, and eligibility for limited/excepted quantity provisions.

Cold Chain

A cold chain is an unbroken sequence of temperature-controlled storage, handling, and transport steps that keeps a temperature-sensitive product inside its defined safe range from the point of manufacture or collection to the point of use. A given movement of goods qualifies as a cold chain only when all of the following hold together: (1) the product itself has a defined temperature specification (e.g., 2-8C for most vaccines and many biologics, or a validated frozen/ultra-cold range) set by the manufacturer or a pharmacopeial standard; (2) every storage and transport step in the sequence -- warehouse, courier, transit hub, receiving site -- uses equipment qualified to hold that range; (3) temperature is continuously monitored and logged, not just checked at the start and end points; and (4) there is a documented procedure for what happens when a monitored excursion occurs (assessing whether the product is still usable, commonly via a Mean Kinetic Temperature calculation per USP <1079.2>, and disposing of or quarantining product that fails). A single unmonitored or unqualified segment -- even if brief -- breaks the chain and invalidates the temperature assurance for everything downstream of it, regardless of how well-controlled the rest of the movement was.

Mean Kinetic Temperature (MKT)

A calculation counts as mean kinetic temperature (MKT), in the USP <1079> sense, if it meets both of the following: (1) it is an Arrhenius-weighted average of a time series of temperature readings, using an assumed activation energy constant, so each reading's contribution scales exponentially rather than linearly with its temperature; and (2) it is expressed as a single equivalent isothermal temperature -- the constant storage temperature that would produce the same overall thermal degradation effect as the actual, fluctuating record over the same period. A plain arithmetic average of the same readings is not MKT, and because degradation reactions generally accelerate exponentially with temperature, MKT is always equal to or slightly above the simple arithmetic mean -- never below it.

Capital Equipment

A tangible, non-consumable asset with a useful life of more than one year and a per-unit acquisition cost that meets or exceeds an institution's capitalization threshold, recorded on the fixed-asset register and depreciated over its useful life rather than expensed in the year of purchase.

IQ/OQ/PQ (Installation, Operational, and Performance Qualification)

IQ/OQ/PQ is the three-stage documented qualification sequence used to prove equipment, instruments, utilities, or systems were installed correctly (Installation Qualification), operate correctly across their full specified range (Operational Qualification), and perform consistently under actual conditions of use (Performance Qualification). An activity counts as IQ/OQ/PQ only when it produces signed, documented evidence tied to pre-defined acceptance criteria for that specific stage and that specific unit as installed — vendor factory testing, calibration, and routine preventive maintenance are related but distinct activities that do not by themselves satisfy any of the three stages.

TCET (Transitional Coverage for Emerging Technologies)

TCET (Transitional Coverage for Emerging Technologies) is a CMS coverage pathway, finalized August 2024 (final procedural notice CMS-3421-FN, effective August 12, 2024), that expedites Medicare national coverage for a limited set of FDA-designated Breakthrough Devices by running the device through CMS's existing National Coverage Determination (NCD) and Coverage with Evidence Development (CED) machinery on an accelerated, pre-planned timeline rather than creating a new coverage authority. A device becomes TCET-eligible only if it holds FDA Breakthrough Device designation, has received FDA market authorization, falls within an existing Medicare benefit category, and is not already the subject of an NCD; CMS finalized an exclusion for digital-only technologies and capped the pathway at five new candidates accepted per year, reviewed on a quarterly cycle. A manufacturer engages CMS well before authorization: a non-binding Letter of Intent roughly 18-24 months out, formal self-nomination roughly 12 months out, a CMS-contractor-generated evidence preview identifying gaps in the existing clinical evidence, and a manufacturer-authored Evidence Development Plan (EDP) mapping how those gaps will be closed. If accepted, CMS pursues an NCD conditioned on CED, giving the device national Medicare coverage for several years -- potentially up to roughly five -- while the manufacturer collects the additional outcomes data the evidence preview identified as missing.

PMDA Clinical Trial Notification (CTN)

A Clinical Trial Notification (CTN, chiken todokede) is the regulatory filing a sponsor must submit to Japan's Ministry of Health, Labour and Welfare (MHLW) -- reviewed on MHLW's behalf by the Pharmaceuticals and Medical Devices Agency (PMDA) -- before initiating a clinical trial of an unapproved drug, or a new indication/dosage of an approved drug, in Japan. It is Japan's functional counterpart to a U.S. FDA Investigational New Drug (IND) application, but operates as a notification-and-review-window system rather than an affirmative approval: for an initial CTN, PMDA has a 30-day review period after receipt in which it can raise questions or object; if PMDA raises no objection within that window, the sponsor may proceed to start the trial. A submission counts as a CTN when it is filed under Japan's PMD Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices) and includes the trial protocol, investigational product information, and details of the investigators and institutions where the trial will be conducted.

REMS (Risk Evaluation and Mitigation Strategy)

A REMS is a required FDA drug safety program, authorized under Section 505-1 of the Food, Drug, and Cosmetic Act (added by the 2007 FDAAA), imposed on a drug or biologic when FDA determines its serious risks require controls beyond standard professional labeling. It can combine a Medication Guide, a prescriber/provider communication plan, and Elements to Assure Safe Use (ETASU) such as prescriber or pharmacy certification, restricted dispensing settings, mandatory patient monitoring, or registry enrollment -- with an implementation system required whenever ETASU is used.

Open Database License (ODbL)

The Open Database License (ODbL) is a copyleft license from Open Data Commons (a project of the Open Knowledge Foundation), version 1.0 published June 2009, that grants reuse rights to a database subject to attribution and share-alike conditions, drafted specifically around database rights and database structure/contents rather than adapted from a creative-works copyright license.

Digitally Anonymised Data

Digitally anonymised data is an electronic dataset that has been processed with computational techniques so that no living individual can reasonably be re-identified from it, either on its own or by combination with other information a realistic adversary could plausibly obtain, and no key, lookup table, or other additional information exists anywhere that could reverse the process. It differs from data that is merely stored in digital form and stripped of obvious direct identifiers: to count as digitally anonymised, a dataset has to pass the same substantive test any anonymisation method must meet under frameworks such as GDPR Recital 26 (identifiability assessed against 'all the means reasonably likely to be used', accounting for cost, time, and available technology) -- the 'digitally' in the term describes how the anonymisation was performed (masking, generalisation, aggregation, noise addition, k-anonymity/differential-privacy methods, or synthetic-data generation applied by software to an electronic source dataset), not a lower or different bar than anonymisation achieved by any other means. If a re-identification key is retained anywhere, even encrypted or access-controlled, the output is pseudonymised data, not digitally anonymised data, and remains personal data under GDPR (Recital 26; Article 4(5)).

Advarra IRB

Advarra is a commercial (independent) Institutional Review Board (IRB) provider based in Columbia, Maryland, formed in 2017 through the merger of Chesapeake IRB and Schulman IRB and expanded in 2019 through the acquisition of Quorum Review IRB. It is one of the largest commercial IRBs operating in the United States, reviewing human-subjects research on a fee-for-service basis for pharmaceutical, biotech, medical-device, and academic sponsors, and is frequently designated as the <a href='/dictionary/term/central-irb-single-irb-sirb'>central IRB / single IRB of record (sIRB)</a> for multi-site clinical trials. Advarra is registered with the Office for Human Research Protections (OHRP) under 45 CFR 46 and with FDA under 21 CFR Part 56, and holds full accreditation from <a href='/dictionary/term/aahrpp-association-for-the-accreditation-of-human-research-protection-programs'>AAHRPP</a>. Sites and sponsors submit and track studies through Advarra's electronic platform, the Center for IRB Intelligence (CIRBI).

Plain Language Summary (PLS)

A plain language summary (PLS) is a short, jargon-free account of a clinical trial's design and results, written so that a layperson — typically framed as a trial participant or member of the public — can understand what the study tested, what it found, and what that means, without needing scientific or medical training. In EU-regulated clinical trials it is a defined regulatory deliverable, not an optional courtesy: under <a href='https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536' target='_blank' rel='noopener'>Regulation (EU) No 536/2014</a> (the EU Clinical Trials Regulation, CTR), sponsors of trials authorised under the Regulation must submit a lay summary of the trial's results to the Clinical Trials Information System (CTIS) alongside the technical results summary, generally within 12 months of the trial's global end date. That deadline extends to up to 30 months for certain non-therapeutic Phase 1 trials, and shortens to 6 months for paediatric trials. Lay summaries must generally be provided in the official language(s) of the EU/EEA member state(s) where the trial was conducted, not only in English.An instance of a PLS is a written summary that (a) covers the trial's purpose, participant population, methods, and results including any relevant safety information, (b) is written for a non-specialist reading level (commonly targeted around a 12-14 year-old reading age in EMA/national guidance), and (c) is submitted as a distinct, identifiable document alongside — not merged into — the technical/scientific summary of results. A document that simply restates the scientific abstract in shorter form, or that omits the trial's actual findings in favour of only describing its design, does not meet the operational bar even if labelled a lay summary.

Patient Consent for Case Report Publication

The written authorization a patient (or parent/guardian/legally authorized representative) gives before a clinical case report describing their presentation, treatment, images, or outcome is submitted to a journal -- required whenever the report contains identifiable information, per ICMJE's patient-privacy recommendations and CARE Guidelines checklist item 13, independent of any separate IRB determination about the underlying case.

IACUC Adverse Event and Unanticipated Outcome Plan

An IACUC adverse event and unanticipated outcome plan is the written contingency component of an approved animal-use protocol specifying: (1) trigger criteria for what counts as an adverse event or unanticipated outcome for that study (pain, distress, injury, illness, or a clinical sign exceeding the approved humane endpoints); (2) who is authorized to act immediately, in practice the Attending Veterinarian or delegated veterinary staff, who can order treatment, analgesia, or euthanasia without prior investigator consent when welfare requires it; (3) a defined internal reporting pathway and timeframe from the observer to veterinary staff to the IACUC office; and (4) a documented outcome record distinguishing an isolated clinical event from a pattern indicating the protocol itself needs IACUC-reviewed modification. Institutions holding a PHS Animal Welfare Assurance must additionally report specific categories of event -- serious or continuing noncompliance, serious deviation from the Guide for the Care and Use of Laboratory Animals, or an IACUC-ordered suspension -- to OLAW under PHS Policy IV.F.3.

TCPS 2 Chapter 7 (Conflicts of Interest)

TCPS 2 (the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans), Chapter 7, "Conflicts of Interest," is the chapter of Canada's tri-agency human-research ethics policy that governs how researchers, research ethics boards (REBs) and institutions identify, disclose and manage conflicts of interest arising in human-participant research. A conflict of interest under Chapter 7 exists whenever a person's or institution's duties toward research participants and the research record could be compromised, or could reasonably appear to be compromised, by a competing personal, financial, professional or institutional interest. The chapter treats real, potential and perceived conflicts as equally disclosable -- a conflict does not need to have actually influenced a decision to trigger Chapter 7's disclosure and management requirements, only to create a reasonable appearance that it might. Chapter 7 applies at three distinct levels: individual conflicts (a researcher's own competing interests), institutional conflicts (the institution's own financial or other stake in a study's outcome), and REB-member conflicts (a board member with a personal or professional stake in a protocol under that board's review).

Data Protection Act 2018, Section 19 (Research Safeguards)

DPA 2018 Section 19 was the UK domestic provision requiring that research/archiving/statistics processing under UK GDPR Article 89(1) not be likely to cause substantial damage or distress, and not be used for decisions about a particular individual unless for approved medical research. It was omitted from 5 February 2026 by the Data (Use and Access) Act 2025; the same safeguards now sit in UK GDPR Articles 84B and 84C.

Participant Health Literacy

Participant health literacy is the degree to which a prospective or enrolled research participant can find, understand, and act on the information needed to make a voluntary decision about joining a study and to follow study procedures once enrolled. In practice, a research team is designing for participant health literacy whenever it (1) writes consent forms, recruitment materials, and result-summary/plain-language-summary documents at a reading level and format the target population can actually process (commonly benchmarked to roughly a 6th-8th grade level, though neither the Common Rule nor FDA regulations set a numeric threshold -- both simply require information 'understandable to the subject'), and (2) actively checks comprehension rather than assuming it, most often via the teach-back method: asking the participant to restate key study facts (purpose, main procedures, risks, voluntariness, right to withdraw) in their own words before consent is finalized. A document or process only counts as addressing health literacy if both elements -- accessible language AND a comprehension check -- are present; a well-simplified form that nobody ever asks the participant to explain back is a partial, not complete, application of the concept.

IRB Approval and Expiration of Recruitment Materials

IRB approval and expiration of recruitment materials refers to the fact that flyers, advertisements, social-media posts, phone/email scripts, screening questionnaires, and other materials used to identify and approach prospective participants are themselves reviewed and approved by the IRB as part of the informed-consent process -- not treated as separate marketing collateral -- and that approval carries its own expiration date, tied to the study's current approval period, independent of whether the underlying protocol itself continues. A recruitment or screening document is an approved recruitment material only for the interval the IRB has authorized; once that interval lapses, the material cannot be used to recruit or screen new participants even if the protocol has not been suspended or terminated and even if continuing review is only pending, not yet complete.

Research Security

Research security is the set of institutional and federal policies, disclosures, and safeguards designed to protect the U.S. federally funded research enterprise against foreign government interference, undisclosed foreign support, and the misappropriation of research and development. The controlling federal definition comes from <a href='/dictionary/term/nspm-33'>National Security Presidential Memorandum 33 (NSPM-33)</a> (issued January 2021) and its implementing guidance from the National Science and Technology Council (NSTC): research security means "safeguarding the research enterprise against the misappropriation of research and development to the detriment of national or economic security, related violations of research integrity, and foreign government interference."An activity, disclosure, or policy is an instance of research security -- as distinct from general information security, export control, or <a href='/dictionary/term/research-integrity'>research integrity</a> -- when it satisfies three conditions together: (1) it concerns federally funded or federally regulated research; (2) it addresses a risk tied to foreign government interference, undisclosed foreign talent recruitment, or misuse of research outputs for national/economic security ends; and (3) it maps to one of the concrete compliance mechanisms federal research agencies now require -- disclosure of foreign financial support and affiliations, foreign travel security, research security training, export control training, and cybersecurity controls for federally funded R&D. Under NSPM-33's implementation, research organizations that receive more than $50 million per year in federal research funding must certify they operate a research security program covering four elements: cybersecurity, foreign travel security, research security training, and export control training.

AAALAC Accreditation Requirements

The specific set of standards and recurring obligations an institution must satisfy to achieve and then keep AAALAC International accreditation: evaluating its animal care and use program against AAALAC's Three Primary Standards (principally the Guide for the Care and Use of Laboratory Animals), submitting a detailed Program Description and hosting an on-site peer review before initial accreditation, then filing an Annual Report every year and undergoing a full site visit roughly every three years to keep that status.

Program of Veterinary Care (PVC)

A Program of Veterinary Care (PVC) is the documented set of policies, procedures, and staffing arrangements through which an institution's Attending Veterinarian provides adequate veterinary care to animals used in research, teaching, and testing. It is a required component of an animal-care-and-use program under Animal Welfare Act regulations (9 CFR 2.33) and, in parallel, under PHS Policy for PHS-supported vertebrate-animal research. A program qualifies as an adequate PVC only if it addresses, at minimum: preventive medicine (quarantine, disease surveillance, herd/colony health monitoring, vaccination and parasite control where applicable); appropriate methods for preventing, controlling, diagnosing, and treating disease and injury; guidance and oversight of surgery (pre-, intra-, and post-operative care) and of anesthesia and analgesia use, including a mechanism for the Attending Veterinarian to require or adjust pain relief; a means of communication so personnel promptly report animal health concerns; and 24-hour availability of emergency veterinary care. Where the Attending Veterinarian serves in a part-time or consultant capacity rather than full-time employment, 9 CFR 2.33 requires the arrangement to be formalized through a written program of veterinary care and regularly scheduled site visits, not an informal or on-call-only relationship.

EU AI Act Annex III (High-Risk Use Cases)

A system falls under EU AI Act Annex III when it (1) is one of the eight listed use-case categories -- biometrics, critical infrastructure, education and vocational training, employment, essential services, law enforcement, migration, or administration of justice -- and (2) performs the specific function that category text describes (e.g., for education: admissions/access decisions, evaluating learning outcomes, assessing appropriate education level, or monitoring prohibited test behaviour). Matching both conditions triggers high-risk status under Article 6(2), subject to the narrow Article 6(3) exception, which itself never applies if the system profiles natural persons.

TCPS 2 Article 3.1 (Free and Informed Consent)

TCPS 2 (the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, 2022 edition) Article 3.1, in Chapter 3 ('The Consent Process'), sets out Canada's core requirement that participation in research involving human participants be based on free, informed, and ongoing consent. A consent process satisfies Article 3.1 when: (1) it is FREE -- given voluntarily, without manipulation, undue influence, or coercion; (2) it is INFORMED -- the prospective participant has enough understandable information about the research's purpose, procedures, reasonably foreseeable risks and potential benefits to make a genuine choice; and (3) it is ONGOING -- treated as a continuing process rather than a single signature, with researchers under a standing obligation to disclose material changes in risk or benefit as the study proceeds, and to reconfirm consent or offer withdrawal where warranted. Research Ethics Boards (REBs) are directed to apply particular scrutiny to trust or dependency relationships (for example, physician-patient or professor-student) where the relationship itself could create undue influence on a prospective participant's decision to take part.

GDPR Article 22 (Automated Decision-Making in Research)

GDPR Article 22(1) gives a data subject 'the right not to be subject to a decision based solely on automated processing, including profiling, which produces legal effects concerning him or her or similarly significantly affects him or her.' A research activity triggers Article 22 only if all three elements hold at once: (1) the decision is made solely by an automated system, with no meaningful human involvement in reaching the specific outcome -- a human merely rubber-stamping an algorithmic output does not count as meaningful involvement, but a human who genuinely reviews the case and can depart from the system's recommendation does; (2) the processing includes profiling or another automated evaluation of the person, not just automated data collection or storage; and (3) the decision produces a legal effect or similarly significant effect on that individual -- something that meaningfully affects their circumstances, behaviour, or choices, not a trivial or cosmetic outcome. In a research context this most commonly arises where an AI/ML system automatically screens, ranks, or excludes real individuals as part of a study -- for example, a clinical-trial-eligibility screening tool that auto-rejects applicants, or an automated participant-selection or risk-stratification algorithm that determines who is invited, enrolled, or offered an intervention -- as opposed to a model that only analyses aggregate or already-anonymised data with no decision made about a specific identifiable person.Article 22(2) narrows this to a qualified right rather than an absolute prohibition: solely automated decisions with legal/significant effect are permitted where (a) necessary for entering into or performing a contract, (b) authorised by Union or Member State law that also lays down suitable safeguards, or (c) based on the data subject's explicit consent. Where (a) or (c) applies, Article 22(3) requires the controller to implement suitable safeguards -- at minimum the right to obtain human intervention, to express a point of view, and to contest the decision. Article 22(4) adds a further restriction: these decisions must not be based on special category data (Article 9(1) -- including data concerning health, which covers most clinical and biomedical research) unless a specific Article 9(2)(a) or (g) exemption applies and suitable safeguards are in place. For research controllers, this means an automated eligibility or selection tool operating on health or genetic data faces a materially higher bar than one operating on non-sensitive data, even where a general Article 6 lawful basis for the underlying processing is otherwise sound.

EU AI Act Article 53 (General-Purpose AI Model Obligations)

Article 53 of the EU AI Act (Regulation (EU) 2024/1689) sets the baseline obligations that apply to every provider of a general-purpose AI (GPAI) model placed on the EU market -- a model trained on large amounts of data using self-supervision at scale, showing significant generality, and capable of competently performing a wide range of distinct tasks (Article 3(63)). A GPAI provider must, at minimum: (1) draw up and keep current technical documentation of the model per Annex XI, available on request to the AI Office and national authorities; (2) draw up and make available to downstream AI-system providers the information and documentation set out in Annex XII needed to understand the model's capabilities and limitations; (3) put in place a policy to comply with EU copyright law, including respecting rightsholders' text-and-data-mining opt-outs reserved under Article 4(3) of Directive (EU) 2019/790; and (4) draw up and publish a sufficiently detailed summary of the content used to train the model, following a template the AI Office provides. These obligations became applicable on 2 August 2025 (Article 113(b)). Models released under a genuinely free and open-source licence, with publicly available weights, architecture, and usage information, are exempt from obligations (1) and (2) above -- but never from the copyright-policy or training-data-summary duties, and never at all if the model is also classified as carrying 'systemic risk.'

EU AI Act Article 6 (High-Risk Classification Rules)

Article 6 of the EU AI Act (Regulation (EU) 2024/1689) is the classification test that determines whether an AI system counts as 'high-risk.' An AI system is high-risk if either: (1) under Article 6(1), it is a safety component of, or is itself, a product covered by EU harmonisation legislation listed in Annex I and that product requires third-party conformity assessment; or (2) under Article 6(2), it falls into one of the eight functional use-case categories listed in Annex III (biometrics; critical infrastructure; education/vocational training; employment/worker management; essential private and public services; law enforcement; migration/asylum/border control; administration of justice and democratic processes). Article 6(3) provides a narrow, documented exception for Annex III systems that perform only a narrow procedural task, improve a completed human activity's result, detect patterns without replacing human assessment, or perform preparatory tasks -- unless the system profiles natural persons, in which case it is always high-risk. Classification under Article 6 is the trigger, not the substance: it determines whether the Title III, Chapter 2 obligations (risk management, data governance, technical documentation, human oversight, and more) apply at all.

Tri-Agency Framework: Responsible Conduct of Research (RCR)

The Tri-Agency Framework: Responsible Conduct of Research is the joint policy of Canada's three federal research funding agencies -- the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Social Sciences and Humanities Research Council of Canada (SSHRC) -- that defines researcher, institution, and Agency responsibilities for research integrity, sets minimum requirements for institutional RCR policies, defines what constitutes a breach of Agency policies, and specifies the process the Agencies follow when addressing allegations of a breach. It applies to research funded in whole or in part by any of the three Agencies, and is administered jointly by the Secretariat on Responsible Conduct of Research (SRCR) and the Interagency Advisory Panel on Responsible Conduct of Research (PRCR). The current edition took effect in 2021, replacing the 2016 version.

EU AI Act Article 5 (Prohibited AI Practices)

Article 5 of Regulation (EU) 2024/1689 (the EU AI Act) lists AI practices that are banned outright across the EU, regardless of sector, risk classification, or intended purpose — including scientific research. A practice falls under Article 5 if it matches one of eight prohibited categories: (a) subliminal or purposefully manipulative/deceptive techniques that materially distort behaviour and cause significant harm; (b) exploitation of vulnerabilities tied to age, disability, or a specific social or economic situation; (c) social scoring by public or private actors leading to detrimental treatment in a context unrelated to the data that generated the score; (d) predictive policing based solely on profiling or personality-trait assessment, without objective, verifiable facts linked to a criminal activity; (e) untargeted scraping of facial images from the internet or CCTV footage to build or expand facial-recognition databases; (f) emotion inference in workplace or education settings, except for narrow medical or safety reasons; (g) biometric categorisation to infer race, political opinion, trade union membership, religion, sex life, or sexual orientation; and (h) real-time remote biometric identification in publicly accessible spaces for law enforcement, prohibited except for three narrowly defined purposes (searching for specific victims of trafficking or missing persons, preventing an imminent and specific terrorist threat, or locating a suspect in specific serious crimes carrying at least a 4-year custodial sentence), each requiring prior judicial or independent administrative authorisation. These provisions applied from 2 February 2025 — six months ahead of most of the rest of the Act — and unlike the Act's high-risk-system obligations, there is no proportionality test, self-assessment route, or conformity-assessment pathway around them: a matching practice is unlawful outright, and violations sit in the Act's highest penalty tier under Article 99 (administrative fines of up to €35 million or 7% of total worldwide annual turnover, whichever is higher).

Favourable Opinion (NHS REC)

The formal outcome an NHS Research Ethics Committee (REC) in the UK issues after reviewing a research proposal, confirming the study raises no outstanding ethical objections -- or only minor points that do not require re-review by the full committee -- so that, subject to any standard conditions, the research may proceed toward HRA Approval (or HCRW Approval in Wales) and site-level activation.

TCPS 2 Article 2.1 (REB Review Requirement)

Article 2.1 of Canada's Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) is the threshold rule that triggers Research Ethics Board (REB) review: research involving living human participants, or research involving human biological materials (including embryos, fetuses, fetal tissue, reproductive materials, and stem cells related to human reproduction), must undergo REB review and receive REB approval before the research commences, and that approval must be maintained for the duration of the research. It is the operational test institutions apply to decide whether a proposed project needs to go to an REB at all -- if a project meets the Article 2.1 description and no Article 2.2-2.4 exception applies, REB review is mandatory; if it does not meet the description (for example, because it is not 'research' as TCPS 2 defines the term, such as certain quality-assurance, quality-improvement, or program-evaluation activities), REB review under this article is not required.

IRB Noncompliance Determination

An IRB noncompliance determination is the formal process and written outcome by which an IRB, or an institution's Human Research Protection Program/compliance office acting on the IRB's behalf, investigates a report that an approved protocol or IRB requirement was not followed and classifies the finding as either administrative/minor noncompliance (handled at routine review) or serious or continuing noncompliance under 45 CFR 46.113 / 21 CFR 56.113, together with whatever corrective action or suspension/termination the finding requires. It is the upstream procedure that produces a serious-or-continuing finding; see the separate IRB Violations term for what that threshold means and OHRP's own compliance-oversight role once a finding is reported.

GDPR Article 5(1)(b) Purpose Limitation (Compatible Research Use)

Article 5(1)(b) of the EU General Data Protection Regulation (GDPR) states the purpose limitation principle: personal data must be "collected for specified, explicit and legitimate purposes and not further processed in a manner that is incompatible with those purposes." The same provision then carves out a specific exception: "further processing for archiving purposes in the public interest, scientific or historical research purposes or statistical purposes shall, in accordance with Article 89(1), not be considered to be incompatible with the initial purposes." In practice, this means a controller who wants to reuse personal data originally collected for another reason (clinical care, a prior study, an administrative register, a commercial service) for a new research purpose does not need to separately satisfy the compatibility test in Article 6(4) for that reuse, provided the processing genuinely falls within one of the four named purposes and Article 89(1) safeguards are in place. It is a compatibility fiction created by the Regulation itself, not a blanket exemption from the rest of the GDPR: the controller still needs a valid Article 6(1) lawful basis for the further processing, still needs an Article 9(2) condition if the data are special category, and still has to apply Article 89(1) safeguards - technical and organisational measures, and pseudonymisation or an equivalent minimisation measure wherever the research purpose can still be fulfilled that way.

GDPR Article 6(1)(e) Public Task Legal Basis

GDPR Article 6(1)(e) is one of six lawful bases in Article 6(1) that can justify processing personal data. It applies where processing is 'necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller.' A processing activity qualifies as an instance of this basis only if two conditions both hold: (1) the controller is carrying out a task that is genuinely public-interest or official-authority in nature -- not merely a task the controller happens to think is worthwhile -- and (2) per Article 6(3), that task is 'laid down by Union law or Member State law to which the controller is subject.' The second condition is the operative test: a public university or public research institute cannot simply assert 'research is in the public interest' and stop there. There must be an identifiable legal basis in national or EU law -- a statute, charter, or regulation establishing the institution's research/education function, or (as is increasingly common) an explicit research-processing provision in a member state's GDPR-implementing legislation -- that the controller can point to as the source of the task. Article 6(3) further requires that this legal basis meet an objective of public interest and be proportionate to the legitimate aim pursued, and it permits (but does not require) the law to specify further conditions such as who may process, purpose limitation, storage periods, and processing operations. Public task is distinct from Article 6(1)(f) legitimate interests, which is explicitly unavailable to public authorities 'in the performance of their tasks' (Article 6(1), final sentence) -- meaning a public university carrying out research cannot fall back on legitimate interests if public task is unavailable or fails; it is also distinct from Article 6(1)(a) consent, which remains valid but carries the withdrawal risk described below.

GDPR Recital 33 (Broad Consent for Scientific Research)

GDPR Recital 33 is the preambular text explaining how consent works for scientific research when the exact processing purpose cannot be fully specified at the time of data collection. It states that it is often not possible to fully identify the purpose of personal data processing for scientific research at the time of collection, and that data subjects should therefore be allowed to give consent to certain areas of scientific research, or to parts of a research project, when this is done in keeping with recognised ethical standards for scientific research. A data-processing activity satisfies Recital 33 when: (1) the research purpose genuinely could not be fully specified at collection because the research programme is exploratory, longitudinal, or intends future secondary uses that are not yet known; (2) the consent describes the research area, field, or project scope at a level a reasonable data subject can understand, rather than describing nothing at all; (3) the data controller applies recognised research-ethics oversight (e.g. an ethics committee or IRB/REC review) and appropriate safeguards under GDPR Article 89(1) (data minimisation, pseudonymisation where feasible); and (4) the data subject retains the ability to consent to only part of the described research, or to withdraw later. Recital 33 is not itself an operative legal obligation — recitals explain and interpret the numbered Articles but do not impose independent duties. In the consent context, the operative provisions are GDPR Article 6(1)(a) (consent as a lawful basis) and, for special category data such as health or genetic information, Article 9(2)(a) (explicit consent) or the Article 9(2)(j) research derogation as implemented in national law. Recital 33 is cited by regulators, ethics committees, and the European Data Protection Board to justify why research consent can be broader and more programme-level than the general GDPR consent standard, which otherwise requires a specific, informed, unambiguous indication of the data subject's wishes for a defined purpose.

Human Fetal Tissue Research (NIH Policy Framework)

Human fetal tissue (HFT) research is research using tissue or cells obtained from a deceased human embryo or fetus, most often following a pregnancy loss. Where federal funding is involved and the tissue was obtained from an induced (elective) abortion, HFT research is governed by a distinct statutory and policy layer on top of the general Common Rule: the NIH Revitalization Act of 1993 (42 U.S.C. §§289g-1, 289g-2), which sets informed-consent and donation conditions and establishes a Human Fetal Tissue Research Ethics Advisory Board (EAB) mechanism for reviewing funding decisions on ethical grounds, plus successive HHS/NIH policy notices that have repeatedly changed whether and how such research may be federally funded.

Subrecipient Risk Assessment

The evaluation a pass-through entity must perform on each proposed subrecipient before making a subaward of federal funds, under 2 CFR 200.332(c) — considering prior experience with similar subawards, results of previous audits, new or substantially changed personnel/systems, and the extent and results of any federal agency monitoring — performed specifically to set the intensity of the monitoring plan applied once the subaward is active.

NREC (National Office for Research Ethics Committees, Ireland)

The NREC (National Office for Research Ethics Committees) is the statutory Irish body, hosted by the Health Research Board (HRB) since 2020, that establishes and administers Ireland's National Research Ethics Committees for legally regulated research: clinical trials of investigational medicinal products (NREC-CT) and clinical investigations of medical devices (NREC-MD), plus committees stood up for specific national needs such as the National Irish COVID-19 Biobank (NICB-REC) and COVID-19 research (NREC COVID-19). A study falls under NREC review, rather than a local HSE, hospital, or university Research Ethics Committee, when it is a Regulated Clinical Trial under the EU Clinical Trials Regulation (536/2014) or a regulated medical-device clinical investigation, in which case a single national ethics opinion from the relevant NREC is required, issued in a coordinated procedure alongside the scientific/regulatory assessment carried out by the Health Products Regulatory Authority (HPRA). Outside that regulated scope, most observational studies, most academic health and social-care research, and research within the HSE and HSE-funded hospitals, ethical review remains the responsibility of local HSE and Hospital Research Ethics Committees, not the NREC.

Waiver of Informed Consent (45 CFR 46.116(f))

A waiver of informed consent under 45 CFR 46.116(f) is an IRB determination that a study may enroll subjects, or use their identifiable private information or identifiable biospecimens, without obtaining informed consent at all -- distinct from merely waiving the signed-form requirement under 46.117(c). An IRB (or, for research eligible for expedited review, an IRB chair or designated reviewer) may approve a full waiver or alteration of consent only after finding, and documenting in the study record, that all five criteria in 46.116(f)(3) are met: (i) the research involves no more than minimal risk to the subjects; (ii) the research could not practicably be carried out without the waiver or alteration; (iii) if the research uses identifiable private information or identifiable biospecimens, it could not practicably be carried out without using that information or those biospecimens in identifiable form; (iv) the waiver or alteration will not adversely affect the rights and welfare of the subjects; and (v) whenever appropriate, subjects or their legally authorized representatives will be provided with additional pertinent information after participation. This mechanism is the standard route for retrospective chart-review and secondary-database research, where re-contacting every prior patient to obtain prospective consent is often not feasible and would itself undermine the value or completeness of the dataset.

Concordat to Support Research Integrity

The UK's sector-wide research integrity framework document, originally published by Universities UK in 2012, revised in 2019, and refreshed in 2025, that individual UK universities, funders, and sector bodies formally sign up to as named signatories. A signatory organisation commits to five thematic commitments and is expected to publish an annual public statement evidencing how it has acted on each one.

ICH E2A (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting)

ICH E2A is the ICH tripartite guideline (Step 4, 1994; adopted by FDA, EMA, and Japan) that defines Adverse Event, Adverse Reaction, Serious, and Unexpected, cascades those into the SUSAR (Suspected Unexpected Serious Adverse Reaction) category, and sets the expedited safety-reporting clock -- 7 calendar days for fatal/life-threatening SUSARs, 15 calendar days for all other SUSARs, measured from sponsor awareness. It is the regulatory-standard-level source that IND Safety Reports, Safety Letters, and national expedited-reporting rules (21 CFR 312.32 in the US; EU Regulation (EU) No 536/2014) all implement.

2 CFR 200 Subpart B (General Provisions)

2 CFR 200 Subpart B ("General Provisions," 2 CFR 200.100-200.113) is the foundational, scope-setting subpart of the OMB Uniform Guidance. It does not itself create administrative, cost, or audit requirements the way Subparts C through F do; instead it establishes the purpose and legal authority behind the whole of 2 CFR 200, defines who and what it applies to (and what is excepted), fixes how it interacts with prior and future agency guidance, assigns OMB and federal-agency implementation responsibilities, and sets two obligations that apply across every award regardless of subject matter: a written conflict-of-interest standard (200.112) and mandatory disclosure of certain violations of federal criminal law (200.113). A requirement belongs to Subpart B if it concerns whether and how the Uniform Guidance applies at all, rather than a specific administrative, cost, or audit rule once it does apply.

Translated Informed Consent Materials

Consent materials count as compliant "translated informed consent" when they make the required disclosure elements of 45 CFR 46.116 (and, for FDA-regulated research, 21 CFR 50.25) understandable to a prospective participant who does not read or speak English proficiently — satisfied through one of two IRB-approved pathways: (1) a fully translated long-form consent document, reviewed and approved by the IRB before use, or (2) the short-form written consent process under 45 CFR 46.117(b)(2) / 21 CFR 50.27(b)(2), in which a brief document in the participant's language states that the required elements were presented orally, backed by a bilingual witness and the English-language summary the person obtaining consent signs. Neither pathway is optional paperwork — both require prospective IRB approval, and neither can be improvised at the bedside or in the field without one.

Safety Letter (Dear Investigator Letter)

A Safety Letter — almost universally called a Dear Investigator Letter (DIL) in practice — is the direct, investigator-facing document a trial sponsor sends to every participating site in a multi-site clinical trial when new safety information emerges that could affect subjects' welfare, the risk-benefit assessment of the investigational product, or how the trial is conducted. It is the notification artifact itself: the letter (or attached safety report) an investigator physically receives, reads, and is expected to act on — distinct from the underlying regulatory reporting mechanisms (an <a href='/dictionary/term/suspected-unexpected-serious-adverse-reaction-susar'>IND Safety Report</a> to FDA, or a periodic <a href='/dictionary/term/development-safety-update-report-dsur'>DSUR</a>) that may trigger it.Under US law, the obligation traces to 21 CFR 312.55 ("Informing investigators"), which requires a sponsor to keep every participating investigator informed of new observations on the drug — particularly adverse effects and safe use — "as the overall investigation proceeds," and specifically to ensure investigators are promptly informed of significant new adverse effects or risks. The regulation names periodically revised <a href='/dictionary/term/investigational-new-drug-ind'>Investigator's Brochure</a> updates, reprints of published studies, and "reports or letters to clinical investigators" as acceptable means of distribution — the Dear Investigator Letter is that last category in standard industry practice. ICH E6(R2) Sections 5.16–5.18 place the parallel expectation on sponsors internationally: ongoing safety evaluation, and prompt notification of investigators, IRBs/ECs, and regulators when new information could affect the conduct of the trial or the risk to subjects.

Medicare Clinical Trial Policy (NCD 310.1)

The Medicare Clinical Trial Policy is the national coverage framework, codified as National Coverage Determination (NCD) 310.1 ("Routine Costs in Clinical Trials"), under which Medicare pays the routine patient-care costs of a beneficiary enrolled in a qualifying clinical trial, plus reasonable and necessary costs of treating complications from participation. A trial only qualifies if it meets three threshold criteria (the studied intervention falls within a Medicare benefit category, the trial has therapeutic intent, and trials of a therapeutic intervention enroll patients with a diagnosed disease) and satisfies at least one deeming criterion: funding or endorsement by NIH, CDC, AHRQ, CMS, DOD, or VA (or by a cooperative group/center they support); conduct under an FDA Investigational New Drug (IND) application; or exemption from IND requirements as a drug trial under 21 CFR 312.2(b)(1). A trial that meets none of these is not automatically excluded, but its sponsor must instead complete CMS's qualifying-trial checklist demonstrating the trial's scientific validity and integrity. Separately, since Change Request 5790 (Transmittal 310, effective 2008), Medicare claims for routine costs under a qualifying trial must report the trial's ClinicalTrials.gov identifier (the NCT number) alongside condition code 30 -- so registration in the National Library of Medicine's public registry functions, in practice, as a billing prerequisite: a claim without a valid NCT number is at risk of denial even if the trial itself otherwise qualifies.

Cognizant Federal Agency

A cognizant federal agency (for indirect costs) is the single federal agency assigned, under 2 CFR 200 Appendix III (institutions of higher education) or Appendix IV (nonprofit organizations), to negotiate and approve a given institution's indirect (F&A) cost rate and to review certain institution-wide compliance matters on that institution's behalf for all federal awarding agencies. It is assigned to the institution as a whole, generally based on which agency has provided the largest share of that institution's federal funding over a recent multi-year period -- it is not chosen by the institution, and it is not the same thing as the awarding agency on any single grant.

Section 117 Foreign Gift and Contract Reporting

An institution triggers Section 117 of the Higher Education Act (20 U.S.C. § 1011f) reporting when it is a covered institution — offering a bachelor's degree or higher (or an at-least-two-year transfer program toward one), accredited by a nationally recognized accrediting agency, and receiving federal financial assistance — and it receives a gift from, or enters a contract with, a foreign source valued at $250,000 or more, either alone or cumulatively with all other gifts and contracts from that same foreign source, within a calendar year. Institutions owned or controlled by a foreign source must separately disclose that relationship, with no dollar threshold. Covered institutions report semiannually to the U.S. Department of Education (historically due January 31 and July 31, for the preceding six-month period); as of January 2026, filings go through ED's new foreignfundinghighered.gov reporting portal.

DOE AI Policy

"DOE AI policy" most precisely refers to the U.S. Department of Energy's Generative Artificial Intelligence Policy (DOE P 2031, "Use of Generative Artificial Intelligence," issued December 29, 2025) -- a departmental directive governing how DOE's own federal workforce and National Laboratory staff may adopt, deploy, and use generative AI tools in their work. It sits inside DOE's broader 200-series management directives and was written to align with the October 2023 White House Executive Order on AI and the March 2024 OMB Memorandum M-24-10 on federal agency AI governance. It is an internal governance instrument, not an applicant-facing submission requirement: it does not create a DOE-wide rule that external grant applicants, proposers, or awardees must disclose generative AI use when submitting a funding opportunity announcement (FOA) response. Where DOE's policy does touch research practice directly is inside the agency: when generative AI contributes to an idea, approach, or invention developed at DOE or a National Laboratory, DOE staff are expected to identify that specific contribution and cite the GenAI tool as part of the research methodology, consistent with the department's broader research-integrity and record-keeping expectations. Research administrators should not assume this term is interchangeable with the applicant-facing generative AI disclosure notices published by other funders -- see NSF AI Policy and Nature Portfolio AI Policy for that different category of policy -- and should always check the specific DOE FOA's own instructions and applicable acquisition regulations for any submission-level AI-disclosure requirement, since DOE has not, as of this writing, published a separate proposer-facing AI-disclosure notice comparable to NSF's.

Comparator Sourcing

Comparator sourcing is the procurement of an already-approved active comparator drug for use as a trial's control-arm treatment (instead of, or alongside, placebo), plus the blinding, chain-of-custody/authenticity verification, and regulatory handling (GMP/GDP, IMP labeling, import licensing) required once that product enters the study.

PHI Exemptions From the HIPAA Privacy Rule

PHI is exempt from the HIPAA Privacy Rule only when it meets one of three conditions: (1) it has been de-identified under the Safe Harbor or Expert Determination method (45 CFR 164.514), (2) it is held by a person or organization that is not a HIPAA covered entity or business associate, or (3) it is a deceased individual's information more than 50 years after death (45 CFR 164.502(f)). PHI that is disclosed for research without individual authorization under a waiver, a review preparatory to research, the decedent-research pathway, or as a Limited Data Set (all under 45 CFR 164.512(i) or 164.514(e)) remains PHI and remains subject to the Privacy Rule -- it is not exempt, merely disclosable through a permitted exception.

Closeout Costs (2 CFR 200.344)

Closeout costs, in the 2 CFR 200 (Uniform Guidance) sense, are not a separate cost category but the set of financial-disposition actions a federal award recipient must complete once the period of performance ends: submitting all required final financial and performance reports, liquidating any remaining obligations, refunding to the federal awarding agency any unobligated balance the recipient is not authorized to retain, and accounting for and disposing of any equipment or property acquired with federal funds. These duties are set out in 2 CFR 200.344 ("Closeout") and, for property specifically, cross-reference 2 CFR 200.310 through 200.316 and 200.330.

Penalty for Misuse of Federal Funds

The 'penalty for misuse of federal funds' is not a single fixed penalty -- it is a tiered range of consequences that scales with the severity, intent, and materiality of the misuse, running from purely administrative remedies through civil liability to, in the most serious cases, criminal prosecution. At the administrative end, a Federal awarding agency acting under 2 CFR 200.339 (Remedies for noncompliance) can temporarily withhold payments, disallow the specific costs and require repayment, impose special (more restrictive) award conditions under 2 CFR 200.208, suspend the recipient's ability to draw down funds from the Payment Management System, or suspend or terminate the award itself in part or in whole. Because misspent federal money routed through a claim for payment or a certified financial report can constitute a 'false claim,' the same conduct can separately trigger civil liability under the False Claims Act (31 U.S.C. 3729-3733) -- treble damages plus a per-claim civil penalty, pursued either by the Department of Justice or by a private whistleblower (a 'relator') in a qui tam action, with no requirement to prove specific intent to defraud ('knowingly' includes reckless disregard). Independent of both administrative remedies and FCA liability, an agency can initiate suspension or debarment proceedings under 2 CFR Part 180, which exclude the recipient (and, government-wide, any of its covered personnel) from receiving further federal awards or subcontracts for a defined period. Where the misuse involves intentional fraud, false statements, or embezzlement of federal funds, criminal statutes -- most commonly 18 U.S.C. 641 (theft or conversion of federal property/funds) and 18 U.S.C. 1001 (false statements) -- can result in prosecution, fines, and imprisonment. These four tracks are not mutually exclusive: a single instance of misused federal grant funds can produce a repayment demand, an FCA settlement, a debarment, and a criminal referral simultaneously, because each track is triggered by a different legal test and pursued by a different actor (the awarding agency, DOJ Civil Division, a qui tam relator, and DOJ Criminal Division or a U.S. Attorney's office, respectively).

NHMRC HREC Registration

NHMRC HREC registration is the process by which an Australian institution formally registers its Human Research Ethics Committee (HREC) with the National Health and Medical Research Council (NHMRC), submitting the committee's membership list, Terms of Reference, and Standard Operating Procedures for review against the composition and operating requirements set out in Section 5 of the National Statement on Ethical Conduct in Human Research. Registration is what makes an institution's HREC eligible to review NHMRC-funded research and is a prerequisite for -- though distinct from -- separate certification under NHMRC's National Certification Scheme for the Ethics Review of Multi-centre Research.

NIH Guidelines for Human Stem Cell Research

The NIH Guidelines for Human Stem Cell Research is the federal oversight framework, issued by the National Institutes of Health in 2009 (following Executive Order 13505) and amended in 2010, that governs whether federally funded research may use a given human embryonic stem cell (hESC) line. A research activity falls under the Guidelines whenever a US institution seeks NIH funding for work involving hESCs derived from embryos donated after in vitro fertilization (IVF) treatment. Under the Guidelines, two conditions must both be satisfied before federal funds may be used: (1) the specific hESC line must be listed on the NIH Human Pluripotent Stem Cell Registry (hPSCR), which NIH adds a line to only after confirming the embryo was donated voluntarily, with specific informed consent, by IVF patients whose decision to donate was kept separate from their clinical fertility care and was not induced by payment; and (2) many institutions additionally require the protocol to clear review by an institutionally convened Embryonic Stem Cell Research Oversight (ESCRO) committee before the work proceeds, a review that is separate from and in addition to standard Institutional Review Board (IRB) review of the original donor-consent process. The Guidelines govern use of already-derived hESC lines; they do not authorize federal funding of embryo derivation itself, which remains separately restricted by the Dickey-Wicker Amendment, an annual appropriations rider unaffected by the 2009 Guidelines.

Vertebrate Animals Section (VAS)

The Vertebrate Animals Section (VAS) is the required narrative component of an NIH grant application or cooperative-agreement proposal covering any proposed use of live vertebrate animals. Per NIH guidance (originally NOT-OD-10-027, simplified by NOT-OD-16-006), it must describe the proposed procedures and species/strains/ages/sex/numbers; justify the choice of species and why a non-animal alternative cannot achieve the research goals; describe interventions minimizing pain and distress, including analgesia, anesthesia, and humane endpoints; and state whether the planned euthanasia method is consistent with the AVMA Guidelines for the Euthanasia of Animals. It is evaluated by NIH Scientific Review Groups as part of merit review and is distinct from, and does not substitute for, the institution’s own IACUC protocol approval and PHS Assurance.

IRB Violations (Serious or Continuing Noncompliance)

An IRB violation, in federal human-subjects-research regulatory usage, is an instance of "serious or continuing noncompliance" with the IRB's requirements, the approved protocol, or applicable regulation — the threshold that triggers the IRB's own suspension/termination authority under 45 CFR 46.113 and 21 CFR 56.113, and that an institution holding a Federalwide Assurance (FWA) is independently obligated to self-report to the HHS Office for Human Research Protections (OHRP) outside the routine continuing-review cycle. This is a narrower, higher-severity category than the broader <a href='/dictionary/term/irb-reportable-events'>IRB reportable event</a> umbrella: a single missed signature or a minor, corrected protocol deviation is ordinarily handled as a routine reportable event or logged at continuing review, not escalated as "noncompliance" in the regulatory sense. What makes a finding an IRB violation, operationally, is severity and/or a pattern: (1) the deviation from the approved protocol or IRB requirements is serious — it affected subject safety, subject rights and welfare, or the integrity of study data — or (2) it is continuing, meaning it is a repeated pattern rather than an isolated, corrected lapse, or the investigator/site has been unresponsive to prior IRB direction to fix it.

Biosafety in Microbiological and Biomedical Laboratories (BMBL)

Biosafety in Microbiological and Biomedical Laboratories (BMBL) is the primary US reference manual for laboratory biosafety practice, jointly produced by the CDC and the NIH and now in its 6th edition (2020). It defines the four Biosafety Level (BSL-1 through BSL-4) containment tiers, the risk-group classification system for infectious agents, and the standard and special microbiological practices, safety equipment, and facility design requirements associated with each tier. BMBL is an advisory best-practice document rather than a standalone binding federal regulation, but it carries practical regulatory force because it is incorporated by reference into binding frameworks, including the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules and the Federal Select Agent Program.

SUSAR (Suspected Unexpected Serious Adverse Reaction)

A SUSAR (Suspected Unexpected Serious Adverse Reaction) is an adverse event in a clinical trial that meets three conditions at the same time: it is serious under the <a href="https://ich.org/page/efficacy-guidelines" target="_blank" rel="noopener noreferrer">ICH E2A</a> seriousness criteria (death, life-threatening, hospitalization/prolongation, persistent or significant disability, congenital anomaly, or another medically important event), the investigator or sponsor judges there is a reasonable possibility it was caused by the investigational product (a suspected causal relationship, not confirmed causation), and it is unexpected — not listed or not consistent in nature, severity, or specificity with the reference safety information in the current Investigator's Brochure (or approved labeling for an active comparator). All three elements must hold; an event failing any one of them is not a SUSAR. Identifying a SUSAR is what triggers expedited, individual-case safety reporting to regulators, separate from and faster than routine trial adverse-event reporting.

Program Income

Program income is gross income earned by a non-Federal entity that is directly generated by a federally supported activity, or earned as a result of a Federal award, during the award's period of performance (2 CFR 200.307(a)). It must be applied to the original purpose of the award using one of three methods -- deduction, addition, or cost sharing/matching -- as specified by the awarding agency's regulations or the award's terms and conditions; deduction applies by default for most recipients, but addition applies by default for institutions of higher education and nonprofit research institutions when no method is specified.

MRC Guidance on GDPR and Confidentiality in Health Research

MRC GDPR and confidentiality guidance refers to the compliance framework the UK Medical Research Council (MRC), acting through UKRI and its MRC Regulatory Support Centre (RSC), sets out for researchers processing personal data -- especially health data -- in MRC-funded or MRC-affiliated research. It treats UK GDPR/Data Protection Act 2018 (DPA 2018) compliance and the separate common law duty of confidentiality as two distinct, cumulative obligations: satisfying one does not satisfy the other, and MRC-funded research is only compliant when both are addressed. Meeting the standard means (1) identifying a lawful basis for processing under UK GDPR Article 6 -- for MRC/UKRI research this is typically 'public task' or 'legitimate interests' rather than consent, since consent as a GDPR lawful basis carries withdrawal rights that are usually impractical for long-running research datasets -- (2) satisfying a separate condition for processing special category (e.g. health) data under UK GDPR Article 9(2) and DPA 2018 Schedule 1, and (3) independently respecting the common law duty of confidence owed to anyone whose confidential information -- most often identifiable NHS or health/social care data -- is accessed or shared, which GDPR compliance alone does not discharge.

Radiation Safety Committee (RSC)

A Radiation Safety Committee (RSC) is an institutional oversight committee, required as a condition of certain NRC or NRC Agreement State radioactive-materials licenses, that reviews and approves research and clinical uses of radioactive material and radiation-producing equipment and oversees the institution's radiation protection program. A committee qualifies as an RSC when it is established under a broad scope byproduct material license (10 CFR 33.13, with membership including the Radiation Safety Officer, a management representative, and trained/experienced users) or a medical use license authorizing two or more types of use (10 CFR 35.24, with membership including an authorized user for each use type, the RSO, a nursing-service representative, and an independent management representative) -- as distinct from an Institutional Biosafety Committee (IBC), which reviews recombinant/synthetic nucleic acid and biological hazards under the NIH Guidelines, and an IACUC, which reviews live-vertebrate-animal research under the Animal Welfare Act and PHS Policy.

Significant Financial Interest (SFI)

A Significant Financial Interest (SFI) is any financial interest an Investigator (or their spouse/dependent children) holds that meets the dollar or equity thresholds defined at 42 CFR 50.603 -- generally, remuneration exceeding $5,000 in the prior 12 months from a single publicly traded entity, or exceeding $5,000 or any equity at all from a single non-publicly traded entity -- subject to specific regulatory exclusions (e.g., the Investigator's own institutional salary, and compensation from U.S. government agencies or U.S. institutions of higher education for seminars/teaching/review-panel service). Meeting the SFI threshold triggers a disclosure obligation to the institution; it does not by itself mean a conflict of interest exists.

SMART IRB Reliance Agreement

The SMART IRB Reliance Agreement is a master common reliance agreement -- a single legal contract that participating US institutions each sign once with the SMART IRB platform -- that pre-establishes the terms under which any two (or more) participating institutions may rely on one another's IRB review for a given multi-site human subjects study. Once an institution has executed the master agreement, individual studies between it and any other participating institution invoke that existing agreement through an online reliance-determination process, rather than each study requiring its own bespoke IRB Authorization Agreement negotiated and signed from scratch.

SERU (Shared E-Resource Understanding)

SERU (Shared Electronic Resource Understanding) is a NISO Recommended Practice (NISO RP-7-2012) that lets a subscribing library and a content provider (publisher, aggregator, or other vendor) forgo negotiating and signing a bespoke license agreement for an e-resource. Instead, both parties rely on a shared set of expectations grounded in existing copyright law and standard library/publisher practice, plus the model understanding set out in the RP-7-2012 document itself, which addresses the roles of the content provider, the subscribing institution, and authorized users; the scope of permitted and restricted use; privacy and confidentiality of usage data; online performance and service provision; and archiving/perpetual access. A given e-resource transaction counts as SERU-based when both the institution and the provider have indicated, typically by each being listed in NISO's SERU Registry, that they accept SERU's terms for that transaction in place of a signed license — at which point the order can be placed and access provisioned without a license ever being drafted, routed to counsel, or countersigned.

Accessibility Remediation Metadata (ARM)

Accessibility Remediation Metadata (ARM) is a metadata model, in development through a NISO working group that began work in January 2024, for documenting the process and outcome of remediating a publication or other content resource for accessibility -- that is, altering an existing, inaccessible format (for example, a scanned PDF with no text layer, or an image-only textbook chapter) into a version usable with assistive technology, and recording what was done, to what standard, for whom, and where the resulting accessible file can be found or requested. ARM does not describe the accessibility of a resource as originally published; it describes remediation work performed after the fact -- who remediated it, which accessibility standard the remediated version targets (for example WCAG or an EPUB Accessibility conformance level), what format it is in, and how it can be discovered and reused so the same item is not remediated redundantly by multiple institutions. A resource is within ARM's scope if it involves an accessible alternative produced from a source resource, has metadata identifying the remediation process/outcome, and is intended to support discovery and/or deposit of that alternative in a shared repository.

Work Made for Hire

A work is a "work made for hire" under US copyright law (17 U.S.C. Section 101) when it falls into one of two categories: (1) a work prepared by an employee within the scope of their employment, or (2) a work specially ordered or commissioned for use in one of nine specific categories (a contribution to a collective work, part of a motion picture or audiovisual work, a translation, a supplementary work, a compilation, an instructional text, a test, answer material for a test, or an atlas) where the parties expressly agree in a signed written instrument that the work is a work made for hire. Under 17 U.S.C. Section 201(b), the employer or commissioning party -- not the individual who actually created the work -- is treated in law as the "author" and default owner of the copyright, unless the parties have agreed otherwise in writing. This is distinct from a copyright assignment: an assignment transfers rights the creator originally held; work-made-for-hire status means the creator never held authorship or copyright in the work to begin with.

Category A Bioterrorism Agents

Category A is the highest-priority tier of CDC's three-tier (A/B/C) bioterrorism-agent classification, used for public-health emergency-preparedness planning rather than as a compliance roster. An agent qualifies as Category A if it can be easily disseminated or transmitted person-to-person, causes high mortality with potential for major public-health impact, might cause public panic and social disruption, and requires special action for public health preparedness (e.g., stockpiling, enhanced surveillance, and public-communication planning). CDC groups six agents/diseases under Category A: anthrax (Bacillus anthracis), botulism (Clostridium botulinum toxin), plague (Yersinia pestis), smallpox (variola major), tularemia (Francisella tularensis), and viral hemorrhagic fevers caused by filoviruses (e.g., Ebola, Marburg) and arenaviruses (e.g., Lassa, Machupo). This is distinct from, though heavily overlapping with, the Federal Select Agent Program's regulated roster: Category A is a preparedness-prioritization label with no independent registration or compliance obligation attached to it directly, while the Select Agent List is the specific set of agents and toxins an entity must register to legally possess, use, or transfer.

IRB Reportable Events

An IRB reportable event is any occurrence, finding, or piece of new information arising during an already-approved, ongoing human subjects study that federal regulation or an institution's Human Research Protection Program (HRPP) policy requires the study team to report to the IRB outside the routine continuing-review cycle. This is distinct from the initial IRB application/approval process (see IRB/REC Approval Process) and from a planned protocol amendment submitted for prior approval before a change is implemented -- a reportable event concerns something that has already happened during the conduct of the study. The umbrella category typically includes: unanticipated problems involving risks to subjects or others (UPIRSOs), protocol deviations (especially those affecting subject safety, rights, or data integrity), adverse events and serious adverse events, subject complaints, breaches of confidentiality, and non-compliance with the approved protocol or applicable regulations.

Simplified Consent Arrangements for Adults Lacking Capacity (UK Clinical Trials)

In UK clinical trials of investigational medicinal products (CTIMPs), "simplified consent arrangements for adults lacking capacity" refers to the alternative consent pathway set out in Schedule 1, Part 5 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) that applies when a prospective or enrolled participant cannot give informed consent for themselves. Rather than the participant's own signature, the regulations require consent from a legal representative acting on the adult's behalf: first a personal legal representative (someone not connected with the conduct of the trial who is suitable by virtue of their relationship with the adult, and who is available and willing to act), or, if no personal legal representative is available, a professional legal representative (typically the doctor primarily responsible for the adult's medical treatment, provided they are independent of the trial, or a person nominated by the relevant health service body). A further, narrower simplification applies to genuinely urgent research: where the trial's protocol has been specifically approved by a recognised Research Ethics Committee for enrolment in urgent situations, an incapacitated adult may be entered into the trial without any prior consultation of a legal representative if urgent action is needed to give the investigational medicinal product and it is not reasonably practicable to consult one first — on condition that consent (or continued participation) is then sought from a legal representative, or the adult themselves if capacity is regained, as soon as reasonably possible afterwards. CTIMPs are explicitly excluded from the separate Mental Capacity Act 2005 research provisions (MCA s.30) precisely because this dedicated Schedule 1 regime governs them instead; other (non-CTIMP) research involving adults who lack capacity in England and Wales instead follows the MCA 2005 consultee-based framework. This term covers the CTIMP-specific, legal-representative pathway only.

MHRA GCP Inspection

An MHRA GCP inspection is an on-site or remote audit conducted by the UK Medicines and Healthcare products Regulatory Agency's GCP Inspectorate to assess whether a clinical trial sponsor, contract research organisation (CRO), or investigator site is conducting research in compliance with the UK Clinical Trials Regulations and the principles of Good Clinical Practice (GCP) set out in ICH E6. Inspections are the mechanism by which the MHRA verifies that trial data submitted in support of a marketing authorisation can be trusted and that participants' rights, safety, and wellbeing were protected during the conduct of the trial.

ICH M4 (Common Technical Document / CTD)

ICH M4 is the International Council for Harmonisation (ICH) multidisciplinary guideline that defines the Common Technical Document (CTD): a standardized, five-module dossier structure for organizing the quality, safety, and efficacy data submitted to regulatory authorities when registering a pharmaceutical for human use. A submission is CTD-compliant when its content is organized into Module 1 (region-specific administrative information), Module 2 (CTD summaries), Module 3 (quality/CMC data), Module 4 (nonclinical study reports), and Module 5 (clinical study reports), with Modules 2-5 following the same harmonized content and ordering regardless of which ICH regulatory authority receives the application. M4 is a family of related documents rather than a single guideline: the overarching M4 organizational guideline is supplemented by M4Q (Quality), M4S (Safety/nonclinical), and M4E (Efficacy/clinical), each specifying the detailed content and ordering for its respective module.

NIH Inclusion Policies (Women, Minorities, and Across the Lifespan)

A study satisfies NIH inclusion requirements when its application describes the planned participant population by sex/gender, race/ethnicity, and age range appropriate to the science; provides a compelling rationale for any exclusion of women, a minority group, or an age range rather than defaulting to exclusion; and, for Phase III trials, includes a valid analysis plan for whether effects differ by sex/gender and race/ethnicity. This combines two distinct NIH policies: the statutory Inclusion of Women and Minorities policy (sex/gender and race/ethnicity, in force since the 1993 NIH Revitalization Act) and the Inclusion Across the Lifespan policy (age, including children and older adults, in force since January 25, 2019 under NOT-OD-18-116).

USDA Research Security Training Requirement

The USDA Research Security Training Requirement is the U.S. Department of Agriculture's implementation of the government-wide research-security training mandate created by Section 10634 of the CHIPS and Science Act of 2022 (42 U.S.C. Section 19234) and directed by NSPM-33 — the same policy family behind the parallel DOE and NASA requirements. Multiple institutional sponsored-programs offices report that USDA introduced the requirement via Secretary's Memorandum SM 1078-014 (dated July 8, 2025) and folded it into USDA's General Terms and Conditions for financial assistance awards, effective December 31, 2025: named 'covered individuals' on a USDA-funded application or award must complete an approved research-security training course, with completion certified to USDA as part of the award's terms and conditions. CASRAI could not independently confirm this text against a primary usda.gov source at the time of writing (the USDA PDF did not load during verification); treat the SM 1078-014 number and December 31, 2025 effective date as reported-tier pending direct confirmation against USDA's own published memorandum and General Terms and Conditions before relying on them for a compliance deadline.

45 CFR 46 Subpart C (Additional Protections for Prisoners in Research)

The section of the Common Rule (45 CFR 46, §§46.301-46.306) that governs HHS-conducted or HHS-funded biomedical or behavioral research involving prisoners as subjects. A protocol falls under Subpart C whenever a subject meets the §46.303 definition of "prisoner" — involuntary confinement or detention in a penal institution, including pretrial detainees and individuals in alternative-to-incarceration facilities. The reviewing IRB must satisfy the §46.304 composition requirements (a non-prison-affiliated majority plus at least one prisoner or prisoner representative), make the additional findings required by §46.305, and may approve the research only if it fits one of the four categories permitted under §46.306.

FAR Part 31 (Contract Cost Principles and Procedures)

FAR Part 31 (48 CFR Part 31), 'Contract Cost Principles and Procedures,' is the section of the Federal Acquisition Regulation that governs which costs a contractor -- including a university or research institution performing a federally funded CONTRACT rather than a grant -- may charge to, or recover from, the U.S. government. A cost is chargeable under FAR Part 31 only if it independently satisfies three tests set out in FAR 31.201-2: it must be reasonable (FAR 31.201-3, the 'prudent person' standard), allocable to the specific contract (FAR 31.201-4), and, where the contractor is subject to Cost Accounting Standards, measured, assigned, and allocated consistently with the applicable CAS. Subpart 31.2 (Contracts with Commercial Organizations) is the subpart most relevant to universities and other non-profit or commercial entities performing federal contract research; FAR 31.205 then works through more than 50 named 'selected cost' categories -- compensation, independent R&D and bid-and-proposal costs, entertainment, alcoholic beverages, fines and penalties, lobbying, and more -- either allowing them outright, allowing them subject to a stated limitation, or declaring them expressly unallowable regardless of reasonableness or allocability. FAR 31.201-6 additionally requires a contractor's accounting system to identify and separately account for unallowable costs so they are never included in a billing, claim, or proposal to the government.

Appearance of a Conflict of Interest

An appearance (or perceived) conflict of interest exists when a reasonable, informed outside observer could conclude that a researcher's, reviewer's, or official's outside relationships or interests might improperly influence their professional judgment -- even though, on closer examination, no actual conflict is present (there is no real financial or professional stake in the specific decision, or the relationship in fact has no bearing on it). It is judged from the observer's vantage point, not the individual's own confidence in their objectivity, which is precisely why most institutional, funder, and journal conflict-of-interest policies require an appearance-level situation to be disclosed and managed on essentially the same terms as an actual conflict: unmanaged appearances erode trust in research even when no bias actually occurred.

USDA Covered Species

The set of animal species that fall within the Animal Welfare Act's (AWA) statutory definition of "animal" under 9 CFR 1.1, and are therefore subject to USDA APHIS registration, inspection, and recordkeeping requirements. A species is "covered" if it is a live or dead dog, cat, non-human primate, guinea pig, hamster, rabbit, or other warm-blooded animal used or intended for use in research, teaching, testing, experimentation, or exhibition, or as a pet. Critically, the AWA's definition of "animal" explicitly excludes birds, rats of the genus Rattus, and mice of the genus Mus that are bred for use in research, as well as cold-blooded species (fish, amphibians, reptiles) and most farm animals used for food/fiber production research. Because purpose-bred rats, mice, and birds are the large majority of animals used in US biomedical research, most laboratory animals are, by this narrow legal definition, not "covered species" under the AWA -- even though the same animals are typically still covered under other frameworks (chiefly <a href='/dictionary/term/phs-policy'>PHS Policy</a>) when the research is federally funded.

Attending Veterinarian (AV)

The Attending Veterinarian (AV) is the credentialed veterinarian (DVM/VMD) with direct or delegated authority and responsibility for the health and well-being of all research, teaching, and testing animals at an institution. Required under the Animal Welfare Act (9 CFR 2.33) and PHS Policy, the AV is a voting IACUC member and holds documented authority to provide or order veterinary treatment, require appropriate anesthesia/analgesia, and suspend a procedure or study causing unrelieved animal pain or distress.

Clinical Data Registry

A clinical data registry is an organized system that collects standardized, defined-variable clinical and outcomes data on patients sharing a common condition, procedure, exposure, or device, on an ongoing rather than fixed-enrollment basis. What makes a data-collection effort a registry, rather than an ordinary clinical database or a clinical trial, is a combination of: (1) a defined denominator population identified by disease, procedure, or exposure, not by eligibility for a specific tested intervention; (2) a standardized, pre-specified data dictionary applied consistently across contributing sites, enabling pooled and benchmarked analysis; and (3) an ongoing or periodically re-opened collection window rather than a protocol-bound enrollment period. Registries are most often sponsored by a medical specialty society, a health system, a public health agency, or a manufacturer under a post-market surveillance obligation, and their stated purposes typically include quality improvement and benchmarking, observational research, public health surveillance, and, in a growing but still bounded set of cases, support for regulatory decision-making.

45 CFR 46 Subpart A (Basic HHS Policy for Protection of Human Research Subjects)

The foundational section of the Common Rule (45 CFR 46, §§46.101-46.124) that establishes the general framework HHS-conducted or HHS-funded human-subjects research must satisfy: which activities and institutions it covers (§46.101), the core definitions of "human subject" and "research" (§46.102), the institutional assurance and IRB registration structure (§46.103), the eight categories of exempt research (§46.104), IRB membership and operating requirements (§46.107-46.115), and the general standards for informed consent (§46.116-46.117). Subpart A is the baseline every other subpart (B, C, D) layers additional, population-specific protections on top of — in ordinary usage, "the Common Rule" and "Subpart A" refer to essentially the same body of regulatory text.

HIPAA and Retrospective Research

A retrospective study (most commonly a retrospective chart review) uses protected health information (PHI) that was already recorded in the medical record before the research began, rather than PHI generated by a prospective study protocol. Because the individuals were treated in the past and often cannot practicably be found and asked for HIPAA authorization, retrospective research typically proceeds under 45 CFR 164.512(i)(1)(i): an IRB or Privacy Board grants a full or partial waiver of authorization after documenting, per 164.512(i)(2), that (1) the use/disclosure involves no more than minimal privacy risk, based on an adequate plan to protect identifiers, an adequate plan to destroy identifiers at the earliest opportunity absent a health or research justification to retain them, and written assurances against reuse or redisclosure; (2) the research could not practicably be conducted without the waiver; and (3) the research could not practicably be conducted without access to the PHI. A study only qualifies as retrospective-research-under-waiver if it is genuinely using pre-existing records for a defined research protocol -- not if it is a 'review preparatory to research' (164.512(i)(1)(ii), used only to help design a study or assess feasibility, with no PHI leaving the covered entity) or decedent-only research (164.512(i)(1)(iii)), which are the Rule's two other, separate no-authorization pathways.

Data Protection Act 2018, Schedule 2, Paragraph 27 (Research Exemption)

The provision in Part 6 of Schedule 2 to the UK Data Protection Act 2018 that lets a controller processing personal data for research or statistical purposes disapply specific UK GDPR data-subject rights -- the right of access (Article 15(1)-(3)), rectification (Article 16), restriction of processing (Article 18(1)), and objection (Article 21(1)) -- to the extent that applying them would prevent or seriously impair achievement of the research or statistical purposes, provided the processing also satisfies the UK GDPR's research-safeguards requirements. The access-right disapplication carries an additional, narrower condition: it applies only where the results of the research or any resulting statistics are not made available in a form that identifies a data subject.

Exception from Informed Consent (EFIC) for Emergency Research

EFIC (Exception from Informed Consent) is the regulatory pathway under 21 CFR 50.24 that permits FDA-regulated clinical investigations of a drug, biologic, or device to enroll subjects in a life-threatening emergency without prospective informed consent from the subject or a legally authorized representative (LAR). A study qualifies as EFIC only when all of the following are true: (1) subjects are in a life-threatening situation for which available treatments are unproven or unsatisfactory; (2) obtaining informed consent is not feasible because the condition requires intervention before consent from the subject or LAR can reasonably be obtained; (3) participation holds the prospect of direct benefit to the subject; (4) the research could not practicably be carried out without the waiver; and (5) additional protections are in place, most notably community consultation and public disclosure conducted before the study begins, and an independent data monitoring committee. IRB approval of the full protocol, including the community consultation and disclosure plan, is required before enrollment can start under the exception.

45 CFR 46 Subpart B (Additional Protections for Pregnant Women, Human Fetuses, and Neonates)

The section of the Common Rule (45 CFR 46, §§46.201-46.207) that governs HHS-conducted or HHS-funded research in which the subjects are pregnant women, human fetuses, or neonates. A protocol falls under Subpart B whenever a subject meets the §46.202 definition of pregnant woman, fetus, or neonate; the IRB must then apply the specific risk/benefit and consent conditions for the applicable subject category (§46.204 pregnant women/fetuses, §46.205 neonates, §46.206 material obtained after delivery) before approving the research, with §46.207 available as a narrow, HHS-Secretary-level pathway for research that does not otherwise qualify.

OLAW (Office of Laboratory Animal Welfare)

OLAW is the office within NIH's Office of the Director responsible for implementing and interpreting the PHS Policy on Humane Care and Use of Laboratory Animals: it negotiates and approves each institution's Animal Welfare Assurance, evaluates reports of noncompliance from Assured institutions, and runs a nationwide PHS Policy education program. It governs any live vertebrate animal used in PHS-supported (including NIH-funded) research, testing, or training. OLAW does not replace an institution's own IACUC, and it does not conduct the on-site facility inspections that USDA/APHIS carries out under the Animal Welfare Act -- OLAW's authority runs through the PHS funding relationship, not independent statutory inspection power.

Confidentiality Advisory Group (CAG) / Section 251

The Confidentiality Advisory Group (CAG) is an independent advisory body in England and Wales that reviews applications from researchers and other organisations seeking to access or use confidential patient information without patient consent, and advises whether there is sufficient public interest to justify granting that access. CAG does not itself hold decision-making power: for research applications it advises the Health Research Authority (HRA), which makes the final decision; for non-research applications (for example, national disease registries or public health surveillance) it advises the Secretary of State for Health and Social Care, or in some cases NHS England. The legal basis CAG operates under is Section 251 of the NHS Act 2006, which allows the common law duty of confidentiality to be set aside temporarily where anonymised or pseudonymised data cannot meet the research purpose and seeking individual consent is not practicable. Section 251 is given operational effect through the Health Service (Control of Patient Information) Regulations 2002 (the “COPI Regulations”) — specifically Regulation 5 (support for research and other purposes) and Regulation 3 (support for communicable disease surveillance and other public health risks). Approval obtained this way is commonly referred to as “Section 251 support,” “Regulation 5 support,” or a “CAG approval,” and the terms are used largely interchangeably in UK research-governance practice. CAG membership is drawn from a mix of clinicians, academics, and lay members, reflecting the requirement to weigh both the research/public-interest case and the patient-confidentiality interest.

NASA Research Security Training (GIC 26-02)

NASA's research security training requirement, established under Grant Information Circular (GIC) 26-02 (issued February 2026), requires every 'covered individual' -- a Principal Investigator or Co-PI on a NASA grant or cooperative agreement at any level of effort, or a Co-Investigator committing 10% or more effort annually -- to certify completion of qualifying research security training. The requirement takes effect for proposals and annual progress reports due on or after August 5, 2026, and is evidenced through updated NASA Biographical Sketch and Current and Pending (Other) Support forms rather than a separate standalone certificate.

Equipment (2 CFR 200.1 Definition)

Under 2 CFR 200.1 (Uniform Guidance), "Equipment" is tangible personal property, including IT systems, with (1) a useful life of more than one year AND (2) a per-unit acquisition cost equal to or exceeding the lesser of the institution's own capitalization level or $10,000 (raised from a $5,000 federal floor in a 2024 Uniform Guidance revision, effective for awards issued on/after October 1, 2024). NIH applies this same government-wide definition to its own awards rather than a separate NIH-specific threshold. Items failing either prong are classified as "Supplies" instead.

DOE Research Security Training Requirement

DOE's research security training requirement, announced via Policy Flash PF 2025-04 (Financial Assistance Letter FAL 2025-02) under Section 10634 of the CHIPS and Science Act of 2022 (42 U.S.C. Section 19234) and NSPM-33, requires that 'covered individuals' named on a DOE R&D financial-assistance application complete research security training -- addressing cybersecurity, international collaboration/travel, foreign interference, and rules on proper use of funds, disclosure, conflict of commitment, and conflict of interest -- within the 12 months prior to submitting that application. The applicant organization certifies completion for all listed covered individuals via Current and Pending Support disclosure certification; DOE does not require use of any specific pre-approved training course.

PRIM&R (Public Responsibility in Medicine and Research)

PRIM&R (Public Responsibility in Medicine and Research) is a US-based 501(c)(3) nonprofit membership organization, founded in 1974 and headquartered in Boston, Massachusetts, that supports the ethical conduct of research involving human participants and animals. An organization or individual falls within PRIM&R's operational scope when their work touches research oversight -- Institutional Review Boards (IRBs) reviewing human-subjects research, or Institutional Animal Care and Use Committees (IACUCs) overseeing animal research -- rather than the conduct of a specific study itself. PRIM&R does not review protocols or approve studies; it trains and credentials the professionals and administrators who staff the committees that do.

Case Report IRB Exemption

A case report is generally treated as exempt from IRB (Common Rule) jurisdiction when it describes routine clinical care of one patient (or a small, non-systematically-assembled number), written up retrospectively with no predefined data-collection protocol and no intent to test a hypothesis or produce a generalizable conclusion — i.e., it fails the 45 CFR 46.102(l) definition of 'research' even though the patient meets the 46.102(e) 'human subject' definition. The determination is made by the IRB or a delegated research-compliance office, not by the author; institutional thresholds and required documentation vary, and HIPAA authorization/waiver plus patient consent for publication remain separately required regardless of Common Rule status.

Ethical Approval

Ethical approval is the prospective, documented authorization a research ethics body issues before a study involving human participants (or, in a parallel but separate system, live animals) may begin — confirming the protocol's risk-benefit balance, consent process, and participant protections meet the applicable regulatory and ethical standard. It is granted by whichever committee has jurisdiction in a given country, which is why the same underlying requirement is described using different national names.

Joint Associations Group (JAG) on Indirect Costs

The Joint Associations Group (JAG) on Indirect Costs is a coalition of national higher-education and research associations -- including AAU, APLU, AAMC, ACE, AASCU, AIRI, COGR, NACUBO, NAICU, and the Science Philanthropy Alliance -- formed in 2025 to develop and advocate for a replacement model for how the federal government reimburses universities' facilities and administrative (F&A) costs on federally sponsored research. It is a policy-advocacy coalition, not a standards body or a rate-setting authority: it does not itself negotiate or set any institution's indirect cost rate, and it has no regulatory authority under 2 CFR 200. Its output is a set of recommendations submitted to federal officials and Congress, produced through a subject-matter-experts process that draws on people with direct experience in university finance, grant administration, and F&A cost-rate regulation.

Ag Guide (Guide for the Care and Use of Agricultural Animals in Research and Teaching)

An institution follows the Ag Guide (Guide for the Care and Use of Agricultural Animals in Research and Teaching, FASS, 4th edition 2020) when agricultural animals -- livestock, poultry, and other food/fiber species -- are used in research or teaching whose purpose is agricultural (improving nutrition, breeding, management, production efficiency, or food/fiber quality). The determining factor is the purpose and context of the work, not the species alone: the same species used instead for biomedical purposes (e.g., a pig as a cardiovascular-device model) is typically reviewed under the Guide for the Care and Use of Laboratory Animals rather than the Ag Guide.

Randomization Methods in Clinical Trials

A randomization method is the pre-specified, reproducible procedure by which a clinical trial assigns each participant to a treatment or control arm based on chance rather than on the choice of the investigator, the participant, or any deterministic rule (e.g., alternating assignment or day-of-week). A procedure qualifies as randomization only if the allocation sequence is generated by a chance mechanism, is concealed from whoever enrolls participants until after enrollment (allocation concealment), and is documented so the trial's statistical analysis plan can account for it. The choice of method -- simple, block, stratified, or covariate-adaptive -- determines how tightly the resulting treatment groups are balanced on sample size and on prognostic factors, but all four share the same underlying purpose described by ICH E9, Statistical Principles for Clinical Trials: minimizing selection bias in treatment assignment and providing a sound statistical basis for comparing groups.

Time and Effort Reporting

The institutional system for documenting that salary and wages charged to, or cost-shared against, a federal award correspond to the effort an employee actually performed on that award, satisfying the internal-control standard at 2 CFR 200.430(g). It covers the full cycle -- budgeting effort at proposal stage, recording/monitoring effort during the award period, and after-the-fact review or confirmation (often called effort certification) that reconciles charged percentages against actual activity -- and does not correspond to any single federally mandated form; institutions design their own compliant forms or systems (Plan Confirmation, After-the-Fact Activity Records, Multiple Confirmation Records, or electronic effort-reporting platforms) as long as the underlying system provides reasonable assurance charges are accurate, allowable, and properly allocated based on records reflecting total compensated activity not exceeding 100 percent.

Research Ethics Board (REB)

A Research Ethics Board (REB) is the committee constituted under Canada's TCPS2 (Tri-Council Policy Statement) at institutions eligible for CIHR, NSERC, or SSHRC funding that reviews, approves, requires modification of, or disapproves research involving human participants before that research may begin. It is the Canadian institutional counterpart to a US Institutional Review Board (IRB): the same underlying function of prospective ethics review, carried out under different national policy and terminology.

Umbrella Trial

An umbrella trial is a clinical trial design in which multiple investigational therapies are evaluated within a single disease population under one overarching master protocol, with each treatment arm matched to a different biomarker or molecular subtype found within that disease. The disease is held constant across the trial; the drug arm assigned to a given patient varies according to the biomarker their tumor or condition carries. FDA formally recognizes the umbrella trial as one of three related master-protocol designs, alongside the basket trial and the platform trial, in its guidance on master protocols for oncology drug and biologic development.

Endpoint Adjudication Committee (CEC)

An Endpoint Adjudication Committee (EAC) — often called a Clinical Events Committee (CEC) — is an independent group of clinical experts, typically blinded to each participant's treatment assignment, that reviews reported clinical events (deaths, hospitalizations, strokes, myocardial infarctions, and other complex or subjective outcomes) against pre-specified, standardized criteria defined in the trial protocol and a dedicated adjudication charter, and issues a formal, documented determination of whether each event meets the definition of a study endpoint. Adjudication exists to remove site-to-site and investigator-to-investigator variability in how an outcome gets diagnosed and classified — a real risk whenever the endpoint depends on clinical judgment rather than a single objective lab value — and it is a distinct function from safety oversight: a CEC classifies individual events against fixed criteria, it does not conduct comparative interim analyses across arms or recommend stopping the trial.

2 CFR 200 Subpart D (Post-Federal Award Requirements)

2 CFR 200 Subpart D (§§200.300–200.346) is the set of Uniform Guidance provisions governing how an already-made federal grant or cooperative agreement is administered, from the recipient's financial management system and internal controls through property/procurement standards, performance and financial reporting, subrecipient monitoring, record retention, and closeout. A requirement falls under Subpart D if it governs the administration of an active award; requirements governing the application/award-decision process belong to Subpart C, and the allowability of specific costs is governed by Subpart E.

FDP Data Transfer and Use Agreement (DTUA)

A Data Transfer and Use Agreement (DTUA) is the standardized data-sharing contract template published by the Federal Demonstration Partnership (FDP) for moving research data between U.S.-based nonprofit and/or governmental organizations for research or public health purposes. An agreement qualifies as an FDP DTUA when it follows the FDP's modular structure -- a Face Page plus a set of standard Attachments -- rather than being negotiated from scratch between the transferring institution (discloser) and receiving institution (recipient). The template is maintained by the FDP's Data Stewardship Subcommittee (within the Research Compliance Committee) and exists specifically to cut the time and legal back-and-forth that fully bespoke data-sharing agreements require, by giving both sides' institutional counsel a pre-vetted starting point with known, community-reviewed language.

Estimand Framework

The estimand framework, introduced in the ICH E9(R1) addendum to 'Statistical Principles for Clinical Trials' (final version adopted November 2019), is the structured approach a clinical trial protocol uses to state precisely, before the trial is analyzed, what treatment effect the trial is actually designed to estimate. A trial's estimand is defined by specifying five attributes: (1) the target population (the patients the clinical question is about), (2) the treatment conditions being compared, (3) the variable or endpoint measured for each participant, (4) the strategy for handling intercurrent events -- post-randomization events, such as treatment discontinuation, use of rescue medication, or death, that affect either the interpretation or the existence of the planned measurement -- and (5) the population-level summary used to compare the treatment conditions (for example, a difference in means, an odds ratio, or a hazard ratio). A trial only has a well-defined estimand when all five attributes are specified together and agreed before unblinding; changing how one attribute is handled (most consequentially, the intercurrent-event strategy) changes what the resulting number actually means, even if the same raw data and the same statistical test are used to produce it.

Assent vs. Consent (in Research)

Assent is the affirmative agreement of a prospective research subject who lacks the legal capacity to give informed consent on their own behalf -- typically a minor -- to take part in a research study. Under 45 CFR 46 Subpart D (§46.402(b), §46.408), assent is distinct from, and required in addition to, the informed permission of a parent or legally authorized guardian: a child's willingness to participate does not substitute for parental permission, and parental permission does not substitute for the child's own assent where an Institutional Review Board (IRB) has determined the child is capable of providing it. Critically, assent must be an affirmative 'yes' -- the regulation explicitly states that a child's mere failure to object, absent some affirmative agreement, may not be construed as assent. The IRB decides, on a study-by-study or even subject-by-subject basis, whether assent is required, how it should be solicited (verbally, in writing, or via an age-appropriate script), and whether it may be waived under the conditions set out in §46.408(a).

Registrational Trial

A registrational trial (also called a pivotal trial) is a clinical study designed and executed specifically to generate the primary efficacy and safety evidence submitted in a marketing application — a New Drug Application (NDA), Biologics License Application (BLA), or comparable submission — to a regulatory authority such as FDA. What makes a trial ‘registrational’ is not its phase number but its regulatory purpose: it is prospectively designed as an adequate and well-controlled investigation under 21 CFR 314.126, with a prespecified primary endpoint and statistical analysis plan agreed with the regulator (often via a Special Protocol Assessment), and powered to provide the ‘substantial evidence of effectiveness’ the Federal Food, Drug, and Cosmetic Act requires for approval. Most registrational trials are Phase 3 studies, but a well-controlled Phase 2 trial can serve the same function in accelerated-approval or rare-disease programs where a full Phase 3 program is used to confirm benefit post-approval.

Site Qualification Visit (SQV)

A Site Qualification Visit (SQV) is the pre-selection assessment visit a sponsor or CRO conducts at a prospective investigative site, before that site is contracted or selected for a specific clinical trial, to evaluate whether it should be chosen. A visit counts as an SQV when its purpose is evaluative and its timing is pre-selection: it examines the site's facilities and equipment, staff qualifications and prior trial experience, patient population and recruitment feasibility, and quality systems/SOPs, in order to inform a go/no-go selection decision. A visit is NOT an SQV if it occurs after the site has already been selected, contracted, and IRB-approved and is instead confirming the site is ready to begin enrollment -- that is a Site Initiation Visit (SIV) -- or if it occurs during active enrollment to review ongoing conduct, which is a routine monitoring visit.

Unallowable Cost (2 CFR 200)

An unallowable cost under 2 CFR 200 is any expense that federal cost-principle rules bar an institution from charging to a federal award, whether as a direct charge or through the indirect (F&A) cost rate. A cost becomes unallowable in one of two ways under Subpart E. First, it can fail the general allowability test at 2 CFR 200.403 -- it is not necessary and reasonable for the award, not allocable to it, treated inconsistently with how the institution handles like costs, non-compliant with GAAP or the award's own terms, double-counted toward a cost-sharing commitment, or inadequately documented. Second, and distinctly, it can fall into one of the specifically-named categories in the 'selected items of cost' catalog at 200.421-200.475, which addresses named cost types one by one -- alcoholic beverages, entertainment, lobbying, fines and penalties, bad debts, contributions and donations, fundraising, and dozens more -- regardless of whether the institution would otherwise treat the cost as reasonable or allocable. This second route is what distinguishes 'unallowable' from a cost that merely fails allocability or reasonableness on its own facts: a cost can be perfectly reasonable and allocable to a specific project and still be unallowable outright because Subpart E names that category of cost as barred. Per 200.420, the named-category list is illustrative, not exhaustive -- an unlisted cost item is not automatically allowable; it still has to clear the general 200.403 test and is evaluated by analogy to similar listed items. Unallowable costs must be identified and excluded from any proposal, invoice, or financial report submitted to the federal government, and from the base used to calculate the institution's indirect cost rate -- charging one to a federal award, intentionally or through inadequate internal controls, is one of the most commonly cited findings in a Single Audit under 2 CFR 200 Subpart F.

ALCOA+ (Clinical Trial Data Integrity Principles)

ALCOA+ is the nine-attribute framework regulators use to judge whether a clinical-trial data record is trustworthy enough to support a marketing application or inspection finding. A record satisfies ALCOA+ when it is Attributable (traceable to the specific person or system that created it, with no shared logins or unattributed edits), Legible (readable and permanent for the life of the record, including any correction), Contemporaneous (recorded at the time the activity occurred, not reconstructed later from memory), Original (the first recording of the data, or a verified true copy carrying equivalent authority), and Accurate (free of error, and reflecting what actually happened) -- the original five FDA ALCOA attributes -- plus Complete (nothing selectively omitted, including repeat or rejected results), Consistent (chronologically dated, time-stamped, and internally coherent), Enduring (surviving on durable media for the full required retention period), and Available (retrievable for review, audit, or inspection throughout that period). A record that fails any one of the nine is a data-integrity finding, regardless of whether the underlying clinical result itself is otherwise plausible.

Bayesian Adaptive Design

A Bayesian adaptive design is a clinical trial design in which the statistical framework starts from a prior probability distribution over treatment effects and formally updates that distribution into a posterior distribution as outcome data accumulate during the trial, using Bayes' theorem rather than waiting for a single fixed-sample-size final analysis. What makes a design specifically Bayesian-adaptive, rather than merely adaptive, is that the pre-specified adaptation rules (whether to modify randomization allocation, stop a trial arm early for efficacy or futility, or re-estimate sample size) are driven by these continuously updated posterior probabilities rather than by frequentist p-value or alpha-spending boundaries alone. The most common operational form is Bayesian response-adaptive randomization: the probability that a newly enrolled participant is assigned to a given arm shifts over the course of the trial toward arms whose posterior probability of superiority is higher, based on outcomes observed so far in the shared, concurrently randomized control comparison. This distinguishes a Bayesian adaptive design from a conventional frequentist fixed-sample design, in which the randomization ratio and total sample size are fixed at the outset by a power calculation and the treatment-effect hypothesis is tested once, at a single pre-planned analysis (or at a small number of pre-specified interim looks using a fixed alpha-spending function), with no allocation-ratio changes based on relative arm performance mid-trial.

Pre-Screening

Pre-screening is the informal, preliminary process of assessing whether a prospective clinical trial participant is likely to meet inclusion/exclusion criteria, conducted before the protocol-defined formal screening visit and generally before the participant signs the informed consent form (ICF). It typically takes the form of a brief phone or in-person eligibility interview using an IRB-approved script, or a review of existing medical records/EHR data conducted under a HIPAA waiver of authorization or the reviews-preparatory-to-research provision (45 CFR 164.512(i)). A candidate excluded at this stage never enters the trial's formal screening and enrollment log and is not counted toward the trial's screen failure rate.

HREC (Human Research Ethics Committee)

The Australian term for the committee that reviews and approves research involving human participants before it may lawfully or ethically proceed. An HREC is constituted and registered under the National Health and Medical Research Council (NHMRC)'s National Statement on Ethical Conduct in Human Research, and its review is the Australian institutional counterpart to an IRB (Institutional Review Board) in the United States or an REC (Research Ethics Committee) in the UK/EU. A study is subject to HREC review whenever it involves human participants, their identifiable data, or their tissue and is designed to produce generalisable knowledge; the depth of that review is graded by risk rather than uniform for every protocol.

Screen Failure

A participant who provides informed consent and enters the protocol-defined screening process for a clinical trial, but is not subsequently randomized or assigned to study intervention because they fail to meet one or more inclusion/exclusion criteria, withdraw consent before randomization, or otherwise become ineligible prior to enrollment. The defining boundary is randomization/assignment to study intervention: everything before that point that ends without assignment is a screen failure; anything after it is a post-randomization withdrawal or discontinuation, not a screen failure.

Equivalence Trial

An equivalence trial is a clinical trial designed to show that a new intervention's effect is neither meaningfully better nor meaningfully worse than an active comparator -- the treatment difference must fall within a pre-specified equivalence margin in both directions. It is one of three ways a comparative trial's primary hypothesis can be framed at the protocol design stage: a superiority trial sets out to show one arm is better than another (or than placebo); a non-inferiority trial sets out to show a new arm is not unacceptably worse than an active comparator, using only a single lower margin; an equivalence trial requires the treatment difference's confidence interval to fall entirely within a symmetric two-sided margin, written (-delta, +delta), that was fixed before the trial started as the largest difference still considered clinically unimportant. Which of the three applies is a design decision documented in the protocol and statistical analysis plan -- it is not something inferred after the fact from a trial's results.

Study Data Tabulation Model (SDTM)

The Study Data Tabulation Model (SDTM) is a CDISC foundational standard that defines a standard structure for organizing clinical trial data into a set of named, model-conformant domain datasets (e.g. DM, AE, VS) for submission to regulatory authorities such as the FDA and Japan's PMDA. A dataset counts as SDTM-conformant when its observations are classified into one of SDTM's general observation classes (Interventions, Events, Findings, or Findings About), each variable maps to a controlled SDTM domain/variable name, and the dataset is accompanied by a define.xml metadata file describing its structure. SDTM governs the submission-ready tabulation format, not how data is collected at the site (that is CDASH) and not the software used to capture it (that is EDC).

Serious Adverse Event (SAE)

An adverse event (AE) that meets at least one of six regulatory seriousness criteria defined by ICH E2A, regardless of causality or perceived clinical severity: it results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another medically important event that the investigator judges may jeopardize the subject or require intervention to prevent one of the other outcomes. Seriousness is a fixed regulatory classification, distinct from clinical severity (mild/moderate/severe) and distinct from causality.

Centralized Monitoring

Centralized monitoring is a clinical-trial oversight technique in which qualified personnel -- typically data managers, biostatisticians, or medical monitors -- remotely and systematically review accumulating trial data across all participating sites (via EDC, laboratory feeds, and other data streams), rather than verifying individual records in person at each site. It is a data-level, aggregate, cross-site review aimed at identifying which sites or subjects actually need targeted follow-up, as opposed to applying uniform monitoring effort everywhere regardless of risk. Centralized monitoring is one specific technique within the broader Risk-Based Monitoring (RBM) strategy -- a component of RBM, not synonymous with it.

Platform Trial

A platform trial is a clinical trial conducted under a single master protocol that evaluates multiple interventions against a shared control arm, for a single disease or condition, on a perpetual or long-running basis — arms can be added or dropped over time as interventions are found effective, futile, or superseded, without stopping the trial and writing a new protocol from scratch. The FDA's 2018/2022 master-protocol guidance groups platform trials alongside two related but distinct designs sharing the same master-protocol infrastructure: <a href='/dictionary/term/basket-trial'>basket trials</a> (one intervention tested across multiple diseases or molecular subtypes) and umbrella trials (multiple interventions tested for one disease, but with a fixed, pre-specified set of arms rather than an open-ended one). What makes a design a platform trial specifically, rather than a generic multi-arm study, is the combination of (1) a single overarching master protocol and statistical analysis plan governing all arms, (2) a shared, concurrently randomized control group that multiple experimental arms are compared against, and (3) a pre-specified adaptive mechanism — typically Bayesian response-adaptive randomization or interim futility/efficacy stopping rules — for adding, dropping, or reallocating arms as data accumulate.

Late-Phase Clinical Study

A late-phase clinical study is a Phase IIIb or Phase IV clinical investigation of a drug or biologic conducted at, or just after, regulatory marketing submission or approval, rather than during the pre-approval IND-governed Phase 1-3 sequence defined at 21 CFR 312.21. Late-phase studies do not primarily generate the initial efficacy/safety data needed for approval; instead they expand the evidence base after (or just before) approval, supporting label expansion, fulfilling FDA-mandated Postmarketing Requirements (PMRs) or voluntary Postmarketing Commitments (PMCs), and generating real-world evidence (RWE) and pharmacovigilance data on an approved product's safety and effectiveness in broader, real-world populations.

Sub-Investigator

A sub-investigator is a member of a clinical trial site team who is designated and supervised by the principal investigator (PI) to perform critical trial-related procedures and/or make important trial-related decisions, without themselves holding overall responsibility for the trial's conduct at that site. Under FDA regulations, the PI signs the <a href='/dictionary/term/fda-form-1572'>FDA Form 1572 (Statement of Investigator)</a> and lists sub-investigators by name as persons assisting in the investigation (21 CFR 312.53(c)); sub-investigators do not sign the 1572 themselves. What specific duties a given sub-investigator is authorized to perform is documented separately, on the site's <a href='/dictionary/term/delegation-of-authority-log'>Delegation of Authority (DoA) log</a>, which the PI is responsible for maintaining under ICH E6(R2) Section 4.1.5. Common sub-investigator duties include obtaining informed consent, conducting protocol-specified assessments, and making eligibility or safety-related clinical judgments -- but the PI retains ultimate accountability for the trial's conduct at the site under 21 CFR 312.60, regardless of which duties are delegated.

3Rs (Replacement, Reduction, Refinement)

The 3Rs -- Replacement, Reduction, and Refinement -- are the founding ethical framework for the humane use of animals in research. A protocol satisfies the 3Rs when it documents, for the specific study: (1) Replacement -- whether a non-animal or less-sentient alternative (in vitro, in silico, or lower-order organism) could answer the scientific question instead; (2) Reduction -- that the number of animals proposed is the minimum needed for a statistically and scientifically valid result, no more; and (3) Refinement -- that procedures, housing, and endpoints are designed to minimize pain, distress, and suffering for the animals that are still used. The 3Rs are not a single compliance checkbox but a standing analytic lens applied at every protocol-review stage by the Institutional Animal Care and Use Committee (IACUC).

OECD AI Principles

The OECD AI Principles are the first intergovernmental standard on artificial intelligence, adopted by OECD member and partner governments in May 2019 and updated in May 2024 to address general-purpose and generative AI. They consist of five values-based principles for trustworthy AI (inclusive growth/sustainable development/well-being; human rights, democratic values and fairness including privacy; transparency and explainability; robustness, security and safety; and accountability) plus five recommendations for policymakers (invest in AI research and development; foster an inclusive AI-enabling ecosystem; shape an enabling, interoperable governance and policy environment; build human capacity and prepare for labour-market transition; and pursue international co-operation for trustworthy AI). As of the 2024 update, 47 countries and jurisdictions adhere to the Principles, including all OECD members, the European Union, and several non-member states. A research institution or research-performing organization can treat the Principles as an operational baseline for AI governance when: (1) it can point to a documented AI risk-management or oversight process addressing all five values-based principles (not just one, e.g. privacy) as applied to a specific AI use case in the research lifecycle; (2) that process is proportionate to the AI system's stage and context of use rather than a single one-time sign-off; and (3) it is paired with actual transparency to affected parties (participants, authors, reviewers) about where and how AI was used. Simply having an internal 'AI policy' document does not, on its own, satisfy the Principles — the OECD frames them as principles for actors across the AI system lifecycle, not a checklist to file away.

Good Clinical Data Management Practices (GCDMP)

A clinical data management (CDM) process, procedure, or document is following Good Clinical Data Management Practices (GCDMP) when it is explicitly built against a specific chapter of SCDM's published GCDMP document -- covering an area such as CRF/eCRF design, database design and validation, discrepancy management, medical coding, database lock, or data transfer/archival -- and can be shown to meet that chapter's Minimum Standards tier (the baseline for defensible CDM) or its Best Practices tier (a higher-maturity level beyond the minimum). GCDMP is a practice/process standard, not software: an EDC or CDMS platform is the technology a GCDMP-conformant process typically runs through, not GCDMP itself.

Source Data Verification (SDV)

Source data verification (SDV) is the clinical-trial monitoring activity of comparing data entered on a case report form (CRF or eCRF) against the source document it was transcribed from -- a clinic note, hospital chart, lab report, imaging read, ECG tracing, or participant diary -- to confirm that the CRF entry is accurate, complete, and consistent with the original record. SDV checks a specific, already-transcribed value against its origin; it is a monitoring/quality-control activity, not a data-entry platform. Neither ICH E6 nor FDA guidance has ever required verifying 100% of CRF fields against source; since the early 2010s, regulatory guidance has explicitly encouraged sponsors to target SDV, as part of a broader risk-based monitoring (RBM) strategy, toward the data most critical to participant safety and primary trial endpoints rather than exhaustively verifying every field by default.

Congressionally Directed Funding (Earmarks)

A federal research award is Congressionally Directed Funding (commonly called an earmark, or 'Community Project Funding' / 'Congressionally Directed Spending' in current House and Senate terminology) when Congress specifies, in appropriations bill or accompanying report language, a particular recipient, project, or narrow topic area for a defined amount of budget authority — bypassing the awarding agency's normal competitive, peer-reviewed, or formula-driven selection process. It is distinguished from ordinary agency-administered research funding by the source of the selection decision: for a competitive award, the agency (via merit/peer review) decides who receives funds within a congressionally set appropriation total; for congressionally directed funding, Congress itself (or an individual member, subject to certification and disclosure rules) decides the recipient or topic before the agency ever runs a review. Once such funds reach a university or research institution, two federal anti-lobbying statutes constrain how the recipient can use any federal award dollars in connection with seeking or renewing that funding: 18 U.S.C. § 1913 and 31 U.S.C. § 1352 (the Byrd Anti-Lobbying Amendment), operationalized for grant cost allowability at 2 CFR § 200.450.

Decentralized Clinical Trial (DCT) Platform

A decentralized clinical trial (DCT) platform is the software and connected-service layer that lets some or all trial activities happen away from a traditional investigative site, in line with FDA's trial-conduct model for decentralized elements. In practice a DCT platform is not one thing but an integration of several components under a single participant- and site-facing interface: telehealth/video-visit tooling for remote investigator encounters, eConsent for remote informed consent, home health or mobile-nursing coordination for in-home visits and specimen collection, connections to local or community labs and pharmacies as alternate data-collection or dispensing sites, direct-to-patient (DtP) investigational product (IMP) shipment and chain-of-custody tracking, and eCOA/ePRO or connected devices for participant-reported and sensor-derived data — usually feeding a central EDC and safety database in real time. A trial "uses a DCT platform" when a vendor's connected toolset, rather than a single point solution, is the operational backbone for how remote or hybrid visits are scheduled, conducted, documented, and reconciled against the protocol. The defining administrative complication is that decentralizing activities does not decentralize accountability: the sponsor and the trial's IRB(s) of record remain responsible for GCP compliance, and each local nurse, telehealth clinician, lab, or pharmacy performing a delegated trial activity must be added to the delegation-of-authority log, must practice within a jurisdiction where they are licensed, and must be covered by the same monitoring and oversight expectations as staff at a traditional site.

IDE Application (Investigational Device Exemption Application)

An IDE application is the formal submission a sponsor files with FDA's Center for Devices and Radiological Health under 21 CFR 812.20 to request an Investigational Device Exemption -- FDA authorization to ship and use an unapproved medical device in a clinical study before it has been cleared or approved for commercial distribution. A full IDE application, and FDA's affirmative or default clearance to proceed, is required only for significant risk (SR) device investigations; nonsignificant risk (NSR) studies proceed on abbreviated requirements reviewed by the IRB, without a separate FDA-submitted application.

Paediatric Investigation Plan (PIP)

A Paediatric Investigation Plan (PIP) is the development plan a sponsor must agree with the European Medicines Agency's Paediatric Committee (PDCO) before an EU marketing authorisation application (MAA) can be validated, under Regulation (EC) No 1901/2006. It sets out the studies, age-appropriate formulations, and timelines needed to support use of a medicine in children, and applies to new active substances and to new indications, pharmaceutical forms, or routes of administration for already-authorised products that are still under patent or supplementary protection certificate (SPC) protection. A product is only exempt from the PIP requirement if it has a PDCO-granted waiver (full or class), if it is a generic, well-established-use, homeopathic, or traditional-herbal application under Article 10 of Directive 2001/83/EC, or if all paediatric studies are formally deferred to a later stage of development while the PIP itself is still agreed and on file.

Inventor

Under U.S. patent law, an inventor is a natural person who contributed to the conception of at least one claim of a patented (or claimed) invention, as governed by 35 U.S.C. § 116. Conception is the operative legal test, not construction, funding, supervision, or manuscript authorship: it is the formation, in that person's mind, of a definite and permanent idea of the complete and operative invention, later reduced to a form a person skilled in the art could reproduce without further inventive work. A person who only executes another's detailed instructions, provides routine technical assistance, funds the research, or supervises a lab does not become an inventor by virtue of that role alone. When two or more people jointly satisfy the conception standard, each is a joint inventor under § 116, even if they worked at different times, contributed unequally, did not work together physically, or each contributed to only some of the claims — provided each contributed to the conception of at least one claim in the resulting application. Inventorship is determined claim-by-claim and can change as claims are added, amended, or cancelled during prosecution, which is why university technology transfer offices (TTOs) routinely revisit the named-inventor list as a patent application matures.

Invention

In the university technology-transfer and Bayh-Dole context, an invention is a new and useful process, machine, manufacture, or composition of matter (or a new and useful improvement to one of those) that a researcher has conceived — formed a definite and permanent idea of the complete, operative thing in their mind, not merely identified a problem or a goal (35 U.S.C. § 101; conception standard confirmed under 35 U.S.C. § 116 joint-inventorship case law). An idea alone is not yet an invention in the legal sense used by a technology transfer office (TTO): it becomes one, for disclosure and patenting purposes, once conception is complete and can be documented — typically in a dated lab notebook entry or an <a href='/guides/invention-disclosure'>invention disclosure</a> — even before the invention has been built or tested ("reduced to practice"). Whether that invention is also a subject invention under the Bayh-Dole Act turns on funding: 35 U.S.C. § 201(e) defines a subject invention as any invention of a contractor (a university, other nonprofit, or small business) conceived or first actually reduced to practice in the performance of work under a federal funding agreement. Only subject inventions trigger Bayh-Dole's disclosure, election-of-title, and government-license obligations under 35 U.S.C. §§ 200–212; an invention made entirely on private, unrestricted funds is not a subject invention even though it may still be patentable.

Independent Data Monitoring Committee (IDMC)

An Independent Data Monitoring Committee (IDMC) is an independent group of clinical, statistical, and (where relevant) bioethics experts, external to a trial's sponsor and investigators, that periodically reviews accumulating safety and efficacy data from an ongoing clinical trial and recommends to the sponsor whether the trial should continue, be modified, or stop. 'IDMC' is the term used in EMA's dedicated guideline on the subject and, as of the January 2025 finalization of ICH E6(R3), is also the term used in the current ICH Good Clinical Practice guideline itself. It describes the same underlying body and function as a Data Safety Monitoring Board (DSMB) -- the two terms are not different oversight mechanisms but regional/institutional naming variants for one function, with IDMC more common in EU/EMA and ICH-referencing contexts and DSMB more common in NIH- and US-funded trial contexts.

Sponsor-Investigator

A sponsor-investigator is a specific FDA regulatory designation (21 CFR 312.3 for drugs/biologics; 21 CFR 812.3 for devices) for an individual -- never an institution, company, or group -- who both initiates a clinical investigation and actually conducts it, personally directing the administration, dispensing, or use of the investigational product to subjects. Because one person occupies both roles, that individual must independently satisfy the full set of sponsor obligations (21 CFR 312.50-312.59) and the full set of investigator obligations (21 CFR 312.60-312.70) under the same IND or IDE -- there is no reduced or merged standard for holding both roles at once.

Deferential Vulnerability (Research Ethics)

A type of research-subject vulnerability, identified in Kenneth Kipnis's taxonomy commissioned for the U.S. National Bioethics Advisory Commission (NBAC, 2000/2001), arising from a hierarchical or authority relationship between a prospective subject and the person recruiting or conducting the research -- formal or, more often, informal (e.g., professor/student, employer/employee, treating physician/patient, military superior/subordinate) -- in which the subject may feel unable to freely decline or withdraw from participation, whether from fear of offending the authority figure and incurring retribution or from a genuine desire to please a respected other. It is distinguished from juridic vulnerability (formal legal authority, as with incarceration) by the informality of the compelling relationship, and from population-based vulnerability categories (age, pregnancy, incarceration) by being relational and situational rather than a fixed characteristic of the subject.

45 CFR 46 Subpart D (Additional Protections for Children in Research)

The section of the Common Rule (45 CFR 46, §§46.401-46.409) that governs HHS-conducted or HHS-funded research involving children as subjects. A protocol falls under Subpart D whenever its subjects have not attained the legal age for consent to the research procedures under the law of the jurisdiction where the research will be conducted (§46.402). The IRB must classify the protocol into one of four risk categories -- no greater than minimal risk (§46.404), greater than minimal risk with prospect of direct benefit (§46.405), greater than minimal risk with no direct benefit but likely generalizable knowledge (§46.406), or research not otherwise approvable that HHS’s Secretary determines addresses a serious child-health problem (§46.407) -- and must determine what combination of parental/guardian permission and child assent is required under §46.408 before approving it.

Effort Certification

The process by which an individual with direct, first-hand knowledge of the work performed -- historically the employee themselves or a person with suitable means of verification, such as a supervisor -- attests, after the fact and typically on a periodic basis, that the percentage of salary charged to a sponsored award reasonably reflects the actual effort that person expended on that award during the certification period. Under 2 CFR 200.430 (the Uniform Guidance, effective December 26, 2014), effort certification is no longer a federally mandated, one-size-fits-all form -- it is one acceptable method an institution may build into the 'system of internal control' the regulation actually requires, which must provide reasonable assurance that salary charges are accurate, allowable, and properly allocated, and must be based on records reflecting the total activity for which the employee is compensated (not exceeding 100 percent). Institutions may instead rely on budget estimates on an interim basis, provided the estimation process produces reasonable approximations of actual activity, significant changes in work distribution are documented promptly, and the internal-control system includes periodic after-the-fact review with adjustments where needed. A federal awarding agency retains the authority to require personnel activity reports or prescribed certifications from a specific recipient if that recipient's own internal controls fall short of the standard.

Wearable Devices and Digital Health Technologies (DHTs) in Clinical Trials

A digital health technology (DHT) is defined by FDA as a system that uses computing platforms, connectivity, software, and/or sensors for healthcare and related purposes, used to collect, store, and transmit health-related data. In a clinical trial, a device or software is functioning as a DHT specifically when it is used to remotely acquire data from or about a participant that will be used to support a trial endpoint or otherwise inform a regulatory decision — not merely as a convenience app or a participant engagement tool with no bearing on the data package submitted to a regulator. Wearables (heart rate trackers, actigraphy bands, continuous glucose monitors) are the most visible category, but the term also covers non-worn sensors, implantables, and participant-facing mobile apps that capture symptom or functional data, provided that data feeds into the trial's endpoints or safety monitoring. What distinguishes a DHT from an ordinary electronic data-capture tool is the verification and validation burden it creates: a sponsor must demonstrate the technology reliably captures the intended clinical event or physiological parameter, in the population and context of actual use, before that data can support a trial conclusion.

TransCelerate GCP Mutual Recognition Program

The TransCelerate GCP Mutual Recognition Program is an industry framework, run by TransCelerate BioPharma (a nonprofit collaboration of biopharmaceutical sponsor companies), under which Good Clinical Practice (GCP) training completions from a recognized training provider are accepted by multiple participating sponsor companies rather than each sponsor requiring its own separate GCP training for the same investigator or site staff member. It sits within TransCelerate's Site Qualification and Training (SQT) initiative, which targets the duplicative questionnaires, forms, and training courses that clinical trial sites have historically had to complete separately for each sponsor and, in some cases, for each individual trial. A GCP training provider participates by self-attesting that its course meets minimum criteria aligned with ICH E6 Good Clinical Practice; providers that meet the criteria have their courses made available through TransCelerate's Shared Investigator Platform (SIP), where site staff can complete training once, upload the resulting certificate, and have participating sponsors retrieve and accept it during study start-up instead of re-verifying or re-issuing training separately. A record is a genuine instance of the program when the underlying GCP course completion was issued by a provider recognized under TransCelerate's mutual-recognition criteria and is being accepted, without separate re-training, by a second (or subsequent) participating sponsor company for a different trial or company relationship -- not merely any GCP-aligned course completion in general.

National AI Research Resource (NAIRR)

The National AI Research Resource (NAIRR) is a US federal initiative -- currently operating as the NAIRR Pilot -- that provides researchers, educators, and students with shared access to AI computational infrastructure (supercomputing and cloud allocations), AI-ready datasets, pretrained models, and educational resources, rather than direct cash funding. It is led by the National Science Foundation (NSF) in partnership with more than a dozen other federal agencies, including the Department of Energy (DOE) and National Institutes of Health (NIH), who co-lead a security-focused 'NAIRR Secure' track for sensitive data. Eligible US-based researchers, educators, and graduate students (with a faculty sponsor) apply for time-limited resource allocations -- typically a 3-month Start-Up award or a 12-month Research award -- through a competitive, proposal-based process rather than an open-access account. A project 'uses NAIRR' when it draws on the pilot's pooled portfolio of partner-provided compute, storage, or model resources under an awarded allocation; a project that purchases or funds its own AI hardware, or that uses a single university's internal HPC cluster with no NAIRR allocation, is not a NAIRR activity even if the research itself is AI-related.

Medical Monitor (Clinical Trials)

A Medical Monitor is the physician (or other appropriately qualified clinician) designated by a clinical trial sponsor or its CRO to provide ongoing, cross-site medical and safety oversight: reviewing accumulating adverse events for causality and expectedness, answering investigators' medical eligibility and protocol-interpretation questions, and flagging safety signals for the sponsor or a DSMB. The role requires medical qualification, sponsor-side (not site-based) placement with no direct participant-care relationship, and cross-site safety-judgment scope — it is a de facto function of the sponsor's safety obligations under ICH E6 and 21 CFR 312.32 rather than a term either formally defines in its own glossary.

Biosafety and Biosecurity

Biosafety and biosecurity are the two complementary risk-management frameworks that together govern institutional work with biological materials capable of causing harm. Biosafety is the set of containment practices, equipment, and facility design (see Biosafety Level (BSL)) intended to prevent accidental exposure of personnel or unintended release of a biological agent into the environment. Biosecurity is the set of physical security, access control, personnel-reliability, and material-accountability measures intended to prevent deliberate misuse, theft, loss, or diversion of biological agents or toxins -- the concern is an intentional bad actor, not an accident. A given institutional program is a biosafety-and-biosecurity program only when it addresses both halves: containment/exposure-prevention controls administered through an Institutional Biosafety Committee (IBC) under the NIH Guidelines and the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual, and security/accountability controls administered through the Federal Select Agent Program (jointly run by CDC and USDA-APHIS) for any select agent or toxin on the HHS/USDA Select Agent List, plus Dual-Use Research of Concern (DURC) review where applicable. A program that only locks containment (biosafety) without inventory control and personnel vetting for regulated agents is not biosecure; a program with strict access control but inadequate containment practice is not biosafe. The two are reviewed together but are not interchangeable and are not satisfied by the same control.

Research Integrity Officer (RIO)

The institutional official a research institution formally designates, per 42 CFR § 93.233, to administer its written research-misconduct policy: receiving allegations, conducting the initial assessment of whether they meet the fabrication/falsification/plagiarism definition and fall within institutional jurisdiction, deciding whether to open a formal inquiry, sequestering relevant research records, and appointing inquiry/investigation committees. Institutions that apply for or receive PHS support (NIH, CDC, FDA, and other Public Health Service funding) must designate an RIO as a condition of that support.

Data Safety Monitoring Plan (DSMP)

A Data Safety Monitoring Plan (DSMP) is the written document a study team develops -- usually as part of a grant application or protocol package, before a trial opens -- describing exactly how participant safety data will be monitored throughout the study: who will review the data, how often, what will be reviewed, the mechanism for reporting adverse events to the IRB, the funding agency, and (where applicable) the FDA, and the stopping rules that would trigger pausing or ending the trial. Every NIH-funded clinical trial must have a DSMP, scaled to the trial's size, complexity, and risk -- but not every DSMP requires a full independent Data Safety Monitoring Board (DSMB). A DSMP is the plan document itself; a DSMB is one possible monitoring mechanism a DSMP can specify. For lower-risk trials, the DSMP more commonly designates the principal investigator or an independent safety monitor/medical monitor as the reviewer instead of convening a formal board.

FAR 52.227-11 (Patent Rights — Ownership by the Contractor)

FAR 52.227-11, “Patent Rights—Ownership by the Contractor,” is the patent-rights clause the Federal Acquisition Regulation requires contracting officers to insert into federal procurement <a href='/dictionary/term/federal-contract'>contracts</a> awarded to small business firms and nonprofit organizations (including universities) for experimental, developmental, or research work. It is prescribed by FAR 27.303(b)(1) and is the FAR's own codification of the Bayh-Dole Act's contractor-ownership default — the contract-instrument counterpart to the 37 CFR 401.14 Standard Patent Rights Clause used in grants and cooperative agreements. A federally funded project is governed by 52.227-11, rather than 37 CFR 401.14, specifically because of which funding instrument was used (a procurement contract) rather than because the underlying substantive rights differ.

Retraction vs. Redaction

Retraction and redaction are frequently confused because both involve a publisher acting on already-published content, but they answer different questions and have different consequences for the reader. A RETRACTION withdraws an entire published work from the reliable literature: the journal or publisher determines the findings are unreliable (due to error, misconduct, duplication, or other invalidating factors), issues a public retraction notice explaining why, and the article is prominently marked as retracted while typically remaining accessible for the scholarly record (per COPE's Retraction Guidelines). A REDACTION removes or obscures specific sensitive content within a document -- personal data, classified or export-controlled information, or other legally protected material -- while the document as a whole remains published and in circulation, usually with a note indicating that specific content has been withheld and why. Retraction is a judgment about the validity or integrity of the whole work; redaction is a targeted removal of particular information from an otherwise valid, still-published work. The two are not mutually exclusive: a paper can, in principle, be both redacted (to remove sensitive data) and later retracted (if a separate integrity issue emerges), but neither implies the other.

eSource (Electronic Source Data)

Electronic source data (eSource) is clinical trial data that is first recorded in electronic form at the point of observation -- typed directly into an electronic health record (EHR), an electronic patient-reported outcome (ePRO) or clinical outcome assessment (eCOA) device, or directly into an EDC system during a study visit -- rather than being first written on paper (a clinic note, a lab printout, a paper diary) and later transcribed into an electronic system. The origination point, not the software used to store or display the data, is what makes a given data point eSource: the same EDC platform can hold both eSource data (entered live, not transcribed) and non-eSource data (transcribed from a paper source document) within the same study.

National Research Act of 1974

The National Research Act of 1974 (Public Law 93-348, signed July 12, 1974) is the U.S. federal statute that created the National Research Service Award (NRSA) training-grant program (Title I) and the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, while separately requiring federally funded institutions to use an independent review board for human-subjects research (Title II). It is the statutory origin of the modern IRB requirement and the direct cause of the Belmont Report (1979) and the Common Rule (45 CFR 46).

Researcher Development Concordat

The Researcher Development Concordat (formally the Concordat to Support the Career Development of Researchers) is a UK sector-wide agreement, first launched in 2008 and substantially revised in 2019, that sets out reciprocal commitments among research funders, research organizations (universities and institutes), and researchers themselves for improving the environment, employment conditions, and career development of researchers. An organization is treated as implementing the Concordat when it is a formal signatory, has published a public action plan addressing the Concordat's three principles, and reports progress against that plan on a defined cycle -- not merely by stating general support for researcher development.

IRB Coordinator

The IRB Coordinator (also called IRB Administrator, IRB Analyst, or Human Subjects Protection Coordinator, depending on the institution) is the staff role responsible for the administrative and operational running of an Institutional Review Board (IRB) office — protocol intake and completeness review, meeting scheduling and logistics, correspondence with investigators, tracking continuing-review and other regulatory deadlines, and maintaining the IRB's official records. It is a non-voting, non-determination-making role: the Coordinator supports the board's process but does not review protocols for approval, does not preside over convened meetings, and does not carry the IRB Chair's statutory authority to make or assign expedited-review determinations under 45 CFR 46.110 / 21 CFR 56.110.

IVD Clinical Trials (In Vitro Diagnostic Studies)

An IVD (in vitro diagnostic) clinical trial -- more precisely termed a performance study or, in FDA IDE terminology when one is required, an IVD investigation -- is a study that evaluates a diagnostic test's ability to detect, measure, or characterize a condition or analyte using specimens taken from the human body (blood, urine, tissue, swabs), rather than a study that administers a drug or activates a therapeutic device inside a patient. Because most IVD studies test specimens that have already been collected, or collect them through routine, minimally invasive means, they are regulated as a distinct category from both drug trials (governed in the US by the Investigational New Drug, or IND, pathway) and therapeutic device trials (governed by the Investigational Device Exemption, or IDE, pathway under 21 CFR Part 812). A study is an IVD clinical trial, in the sense this term is used on this site, when its object is establishing or confirming a diagnostic test's analytical performance (does the assay measure the analyte accurately and reproducibly) and/or clinical performance (does the result correlate with the clinical condition it claims to detect) -- not when it evaluates a drug's or device's direct therapeutic effect on a patient.

Commercial IRB

A commercial IRB (also called an independent IRB) is an Institutional Review Board that operates as a standalone, for-profit or non-profit business providing human-subjects ethics review as a paid, fee-for-service function -- rather than as an internal department of the university, hospital, or research institution whose studies it reviews. It is registered with OHRP and, for FDA-regulated research, meets the same 21 CFR Part 56 requirements as any other IRB; the distinguishing feature is organizational independence and a client-billing relationship with the sites and sponsors it reviews for, not a lower regulatory bar. Commercial IRBs (WCG/WIRB and Advarra are the two largest in the U.S. market) are frequently designated as the single IRB (sIRB) of record for multi-site trials, but sites also route single-site industry-sponsored studies to a commercial IRB even when no sIRB mandate applies -- typically because the sponsor requires it, the site has no local IRB, or the site's own IRB lacks capacity or relevant expertise for the study type.

Panel on Research Ethics (PRE)

The Panel on Research Ethics (PRE), formally the Interagency Advisory Panel on Research Ethics, is the body created jointly in 2001 by Canada's three federal research funding agencies (CIHR, NSERC, and SSHRC) to develop, interpret, and steward the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2) on the Agencies' behalf; it does not itself review or approve individual research protocols, which remains the role of institutional Research Ethics Boards (REBs).

UPIRSO (Unanticipated Problem Involving Risks to Subjects or Others)

A UPIRSO is an incident, experience, or outcome in human subjects research that meets all three of OHRP’s reporting criteria: it is unexpected in nature, severity, or frequency given the protocol and subject population; it is related or possibly related to participation in the research; and it suggests subjects or others face greater risk of harm than was previously known. All three prongs must be met — an event failing any one of them is not a UPIRSO under OHRP guidance, even if it is still reportable under another category such as a routine adverse event or protocol deviation. The investigator reports a suspected UPIRSO promptly to the IRB per 21 CFR 56.108(b) (FDA-regulated research) and the institution’s Federalwide Assurance procedures (federally-supported research generally); the institution may then have a further obligation to report certain UPIRSOs to OHRP and the supporting federal agency, on a timeframe set by its own written policies rather than one fixed federal number of days.

International Confidentiality Agreement

A confidentiality agreement (NDA) between parties in different countries, which requires provisions a purely domestic NDA does not: export-control screening of the disclosed information for deemed-export risk, a deliberately chosen governing-law/jurisdiction/dispute-resolution clause that will actually be enforceable across the relevant borders, and, when the confidential information includes personal data, transfer safeguards that satisfy the data-protection law of the disclosing party's jurisdiction (most commonly GDPR Chapter V).

Model Clinical Trial Agreement (mCTA)

A Model Clinical Trial Agreement (mCTA) is a standardized, pre-negotiated template Clinical Trial Agreement published by a national body, funder, or multi-institutional consortium, and intended to be used with little or no clause-by-clause negotiation for each new trial. Adopting sponsors and sites fill in trial-specific variables (protocol reference, budget schedule, site details) against core legal language -- indemnification, IP allocation, publication rights, data ownership -- both sides have already pre-agreed is acceptable. It is defined by the contracting strategy (a fixed starting point institutions commit in advance to accept largely unmodified), not by any single clause, since CTA content itself varies by jurisdiction.

Horizon Europe Article 19 (Ethics)

Article 19 of Regulation (EU) 2021/695 is the Horizon Europe framework Regulation's general ethics clause: it requires all Horizon Europe-funded actions to comply with ethical principles and applicable EU/national/international law, mandates a proposal-stage ethics self-assessment plus Commission screening and, where warranted, a formal ethics assessment (automatic for any action involving human embryonic stem cells or embryos), requires participating entities to hold and keep on file all required national/institutional ethics and data-protection approvals before starting the relevant activity, allows ethics checks during a project's lifetime, and excludes certain fields of research (human reproductive cloning, heritable germline genetic modification, and creating human embryos solely for research or stem-cell procurement) from funding altogether.

Good Publication Practice (GPP)

Good Publication Practice (GPP) is a named, industry-authored set of ethics guidelines for planning, writing, and publishing company-sponsored biomedical research -- primarily pharmaceutical, biotechnology, and medical-device studies. It is maintained by a GPP Steering Committee working with ISMPP (the International Society for Medical Publication Professionals) and published as a peer-reviewed article in Annals of Internal Medicine. The current version is GPP 2022, which superseded GPP3 (2015); GPP3 itself superseded the original GPP2 (2009) and GPP (2003). A study, manuscript, or publication process is GPP-compliant when: authorship is assigned strictly against ICMJE's four authorship criteria (not honorary, guest, or ghost authorship); the funding source and the sponsor's role in study design, analysis, and the decision to publish are disclosed; any professional medical writer's involvement is named and their support disclosed, typically in the acknowledgements; named authors have full access to the data (or a summary sufficient to vouch for it) and control over interpretation and the final decision to publish; and there is a documented intent to publish results regardless of outcome, including negative or inconclusive findings.

Horizon Europe Article 39 (Open Access)

Article 39 of Regulation (EU) 2021/695, the Horizon Europe framework regulation, is the legal provision that creates the programme's binding open science obligations for grant beneficiaries. It has two strands: (1) mandatory immediate open access to peer-reviewed scientific publications resulting from Horizon Europe funding, with no embargo period, licensed under the latest version of Creative Commons Attribution (CC BY) or an equivalent licence (a narrower exception permits CC BY-NC or CC BY-ND for monographs and other long-form outputs); and (2) responsible management of research data under the FAIR principles and the default that data should be 'as open as possible, as closed as necessary,' subject to documented, justified exceptions for IP, personal data, confidentiality, or security. Horizon Europe Grant Agreements incorporate both strands as binding funding conditions, not discretionary guidance.

European Code of Conduct for Research Integrity

The European Code of Conduct for Research Integrity is a specific, named document — not a general principle or a professional network — published by ALLEA (All European Academies), the federation of European academies of sciences and humanities. First issued in 2011 (jointly with the European Science Foundation), it was revised in 2017 and again in 2023. It sets out four principles — reliability, honesty, respect, and accountability — and translates them into good research practices covering research design, data management, methodology, authorship, publication, and peer review, alongside a taxonomy of research misconduct and other research integrity violations. A document or practice is 'covered' by the Code when it is cited as the reference standard in a funding agreement, institutional policy, or national code — most consequentially, the European Commission recognises the Code as the primary research-integrity standard for Horizon Europe, and it is incorporated by reference in the Horizon Europe Model Grant Agreement, making adherence a binding condition of EU research funding rather than a voluntary aspiration.

Horizon Europe Article 7: Gender Equality Plan (GEP)

Article 7 of the Horizon Europe framework regulation (Regulation (EU) 2021/695) makes gender equality a cross-cutting priority of the programme and is the legal basis for the Gender Equality Plan (GEP) eligibility criterion: for Horizon Europe calls with submission deadlines from 2022 onward, public bodies, higher education establishments, and research organisations established in an EU Member State or an Associated Country must have a GEP (or an equivalent gender equality strategy) in place to be eligible to receive funding. It is a legal entity-level eligibility check, not a proposal-evaluation criterion -- an applicant either has a qualifying GEP on file or it does not, and non-compliant public-body, HEI, or research-organisation applicants are ineligible for that call regardless of the scientific merit of their proposal. Private, for-profit entities (companies, including SMEs) are exempt from the requirement.

42 CFR Part 11

42 CFR Part 11 is the federal regulation, titled "Clinical Trials Registration and Results Information Submission," that codifies the ClinicalTrials.gov registration and results-reporting requirements originally created by Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801). Issued by HHS as a Final Rule and effective 18 January 2017 (compliance expected by 18 April 2017), it converts FDAAA 801's statutory mandate into binding, enforceable regulatory text: who counts as the "responsible party" for a trial, which trials are "applicable clinical trials" (ACTs) subject to the rule, the specific data elements and deadlines for registration and results submission, and FDA's civil monetary penalty authority for noncompliance. A trial is governed by 42 CFR Part 11 only if it meets the regulation's ACT definition; broader definitions used by ICMJE or by NIH's own separate results-reporting policy can require registration or reporting for trials that fall outside Part 11's narrower scope.

Investigational New Drug (IND)

A drug or biologic that FDA has authorized, via an active IND application under 21 CFR Part 312, to be shipped and administered to human subjects in a clinical investigation before it has received marketing approval — or an already-approved drug being studied outside the bounds of its approved labeling in a way that meets the triggering criteria in 21 CFR 312.2(b). The term refers interchangeably to the drug's regulatory status, the sponsor's application establishing that status, and the FDA-assigned number the study operates under.

Dual-Use Research of Concern (DURC)

Research is DURC only when it meets a two-part US Government test: it involves one of 15 enumerated select agents/toxins, AND it is reasonably anticipated to produce an outcome in one of seven defined categories of experimental concern (e.g., enhancing transmissibility/virulence, conferring resistance to countermeasures). DURC review by an institution's Institutional Review Entity/IBC is complementary to, not a substitute for, routine biosafety containment review.

Research Animal

An animal that is used, or intended for use, in research, research training, testing, or experimentation, and that therefore falls under one or both of two overlapping US regulatory frameworks: the Animal Welfare Act (which reaches warm-blooded species other than purpose-bred rats, mice, and birds) and PHS Policy on Humane Care and Use of Laboratory Animals (which reaches any live vertebrate used in PHS/NIH-funded work, including species the AWA excludes). Whether a specific animal is a "research animal" for compliance purposes depends on which framework applies to it and to the funding/registration status of the institution using it.

USPTO Office of Enrollment and Discipline (OED)

The Office of Enrollment and Discipline (OED) is the office within the U.S. Patent and Trademark Office's Office of the General Counsel that controls who may represent inventors and applicants before the USPTO in patent matters. It performs two distinct functions: (1) it administers registration -- reviewing each applicant's scientific/technical qualifications, developing and administering the registration examination (the 'patent bar exam'), and maintaining the official roster of registered patent attorneys and patent agents -- and (2) it investigates grievances and administers discipline (from a warning through suspension or exclusion) against practitioners who violate the USPTO Rules of Professional Conduct (37 CFR Part 11). An individual is a 'registered patent practitioner' only if OED has admitted them to practice and their name remains on the active roster; passing a state bar exam alone does not confer patent-prosecution authority, and OED registration alone does not confer authority to give general legal advice, draft licenses, or litigate -- those require a state law license, which is why a registered practitioner is either a 'patent attorney' (also a licensed attorney) or a 'patent agent' (not a lawyer, authorized only to prosecute patent applications before the USPTO).

Nuremberg Code

The Nuremberg Code is a ten-point statement of ethical principles for research involving human subjects, set out in the August 19, 1947 verdict of the U.S. military tribunal in United States v. Karl Brandt et al. (the 'Doctors' Trial') at Nuremberg. It is the operative reference point for a claim that a given human-subjects study meets the minimum ethical floor for legitimate research: the study is judged against the Code when its consent process, scientific justification, and risk controls are being assessed retrospectively as a historical or foundational benchmark, distinct from applying a current regulation such as the Common Rule or an IRB's own protocol-specific determination. Its first and most influential point establishes that the voluntary, informed consent of the human subject is 'absolutely essential' -- the earliest internationally recognized statement of that requirement, and the direct conceptual ancestor of informed-consent requirements in every later research-ethics code and regulation.

45 CFR 164.512(i) (HIPAA Uses and Disclosures for Research Purposes)

The provision of the HIPAA Privacy Rule, at 45 CFR 164.512(i), that permits a covered entity to use or disclose protected health information (PHI) for research without the individual's written authorization, through one of three specific pathways: (1) an Institutional Review Board (IRB) or Privacy Board has approved a waiver or alteration of authorization under the documented criteria at 164.512(i)(1)(i) and (i)(2); (2) the researcher represents the use is solely a review preparatory to research and no PHI will be removed from the covered entity; or (3) the researcher represents the use is solely for research on a decedent's information. A disclosure only qualifies under 164.512(i) if it fits one of these three pathways exactly as documented — it is not a general research exception.

Risk-Benefit Analysis

Risk-benefit analysis is the determination an IRB or REC must make, under the Belmont Report's Beneficence principle and its codification at 45 CFR 46.111(a)(1)-(2), that (1) risks to research participants have been minimized through sound research design, and (2) the residual risks are reasonable in relation to the study's anticipated benefits to participants, if any, and the importance of the resulting knowledge. It is a mandatory precondition for IRB approval, made by the board itself before a study proceeds -- distinct from informed consent, which discloses those already-evaluated risks and benefits to participants so each can decide individually whether to accept them.

Data Transfer Agreement (DTA)

A contract governing the mechanics of transferring a dataset between institutions -- authorised senders and recipients, transmission and security method, and destruction-or-return terms -- distinct from a Data Use Agreement's downstream use restrictions and a Material Transfer Agreement's coverage of physical materials.

ISRCTN

ISRCTN — originally an acronym for International Standard Randomised Controlled Trial Number, now used as the registry's own name — is a UK-based clinical study registry that assigns a permanent, unique identifier (an ISRCTN number) to a study at or before its start. A study qualifies as "ISRCTN-registered" when its investigator or sponsor has submitted the required minimum data set (design, intervention, population, primary/secondary outcomes, sponsor, funder) through isrctn.com, the entry has passed the registry's validation checks, and it has been assigned a permanent identifier in the format ISRCTN followed by an eight-digit number (for example, ISRCTN12345678). Unlike its original RCT-only scope, ISRCTN now accepts any study assessing the effect of a health intervention on a human population, including non-randomised interventional studies and some observational designs — the acronym is retained for historical/branding reasons but no longer describes the registry's actual scope.

eConsent (Electronic Informed Consent)

eConsent (electronic informed consent) is the use of an electronic system, often incorporating multimedia such as video or interactive comprehension checks, to present IRB-approved informed consent information and capture a participant's electronic signature in place of a paper form. A process counts as eConsent when it delivers the required consent content electronically, preserves a genuine opportunity for the participant to ask questions before signing, captures an attributable electronic signature that is time-stamped and non-detachably linked to the specific document version reviewed, and provides the participant a copy of the signed consent. For FDA-regulated clinical investigations, the electronic signature must meet 21 CFR Part 11's criteria; FDA and OHRP's December 2016 joint guidance additionally recommends that IRBs review the electronic process and interface itself, not just the consent language.

ICH Q1 (Stability Testing Guidance)

ICH Q1 is the International Council for Harmonisation's guideline series covering the stability testing that establishes a drug substance's or drug product's shelf-life (expiration dating period), retest period, and required storage/labeling conditions. The historical Q1 series — Q1A(R2) (stability testing of new drug substances and products, revised 2003), Q1B (photostability testing, 1996), Q1C (stability testing for new dosage forms, 1996), Q1D (bracketing and matrixing study designs, 2002), and Q1E (evaluation of stability data, 2003) — together with the biotechnology/biological product stability guideline Q5C (1995), remain the operative reference guidance as of this writing. ICH is consolidating the entire series (plus Q5C) into a single revised Q1 guideline, extended in scope to cover both synthetic and biological products; that consolidated draft reached ICH Step 2b (public consultation) on 11 April 2025 and has not yet reached Step 4 (final guideline) — until it does, and each region formally adopts it, the existing Q1A-Q1E/Q5C texts remain the applicable standard.

FFATA Reporting

FFATA reporting is the mandatory disclosure of subaward and executive-compensation information required under the Federal Funding Accountability and Transparency Act of 2006. A prime recipient of a federal award (or a pass-through entity issuing subawards under it) must report each subaward action of $30,000 or more in federal funds through SAM.gov (successor to the retired FSRS.gov, migrated around March 2025), by the end of the month following the month in which the obligation was made. Recipients meeting a two-part revenue test must also report the compensation of their five most highly compensated executives. The reporting obligation sits with the pass-through entity, not the subrecipient, and the resulting data feeds USASpending.gov for public transparency.

Tuskegee Syphilis Study

The Tuskegee Syphilis Study refers specifically to the U.S. Public Health Service's Study of Untreated Syphilis in the Negro Male, conducted in Macon County, Alabama from 1932 to 1972, in which roughly 600 Black men (399 with latent syphilis, 201 as an uninformed control group) were enrolled without being told their actual diagnosis or the study's purpose, and were denied treatment -- including penicillin once it became the standard cure in the 1940s -- so researchers could observe the untreated disease's natural progression. The term is invoked today as the specific, documented U.S. case of research conducted without informed consent, through active deception, targeting a vulnerable population defined by race, and involving the deliberate denial of available treatment; its 1972 public exposure is the direct legislative trigger for the National Research Act of 1974 and, through the National Commission it created, the 1979 Belmont Report.

ICH E6(R2) (Good Clinical Practice, 2016 Addendum)

ICH E6(R2) is the 2016 integrated addendum to ICH's original E6(R1) (1996) Good Clinical Practice guideline, reaching ICH Step 4 on 9 November 2016 and adopted as final FDA guidance on 1 March 2018. It layers new provisions onto (not replacing) E6(R1): a new Section 5.0 (Quality Management, including risk-based quality management and quality tolerance limits) and a revised Section 5.18 (Monitoring, formally recognizing centralized and risk-based monitoring alongside traditional on-site visits). It was superseded as ICH's current core guideline by ICH E6(R3) (Principles + Annex 1 finalized January 2025), but remains the applicable GCP text for any trial, institution, or jurisdiction that has not transitioned to E6(R3), including many trials authorized and still running under it.

NIH Genomic Data Sharing (GDS) Policy

A study falls under NIH's Genomic Data Sharing (GDS) Policy (2014) when it is NIH-funded and generates large-scale human or non-human genomic data (GWAS, SNP arrays, WGS/WES, transcriptomic, epigenomic, metagenomic, or gene-expression data). Covered human-data studies must use GDS-specific prospective informed consent language, obtain an Institutional Certification from the awardee institution (via its Signing Official, in coordination with the IRB) confirming consistency with participant consent, and submit data to an NIH-designated controlled-access repository -- dbGaP for most human genomic data -- under a Data Use Certification Agreement. The GDS Policy predates and operates alongside, not inside, the broader 2023 NIH Data Management and Sharing (DMS) Policy.

AAHRPP (Association for the Accreditation of Human Research Protection Programs)

AAHRPP is an independent, non-profit accrediting body that reviews and certifies an institution's entire Human Research Protection Program (HRPP) -- not an individual researcher, and not a single IRB committee in isolation, but the full organizational system of policies, procedures, and oversight structures that protects human research participants. Accreditation is voluntary and organizational-level: an institution (a university, hospital, independent IRB, government agency, or research organization) applies, undergoes a self-assessment against AAHRPP's published standards, and is then peer-reviewed by a site visit team of experienced research-protection professionals before AAHRPP's Council on Accreditation makes a determination. A program either holds current AAHRPP accreditation or it does not -- there is no equivalent to an individual passing an exam. This is the key distinction from an individual credential such as CIP (Certified IRB Professional) or from completing required human-subjects training through a platform like CITI: those attach to a person; AAHRPP accreditation attaches to the institution's program as a whole.

CRADA (Cooperative Research and Development Agreement)

A formal, written collaborative R&D agreement between one or more federal laboratories and one or more non-federal parties, authorized under the Federal Technology Transfer Act (15 U.S.C. 3710a), under which the federal laboratory may contribute personnel, services, facilities, equipment, or intellectual property (but never funds) while the non-federal partner may contribute funding, personnel, or other resources toward a jointly performed, mission-consistent research effort.

Priority Review Voucher (PRV)

A priority review voucher (PRV) is a transferable FDA incentive awarded when a sponsor wins approval of a qualifying drug or biologic under the rare pediatric disease PRV program (FD&C Act section 529) or the tropical disease PRV program (FD&C Act section 524). The voucher lets its holder — the original sponsor or a company it is sold to — redeem it for priority review (a six-month FDA review goal) instead of standard review (a ten-month goal) on a different, later marketing application.

Research (45 CFR 46.102(l))

Under the Common Rule, "research" is a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge (45 CFR 46.102(l)). An activity is IRB-reviewable human-subjects research only if it meets this systematic-investigation/generalizable-knowledge test AND separately involves a "human subject" under 46.102(e); an activity can be highly systematic and still fall outside the definition if it isn't designed to produce generalizable knowledge (the basis for excluding most quality-improvement and program-evaluation work), or if it falls into one of four categories the regulation expressly deems not to be research: scholarly/journalistic activities, public health surveillance, criminal-justice data collection, and authorized national-security operations.

TCPS2 Chapter 9 (Research Involving Indigenous Peoples)

TCPS2 Chapter 9 is the section of Canada's Tri-Council Policy Statement (TCPS 2, 2022) interpreting how the Policy's core ethical principles apply to research involving First Nations, Inuit, and Métis peoples: it calls for community engagement, a documented research agreement, and, where a recognized community authority exists, review at both the institutional REB and community level before recruitment or data collection begins.

21 CFR Part 50 (Protection of Human Subjects)

21 CFR Part 50 is the FDA's own human-subjects protection regulation. It applies to clinical investigations of products that fall under FDA's regulatory jurisdiction under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act -- drugs, biologics, and medical devices for human use -- regardless of who funds the study. It sets the informed-consent requirements FDA holds sponsors and investigators to (Subpart B), and adds extra safeguards when children are enrolled (Subpart D). A study triggers Part 50 when it is 'regulated by FDA' under sections 505(i) or 520(g) of the FD&C Act (i.e. it supports or could support an IND or IDE, or the drug/device is otherwise subject to FDA jurisdiction) -- not because a federal agency is paying for it. That funding-vs-jurisdiction distinction is what separates Part 50 from 45 CFR 46 (the Common Rule), and many trials involving both a federal funder and an FDA-regulated product must satisfy both simultaneously.

Patent Exhaustion Doctrine

Patent exhaustion (the patent first-sale doctrine) holds that once a patent owner, or someone the patent owner has authorized, sells a patented item, the patent owner's exclusive rights over that specific item are exhausted -- the purchaser and any later owner may use, repair, or resell it without committing patent infringement, regardless of restrictions the patentee attaches to the sale. Under Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017), this applies to authorized sales anywhere in the world, not just U.S. sales, and any post-sale restriction the patentee wants to enforce has to be pursued as a contract claim against the buyer, not a patent infringement claim.

Trial Master File (TMF)

The Trial Master File (TMF) is the complete, organized collection of essential documents that individually and collectively permit evaluation of the conduct of a clinical trial and the quality of the data it produced, as defined by ICH E6(R2) Section 8. A document belongs in the TMF if it is on the ICH E6 essential-documents list (or a sponsor's/site's approved TMF index derived from it) and falls into one of three time-based groupings: documents generated before the clinical phase begins (protocol, investigator's brochure, IRB/IEC approval, signed agreements), documents generated during the conduct of the trial (protocol amendments, monitoring visit reports, informed consent forms, drug/device accountability records, adverse event reports), and documents generated after the trial is completed or terminated (final study report, subject identification code list, audit certificate). A sponsor maintains a central TMF; each investigator site maintains a parallel Investigator Site File (ISF) covering the same essential-document categories at site level. Today the TMF is almost always maintained electronically as an eTMF, commonly organized using the TMF Reference Model's zone/section/artifact taxonomy rather than an ad hoc folder structure.

IND-Enabling Studies

IND-enabling studies are the package of nonclinical (preclinical) pharmacology, pharmacokinetics/ADME, and toxicology studies a sponsor must complete before filing an <a href='/dictionary/term/investigational-new-drug-ind'>Investigational New Drug (IND)</a> application with FDA. Their purpose is narrow and specific: to generate the data supporting a reasonable expectation that the drug can be tested safely in humans at a defined starting dose, not to demonstrate efficacy or complete the full nonclinical program a marketing application will eventually require. The scope and design of the package is governed principally by <a href='https://www.fda.gov/media/71542/download' target='_blank' rel='noopener'>ICH M3(R2)</a>, "Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals," which FDA has adopted as guidance.A study is IND-enabling if its data is used to support the safety rationale in an IND submission's pharmacology/toxicology section (21 CFR 312.23(a)(8)) — as distinct from later-stage nonclinical studies (e.g., carcinogenicity, reproductive toxicology at later phases) conducted after first-in-human dosing has already begun, which support later clinical phases or the eventual marketing application rather than the initial IND filing itself.

HHS Grants Policy Statement (HHS GPS)

The HHS Grants Policy Statement (HHS GPS) is the U.S. Department of Health and Human Services' department-wide reference document setting out the general terms and conditions that apply to HHS discretionary grant and cooperative agreement awards. It is issued and maintained by HHS's Division of Policy, Oversight, Evaluation, and Training (DPOET), within the Office of the Assistant Secretary for Financial Resources (ASFR), and is incorporated by reference into the Notice of Award for HHS discretionary awards it covers. Critically, the HHS GPS is not universal across every HHS component: the National Institutes of Health maintains its own, separate <a href='/dictionary/term/nih-grants-policy-statement'>NIH Grants Policy Statement (NIH GPS)</a>, and NIH awards are governed by that document rather than the HHS GPS. Other HHS operating divisions -- including CDC, HRSA, SAMHSA, AHRQ, and ACF -- use the HHS GPS as their primary grants policy document, in each case supplementing it with their own agency-specific program guidance where needed.

FDA Adverse Event Reporting System (FAERS)

A post-marketing surveillance database maintained by the U.S. Food and Drug Administration that collects reports of adverse events and medication errors associated with drugs and biologics already on the U.S. market. FAERS is fed by two distinct report streams: mandatory reports that drug and biologic manufacturers (application holders) are legally required to submit under 21 CFR 314.80 and 21 CFR 600.80, and voluntary reports submitted through MedWatch, FDA's Safety Information and Adverse Event Reporting Program, by healthcare professionals, patients, and consumers. FAERS is scoped to drugs and biologics only: vaccine adverse events go to VAERS (co-managed by CDC and FDA), device events go to MAUDE, and the EU's structural counterpart is EudraVigilance. It is also operationally distinct from the pre-market Investigational New Drug (IND) safety reporting obligations under 21 CFR 312.32: FAERS covers a marketed product's real-world use after approval, not an investigational product still under a trial protocol.

Active Substance Master File (ASMF)

An EU/EEA regulatory submission format for a single active substance's manufacturing and quality-control data, split into a non-confidential Applicant's Part (submitted as part of a marketing authorisation application or IMPD) and a confidential Restricted Part (submitted directly to the competent authority by the active-substance manufacturer), and referenced by — never substituting for — the medicinal-product submission it supports.

FDA Recognized Consensus Standards

An FDA Recognized Consensus Standard is a voluntary standard developed by a recognized standards development organization (SDO) -- such as ISO, ASTM International, AAMI, IEC, or CLSI -- that FDA has formally reviewed and added to its 'Recognized Consensus Standards: Medical Devices' database. A standard qualifies as an instance of this category only once FDA has completed its own review and listed it (with a recognition number and a stated extent of recognition -- full, partial, or recognized with FDA-identified deviations); merely being a published ISO/ASTM/AAMI standard, or being commonly cited in industry practice, is not sufficient on its own. Recognition lets a device manufacturer submit a Declaration of Conformity (DoC) to that standard in a premarket submission -- attesting the device conforms (in full or with disclosed deviations) and providing a summary of test methods and results -- rather than submitting the full underlying test data for independent FDA review. The legal basis is Section 514 of the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Modernization Act of 1997 (FDAMA), which directed FDA to establish this recognition process specifically to reduce duplicative review burden for both industry and the agency. FDA can also withdraw or limit recognition (for example when a standard is superseded by a newer edition), so the database -- not the standard's existence or prior use -- is the authoritative, current record of what may be cited via a DoC at any given time.

Safety Data Exchange Agreement (SDEA)

A Safety Data Exchange Agreement (SDEA) is a written contract between two or more legally distinct parties who share development, marketing, licensing, distribution, or co-promotion rights to the same medicinal product, defining how each party will exchange safety information -- adverse event and adverse drug reaction reports, product complaints with a safety component, literature findings, and aggregate safety reports -- so that each party can independently meet its own national and regional pharmacovigilance reporting obligations. An agreement qualifies as an SDEA (rather than some other contract) when it specifies, at minimum: which party holds which pharmacovigilance responsibilities (case intake, medical review, causality assessment, expedited and periodic reporting, literature surveillance, signal detection); the format and timelines for exchanging individual case safety reports (ICSRs) and aggregate reports such as PSURs between the parties, typically set tighter than the underlying regulatory deadlines to leave room for each party's own downstream submission; reconciliation procedures to confirm no cases were missed on either side; and named contacts, including each party's Qualified Person Responsible for Pharmacovigilance (QPPV) where EU obligations apply. SDEAs are prepared with reference to ICH E2A/E2B/E2D definitions and reporting standards and, in the EU, to the EMA's Good Pharmacovigilance Practices (GVP) modules; they can be bipartite (two parties) or tripartite (three, e.g. when a contract research organization or specialty distributor is also party to the arrangement).

Limited Data Set (HIPAA)

A dataset qualifies as a HIPAA limited data set under 45 CFR 164.514(e) when a covered entity removes the 16 direct identifiers enumerated at 164.514(e)(2) (names, contact details, medical record/account/certificate numbers, device and biometric identifiers, full-face photos, and similar) while retaining permitted indirect identifiers -- full dates and geographic subdivisions down to town, city, state, and zip code -- and discloses the resulting dataset only for research, public health, or health care operations to a recipient who has signed a Data Use Agreement restricting its use, access, safeguarding, and redisclosure, and prohibiting re-identification attempts. It remains protected health information (PHI) and stays subject to the Privacy Rule, unlike data that has been fully de-identified under 164.514(a)-(b).

Independent Ethics Committee (IEC)

An Independent Ethics Committee (IEC) is the international/non-US regulatory term for the independent body that reviews and approves a clinical trial's protocol, informed consent materials, investigator qualifications, and facilities before enrollment begins, and continues to oversee the trial's ethical conduct throughout its life, to protect the rights, safety, and wellbeing of trial participants. It performs the identical core function as a US Institutional Review Board (IRB): both are independent bodies of medical, scientific, and non-scientific members that review research involving human subjects against the same underlying principles in ICH E6 Good Clinical Practice (GCP). The two terms describe the same regulatory role arising from different national and regional legal traditions, not two different sets of responsibilities -- which is why ICH E6(R2) and industry practice almost always write the pairing as a single unit, 'IRB/IEC.'

New Approach Methodologies (NAMs)

A technology or method (in vitro assay, organ-on-chip/microphysiological system, in silico/computational model, or human-relevant cell-based model) developed or applied specifically to generate safety/efficacy data in place of, or alongside, an animal study a regulatory pathway would otherwise require or expect. The "new approach" framing is relative to the existing animal-testing default in a given regulatory pathway (principally FDA drug/biologic review), not a general claim of scientific novelty for the underlying technology itself.

Concordat on Open Research Data

The Concordat on Open Research Data is a UK sector-wide policy framework, published 28 July 2016 by the Higher Education Funding Council for England (HEFCE), Research Councils UK (RCUK, since absorbed into UK Research and Innovation, UKRI), Universities UK, and the Wellcome Trust, setting out ten principles for how researchers, research organisations, and funders should approach making research data openly available. It is not a regulation, mandate, or legal instrument: an institution, funder, or research group operationalises the Concordat when its research data policy, Data Management Plan (DMP) guidance, or grant terms explicitly build in the ten principles — for example, requiring a documented, case-by-case justification for any restriction on data openness (Principle 2), recognising a researcher's right to a reasonable first-use period before data must be shared (Principle 4), or expecting data underlying a publication to be accessible, citable via a persistent identifier, and retained for at least ten years from the publication date (Principle 8).

Research Pharmacy (Investigational Drug Service, IDS)

A research pharmacy — also called an Investigational Drug Service (IDS) — is the specialized pharmacy unit responsible for the receipt, storage, accountability, preparation, dispensing, and (where applicable) return or destruction of investigational products used in clinical trials, operating under the protocol and Good Clinical Practice (GCP) rather than under routine hospital-formulary dispensing rules. A pharmacy operation qualifies as a research pharmacy when it (1) receives and stores investigational product under sponsor- and manufacturer-specified conditions separate from commercial stock, (2) maintains a full chain-of-custody accountability record for every unit from receipt through final disposition, (3) dispenses only against a valid protocol-specific order tied to subject eligibility and randomization assignment, and (4) where the trial is blinded, restricts access to the randomization code to designated unblinded staff who function independently of the study team members assessing outcomes.

FDA Form 356h

FDA Form 356h ("Application to Market a New or Abbreviated New Drug or Biologic for Human Use") is the standardized cover form an applicant files with a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA). It identifies the applicant and product, states the application type and submission type (original, resubmission, or supplement), indexes the enclosed technical sections, and carries the signed certification statements required for FDA to accept the submission for review. It applies only to drug/biologic marketing applications reviewed by CDER or CBER -- it is not used for medical device submissions, which use a separate CDRH cover sheet (Form 3514).

FDA Priority Review

FDA Priority Review is a designation FDA assigns to a marketing application (a New Drug Application, Biologics License Application, or efficacy supplement) for a drug or biologic that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition, compared with available therapy. A Priority Review designation sets FDA's internal review-clock goal at 6 months from the filing date for a first review cycle, instead of the 10-month goal that applies to a Standard Review application. It is one of FDA's four expedited programs for serious conditions, alongside Fast Track, Breakthrough Therapy designation, and Accelerated Approval, but unlike the other three it is a review-timeline classification tied to a completed application rather than a designation sponsors typically request earlier in development.

IRB Chair

The IRB Chair is the IRB member designated to preside over the board's convened meetings and to personally conduct, or assign to an experienced board member, expedited-review determinations under 45 CFR 46.110 / 21 CFR 56.110 -- distinct from a regular voting IRB member (no presiding or independent expedited-review authority) and from the institution's Designated Institutional Official / FWA-signing Institutional Official (an institution-wide compliance-commitment role, not a board-review role).

Bring Your Own Device (BYOD) for Research Data Collection

In research data collection, BYOD (bring your own device) is a practice in which participants or researchers use their own personally-owned smartphone, tablet, or wearable -- rather than a device supplied, configured, and owned by the study -- to run a data-collection app or sensor. What makes an instance BYOD is device ownership and control: the hardware belongs to the participant or researcher, not the study team, so the study cannot fully standardize, lock down, or reclaim it, and must build its data-integrity and security controls around that constraint.

Inducements in Research (Undue Inducement)

An inducement is any payment, benefit, or opportunity a researcher offers to encourage a prospective participant to enroll in or remain in a study. Offering compensation is not itself a problem: the Belmont Report's respect-for-persons and beneficence principles, and their regulatory implementation at 45 CFR 46.116(a)(1) (Common Rule) and 21 CFR 50.20 (FDA), treat reasonable payment for time and burden as compatible with voluntary consent. An inducement becomes an undue inducement when its size or structure is large enough, or contingent enough, to impair a prospective participant's ability to weigh the study's risks and benefits rationally -- functioning as pressure to enroll or stay enrolled rather than as compensation for burden. Under 45 CFR 46.111(b), an IRB must determine that consent will be sought under circumstances that minimize the possibility of coercion or undue influence; review of the payment plan (amount, schedule, and any completion contingency) is the concrete mechanism through which that determination gets made for offers of payment specifically.

Risk Indicators and Risk Thresholds

A risk indicator is a specific, observable fact about an applicant, recipient, or subrecipient that correlates with an elevated likelihood of noncompliance, financial mismanagement, or poor performance on a federal award — for example, a prior single audit finding, financial instability, a new or first-time awardee with no federal-award history, or an irregular or unnegotiated F&A (indirect cost) rate. A risk threshold is the predetermined materiality level at which an accumulation or severity of risk indicators requires an awarding agency or pass-through entity to escalate its oversight response — from routine monitoring to enhanced monitoring, imposition of specific award conditions, or formal high-risk designation. Together they form the operating vocabulary of risk-based monitoring: instead of applying identical oversight to every award in a portfolio, an agency or institution calibrates monitoring intensity to where the indicators and thresholds say the actual risk is concentrated.

Clinical Study Report (CSR)

A Clinical Study Report (CSR) is the comprehensive, standalone document summarizing the design, conduct, and results of a single clinical trial, prepared in the format defined by ICH E3 (Structure and Content of Clinical Study Reports) so that any ICH regulatory authority can evaluate the trial on its own terms. A document qualifies as a CSR, rather than a lesser trial-reporting artifact, when it (a) integrates the full trial narrative -- objectives, methods, efficacy and safety results, and statistical analyses -- into one report keyed to a specific protocol, and (b) is structured to ICH E3's numbered outline (title page; a roughly three-page synopsis; ethics; investigators; introduction; study objectives; investigational plan; study patients; efficacy and safety evaluation; discussion and conclusions; tables, figures, and appendices), whether or not every section header is used verbatim. A CSR is compiled after database lock, once the trial's data are final, and is submitted to regulators as part of a marketing application (e.g., an NDA, BLA, or MAA) rather than published as an independent research output.

CAP Biorepository Accreditation Program (CAP-BAP)

The CAP Biorepository Accreditation Program (CAP-BAP) is a voluntary, formal accreditation program run by the College of American Pathologists (CAP), established in 2012 as the first accreditation program specifically for biorepositories. A biorepository is accredited when it undergoes and passes an on-site peer-inspection assessment against a defined set of CAP accreditation checklists covering the Biorepository-specific checklist plus the shared Laboratory General, Director Assessment, and All Common checklists, is re-inspected on-site every two years, and completes a self-inspection using the same checklists in the intervening off-year. The checklists address consent and protection of research participants, specimen collection and chain of custody, institutional governance documents such as material transfer agreements, and long-term preservation infrastructure (equipment maintenance, temperature monitoring, backup systems). CAP-BAP draws on guidance from ISBER, the NCI, and the OECD in building its checklists but is itself a distinct, CAP-branded accreditation credential, not a re-badging of either.

ICF (Informed Consent Form)

The specific written document, IRB-approved before use, that restates a study's required disclosure elements (45 CFR 46.116(b)-(c); for FDA-regulated research, 21 CFR 50.25) for a prospective participant to read and sign. Distinct from the informed-consent process itself, which is documented separately under 45 CFR 46.117 / 21 CFR 50.27 and can, in limited cases (e.g. a documentation waiver, or the short-form pathway for non-English speakers), occur without a conventional long-form signed ICF.

Conflict of Commitment (COC)

A conflict of commitment (COC) exists when the time and effort a researcher or faculty member devotes to outside professional activities -- consulting, a second job, board service, an external appointment, or a startup role -- interferes with, or exceeds institutional limits on, the effort owed to their primary institutional obligations. It is a time-allocation problem, not a financial-bias problem: a COC can exist with no money involved (an unpaid but time-consuming board seat), and a significant financial conflict of interest can exist with no conflict of commitment at all (passive equity with no time commitment). Institutions typically manage COC through annual outside-activities disclosure, defined time caps, and cross-checking against sponsored-award effort reporting, distinct from the financial-disclosure process used for conflict of interest.

ISO 20387 (Biobanking)

ISO 20387:2018, Biotechnology — Biobanking — General requirements for biobanking, is the international standard specifying requirements for the competence, impartiality, and consistent operation of biobanks. It applies to organisations biobanking biological material and associated data from humans, animals, plants, fungi, and microorganisms for research and development, covering the full chain of collection, preparation, preservation, storage, and distribution of biospecimens. Structurally, it draws on the general competence requirements of ISO/IEC 17025 (testing and calibration laboratories) and the quality-management-system requirements of ISO 9001, adapted specifically for biobanking. A biobank meets ISO 20387 when a national accreditation body (for example UKAS in the UK or ANAB in the US, both operating under the same international accreditation framework as ISO/IEC 17025 labs) has formally assessed and accredited its quality management system, sample traceability, and impartiality — not merely when it follows informal best-practice guidance.

35 U.S.C. § 282 (Presumption of Patent Validity and Invalidity Defenses)

35 U.S.C. § 282 is the U.S. Patent Act provision that (a) presumes an issued patent, and each claim of it independently, to be valid, and places the burden of proving otherwise on the party asserting invalidity, and (b) lists the categories of defenses available to a defendant in a patent infringement action. A fact pattern is governed by § 282 whenever an issued U.S. patent's validity or enforceability is being contested in litigation — as opposed to during examination at the USPTO, where no presumption of validity yet applies because no patent has issued.Under § 282(a), the presumption attaches at issuance and survives even when the challenged claim relies on prior art the examiner never considered; it does not evaporate simply because a defendant produces new references. In <a href='https://supreme.justia.com/cases/federal/us/564/91/' target='_blank' rel='noopener'>Microsoft Corp. v. i4i Limited Partnership, 564 U.S. 91 (2011)</a>, the Supreme Court held that § 282's presumption requires invalidity to be proved by clear and convincing evidence — a heightened standard above the ordinary civil preponderance-of-the-evidence standard — and that this standard applies uniformly, including to prior art the USPTO never examined.§ 282(b) enumerates the defenses a party may raise in a patent action: (1) noninfringement, absence of liability for infringement, or unenforceability; (2) invalidity of the patent or any claim on any ground specified in Part II of the Patent Act as a condition for patentability — in practice this reaches novelty (<a href='/guides/35-usc-102-patent-novelty-invention-disclosure-timing'>35 U.S.C. § 102</a>), obviousness (35 U.S.C. § 103), and subject-matter eligibility (<a href='/guides/35-usc-101-patentable-subject-matter'>35 U.S.C. § 101</a>); (3) invalidity for failure to comply with the specification, enablement, written-description, or definiteness requirements of <a href='/guides/35-usc-112-specification-enablement-requirement'>35 U.S.C. § 112</a>, or of § 251 (reissue); and (4) any other fact or act made a defense by the Patent Act. Indefiniteness under § 112(b) and lack of enablement under § 112(a) are both raised as § 282(b)(3) defenses, distinct from the novelty and obviousness grounds raised under § 282(b)(2).

File Wrapper (USPTO)

The file wrapper — also called the prosecution history or file history — is the complete official record the U.S. Patent and Trademark Office (USPTO) maintains for a patent application from filing through issuance (or abandonment) and any subsequent post-grant proceedings. It contains every document that passed between the applicant (or the applicant's patent attorney/agent) and the examiner: the application as originally filed, office actions (rejections and objections), applicant responses and claim amendments, examiner's amendments, interview summaries, information disclosure statements (IDS) citing prior art, terminal disclaimers, notices of allowance, and the issued patent itself. The term is a holdover from the paper era, when each application's papers were literally kept in a manila file wrapper; the record is now maintained and served digitally.A document set counts as part of the file wrapper if and only if it was formally entered into the application's official record by the USPTO — informal correspondence, examiner's personal notes not made of record, and an applicant's internal drafts never filed do not qualify, even if they discuss the same application.

ISO 23081 (Records Management Processes — Metadata for Records)

ISO 23081 (Information and documentation — Records management processes — Metadata for records) is the ISO standard that defines the principles and framework governing the metadata records systems must capture so that records can be managed, retrieved, and trusted as evidence throughout their lifecycle. A metadata scheme qualifies as ISO 23081-aligned when it goes beyond simple descriptive metadata (title, creator, date) to capture recordkeeping context: the business process or mandate that created the record, the agents responsible for it, its relationships to other records and aggregations, and its retention/disposition authority. The standard is published in three parts: Part 1 sets out the principles underpinning records metadata; Part 2 gives conceptual and implementation guidance for building a metadata schema consistent with Part 1; Part 3, published as a Technical Report, provides a self-assessment method for evaluating an existing metadata schema against the standard. ISO 23081 was developed by ISO/TC 46/SC 11 as a companion to ISO 15489 (the core international records management standard), translating 15489's principles into a concrete metadata model that records-management systems, archives, and institutional repositories can actually implement.

Development Safety Update Report (DSUR)

The ICH E2F-standardized annual aggregate safety report a sponsor prepares for an investigational product's whole development program as of a single yearly data-lock point, summarizing accumulated safety data across all its trials worldwide and assessing the product's evolving benefit-risk profile — distinct from the event-triggered expedited SUSAR reporting required under 21 CFR 312.32, and often submitted in place of the separate US IND annual report under 21 CFR 312.33.

EU AI Act Article 10 (Data and Data Governance)

Article 10 of the EU AI Act (Regulation (EU) 2024/1689), in Title III, Chapter 2, sets the data-quality and data-governance obligations for the training, validation, and testing datasets used to build high-risk AI systems. A system falls under Article 10 only after it has already met the Act's separate 'high-risk' classification test (an Annex III listed use case, or a safety component covered by Annex I sectoral product law). For a high-risk system built using techniques that involve training models on data, Article 10(2) requires documented data-governance practices covering collection and origin, preparation operations (annotation, labelling, cleaning, updating, enrichment), bias examination, bias-mitigation measures, and identification of data gaps; Article 10(3)-(4) require the training, validation, and testing datasets to be relevant, sufficiently representative, and to the best extent possible free of errors and complete for the system's intended purpose and deployment context. For a high-risk system that does not use such training techniques, Article 10(6) narrows the same requirements to the testing dataset only. Article 10(5) separately permits limited, safeguarded processing of special-category personal data solely to detect and correct bias. It does not apply to AI systems or models developed and used solely for scientific research and development prior to being placed on the market or put into service, per the Article 2(6)/2(8) research exemption.

eCTD (Electronic Common Technical Document)

A regulatory submission qualifies as an eCTD only when its files are organized into the standardized five-module folder hierarchy (Module 1 region-specific administrative/prescribing information, Module 2 CTD summaries, Module 3 quality/CMC, Module 4 nonclinical study reports, Module 5 clinical study reports) AND wrapped in an XML backbone (index.xml) that assigns each file lifecycle-operation metadata (new, append, replace, delete) so a reviewer's system and the sponsor's own submission history can track changes across amendments to the same application. A folder of complete, correctly-labeled PDFs that lacks the XML backbone and Module 1-5 structure is not an eCTD, regardless of content completeness.

Good Clinical Laboratory Practice (GCLP)

Good Clinical Laboratory Practice (GCLP) is the quality standard governing laboratories that analyze human-derived samples from clinical trials -- most centrally bioanalytical work such as pharmacokinetic (PK) sample analysis, biomarker assays, and other trial-support testing. It is a hybrid standard: it applies the study-control, quality-assurance, and data-integrity discipline of <a href='/dictionary/term/good-laboratory-practice-glp'>Good Laboratory Practice (GLP)</a> -- normally written for preclinical, non-human studies under 21 CFR Part 58 -- to a clinical-trial, human-sample setting, while also incorporating the trial-conduct and subject-protection principles of <a href='/dictionary/term/ich-gcp-good-clinical-practice'>Good Clinical Practice (GCP)</a> (ICH E6). A laboratory qualifies as GCLP-compliant when it operates a documented quality management system covering facility/equipment qualification, personnel training records, standard operating procedures, sample chain-of-custody and traceability back to the clinical trial subject, method validation, raw-data integrity and retention, and independent quality assurance oversight -- applied specifically to samples originating from a clinical trial rather than a preclinical study or routine diagnostic workload.

GDPR Article 44 (International Data Transfers)

GDPR Article 44 is the opening provision of Chapter V of the EU General Data Protection Regulation, and states the general principle that governs every transfer of personal data out of the European Economic Area: a transfer to a third country or international organisation may only take place if the conditions in the rest of Chapter V are satisfied, and the level of protection guaranteed by the GDPR must not be undermined -- including for onward transfers from the receiving third country to yet another third country. Article 44 does not itself supply a transfer mechanism; it is the trigger that makes Articles 45-49 mandatory whenever personal data (including pseudonymised research data that remains personal data, per GDPR Article 4(5)) leaves the EEA. For a research collaboration, that means every step of a project involving a non-EEA partner -- shipping a dataset to a US co-investigator, hosting trial data on a non-EEA cloud region, or granting a non-EEA collaborator remote access to an EEA-hosted database -- is a Chapter V transfer, whether or not it is described as a 'transfer' in the project's data management plan.

Human Research Protection Program (HRPP)

A Human Research Protection Program (HRPP) is the complete organizational structure an institution operates to protect the rights and welfare of human research participants -- not a single committee, but the full system of one or more Institutional Review Boards (IRBs), written policies and procedures, an institutional compliance/administrative office, researcher training requirements, conflict-of-interest management, and ongoing monitoring of active research, all operating under the institution's Federalwide Assurance (FWA) with HHS's Office for Human Research Protections (OHRP). The IRB is the HRPP's core review committee, not the whole program; AAHRPP is the external body that voluntarily accredits an institution's HRPP as a unit. An institution operates an HRPP whether or not it ever seeks AAHRPP accreditation -- running a compliant HRPP under the Common Rule (45 CFR 46) and applicable FDA regulations is a baseline legal requirement for institutions conducting covered human-subjects research; AAHRPP accreditation is an optional, additional layer of external, third-party verification on top of it.

Prior Approval

Prior approval (sometimes written “prior written approval”) is the requirement, under <a href='https://www.law.cornell.edu/cfr/text/2/200.407'>2 CFR 200.407</a> of the OMB <a href='/guides/uniform-guidance-2-cfr-200'>Uniform Guidance</a>, that a federal grant recipient obtain the federal awarding agency’s written sign-off before taking a specified action, rather than proceeding and defending the decision after the fact. Something is genuinely a “prior approval” matter — as opposed to routine project management the recipient can handle on its own authority — only if it falls into one of the categories the regulation or the recipient’s own award terms specifically names. Section 200.407 lists sixteen such categories, including cost sharing (200.306), program income (200.307), revision of budget and program plans (200.308), fixed-amount subawards (200.333), compensation for personal services and fringe benefits (200.430–200.431), equipment and capital expenditures (200.439), exchange-rate losses (200.440), fines and penalties (200.441), fundraising costs (200.442), goods or services for personal use (200.445), insurance and indemnification (200.447), organization costs (200.455), pre-award costs (200.458), rearrangement and reconversion costs (200.462), and travel costs (200.475). The regulation is explicit that the absence of prior approval does not, by itself, make a cost unreasonable or unallocable unless prior approval is specifically required for that item — the requirement only bites where it is named.The most frequently triggered prior-approval events sit inside <a href='https://www.law.cornell.edu/cfr/text/2/200.308'>2 CFR 200.308</a>, “Revision of budget and program plans,” which requires a recipient to ask before: changing the scope or objective of the project (even without any budget change), changing key personnel identified by name or position in the award, a PD/PI disengaging from the project for more than three months or reducing time and effort on it by 25 percent or more, redirecting participant support costs to other budget categories, adding a subaward not proposed in the original application, changing the total approved cost-sharing amount, needing additional federal funds to complete the project, moving funds between construction and non-construction categories, or extending the project period beyond what the recipient’s own expanded/automatic authority already covers. Because 200.308’s list is itself an enumerated set — not a general “ask if unsure” standard — a change that doesn’t match one of its named triggers, or one of 200.407’s other named cost categories, does not require prior approval merely because it feels significant to the PI.

Patent Continuation Application

A patent continuation application is any of a family of U.S. nonprovisional applications -- continuation, continuation-in-part (CIP), or divisional -- filed while an earlier-filed 'parent' nonprovisional application is still pending (co-pending), that claims the benefit of the parent's filing date under 35 U.S.C. 120 or 121 and 37 CFR 1.78. What distinguishes the three types is what changes relative to the parent's disclosure and claims: a continuation carries forward the parent's disclosure exactly and pursues new or different claims to the same invention already disclosed; a continuation-in-part repeats a substantial part of the parent's disclosure but adds new matter not found in the parent (the new matter does not get the benefit of the parent's filing date); and a divisional carves out claims to an independent or distinct invention that the parent disclosed but did not claim, typically after the examiner issued a restriction requirement forcing the applicant to elect one invention to pursue in the parent.

PHS Policy (Public Health Service Policy on Humane Care and Use of Laboratory Animals)

The binding NIH policy, administered by the Office of Laboratory Animal Welfare (OLAW) under the Health Research Extension Act of 1985 (42 U.S.C. section 289d), that requires any institution receiving Public Health Service (PHS) funding to hold a written Animal Welfare Assurance accepted by OLAW before conducting or supporting activities involving any live vertebrate animal. It requires the institution's IACUC to review protocols and inspect facilities as OLAW's agent, and requires the animal care program to be based on the Guide for the Care and Use of Laboratory Animals and to comply with USDA's Animal Welfare Regulations as an absolute minimum. It is distinct from the Animal Welfare Act (a separate, funding-independent federal statute with narrower species coverage) and from AAALAC accreditation (a voluntary, non-mandatory private accreditation that does not substitute for the Assurance).

FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators)

FDA Form 3454 ('Certification: Financial Interests and Arrangements of Clinical Investigators') is the form a marketing-application sponsor submits to FDA to certify -- rather than disclose -- that no clinical investigator (or subinvestigator, and no covered spouse or dependent child) who participated in a covered clinical study has any of the disclosable financial interests or arrangements defined at 21 CFR Part 54. It is used only when the sponsor's inquiry into each investigator's financial interests comes back clean; if any investigator has a reportable interest or arrangement, the sponsor files the counterpart form, FDA Form 3455, disclosing it instead. The form must be dated and signed by the applicant's chief financial officer or other responsible corporate official, and it is submitted with the marketing application it supports (an NDA, ANDA, BLA, or PMA/510(k) as applicable) rather than at the start of the trial.

Expedited Review (IRB)

Expedited review is an IRB review pathway, available only when a proposed research activity (or a minor change to already-approved research) presents no more than minimal risk to participants and falls into one of the categories on OHRP's expedited-review category list. Instead of going to a convened meeting of the full board, it is reviewed by the IRB Chairperson personally, or by one or more experienced reviewers the Chairperson designates from the board's membership, under 45 CFR 46.110 (and the parallel FDA provision, 21 CFR 56.110). An expedited reviewer may exercise all the authorities of the full IRB except one: they may not disapprove the research -- a study can only be disapproved through full-board review at a convened meeting. ’Expedited’ describes who conducts the review (chair or designee, not the full board), not a guaranteed fast turnaround.

FDA Process Validation

FDA Process Validation refers to the FDA's January 2011 guidance document "Process Validation: General Principles and Practices" (issued by CDER in cooperation with CBER, ORA, and CVM, superseding the agency's 1987 process-validation guideline), and to the three-stage lifecycle framework it establishes for demonstrating that a pharmaceutical or biologic manufacturing process consistently produces a product meeting its predetermined quality attributes. A manufacturing process is treated as "validated" under this framework only when all three stages have been satisfied: Stage 1 (Process Design), in which the commercial process is defined based on knowledge gained through development and scale-up activities; Stage 2 (Process Qualification), in which the process design is evaluated to confirm the process is capable of reproducible commercial manufacturing, including facility/utility/equipment qualification and Process Performance Qualification (PPQ) runs; and Stage 3 (Continued Process Verification, or CPV), an ongoing program of collecting and statistically trending process and product data during routine commercial production to confirm the process remains in a state of control. This is distinct from clinical-trial protocol validation or software/computer-system validation -- the term specifically denotes manufacturing-process validation for drug substances, drug products, and biologics under current Good Manufacturing Practice (CGMP).

21 CFR Part 56 (Institutional Review Boards)

21 CFR Part 56 is FDA's own regulation governing Institutional Review Board (IRB) review of clinical investigations that fall under FDA's product-jurisdiction authority — chiefly studies conducted under an Investigational New Drug (IND) application (21 CFR Part 312), an Investigational Device Exemption (IDE) (21 CFR Part 812), or otherwise submitted to FDA in support of a research or marketing permit (21 CFR Part 813). Per 21 CFR 56.103, any such clinical investigation must receive IRB approval before it may begin and must remain subject to continuing IRB review for its duration; FDA may refuse to rely on data from an investigation that lacked this initial and continuing IRB oversight. Part 56's trigger is the product/application jurisdiction of the study, not its funding source — it applies whether or not any federal grant money is involved, which is the structural feature that distinguishes it from the Common Rule (45 CFR 46), whose trigger is federal funding or conduct. A single trial can therefore fall under the Common Rule only, Part 56 only, or both at once (for example, an NIH-funded IND drug trial), in which case both regulatory tracks' IRB-review and informed-consent requirements must independently be satisfied.

Biosafety Level 1 (BSL-1)

The CDC/NIH BMBL laboratory-containment tier assigned to a protocol when the biological agent(s) involved are well-characterized and not known to consistently cause disease in healthy adults, and pose minimal potential hazard to laboratory personnel and the environment. An instance of BSL-1 is basic, open-bench microbiological work performed with standard microbiological practices (handwashing, no eating/drinking/mouth pipetting, decontamination of work surfaces) and no specialized primary containment equipment such as a biosafety cabinet, in a laboratory that is not required to be separated from general building traffic.

NIH Research Security Training (RST)

NIH's Research Security Training (RST) requirement, established under NIH Guide Notice NOT-OD-26-017, requires every 'covered individual' -- meaning every senior/key person listed on an NIH grant application -- to complete research security training within the 12 months before the application's due date. Compliance is evidenced through a dual certification: an institutional certification by the Authorized Organizational Representative (AOR) on the SF424 R&R face page, and an individual certification captured through the person's NIH Biographical Sketch in SciENcv. It applies to applications with due dates on or after May 25, 2026.

NIH Financial Conflict of Interest (FCOI) Policy

The federal regulatory framework (42 CFR Part 50, Subpart F for PHS grants/cooperative agreements; 45 CFR Part 94 for PHS contracts) requiring any institution receiving Public Health Service or NIH funding to maintain a written FCOI policy, collect financial disclosures from every Investigator on a covered project, have a designated official review and manage any identified conflict, and report it to the funding agency before award funds are expended.

Site Initiation Visit (SIV)

A Site Initiation Visit (SIV) is the visit -- conducted on-site or remotely by a sponsor or CRO monitor (typically a Clinical Research Associate) -- that formally activates an investigational site for a specific clinical trial, immediately before enrollment may begin. A visit counts as an SIV, regardless of format, when it verifies that all site-activation prerequisites are simultaneously in place: current IRB/IEC approval of the protocol and informed consent form, completed staff training (protocol-specific and Good Clinical Practice) for every individual on the delegation-of-authority log, a complete regulatory/essential-document binder per ICH E6(R2) Section 8, receipt and accountability procedures for investigational product and study supplies, and a working understanding among site staff of source documentation and data-entry (EDC) procedures. A visit is NOT an SIV if it occurs before the site has been contracted and IRB-approved (that is a site-selection/pre-study visit) or after the site has already begun enrolling participants (that is a routine/interim monitoring visit or a close-out visit).

AAALAC International

A private, nonprofit accrediting body (founded 1965, headquartered in Frederick, Maryland) that grants voluntary, triennial peer-review accreditation to animal research, teaching, and testing programs worldwide against three primary standards (the Guide, the Ag Guide, and ETS 123), confirming a program meets or exceeds legally required animal-welfare standards -- distinct from the mandatory Animal Welfare Act (USDA-enforced statute) and PHS Policy (NIH funding condition), neither of which AAALAC accreditation replaces or is required by.

Electronic Trial Master File (eTMF)

An eTMF is a software system -- standalone or a CTMS module -- used to create, store, version-control, quality-check, and track the real-time completeness of a clinical trial’s Trial Master File (TMF) electronically, structured against a reference taxonomy such as the TMF Reference Model and, for FDA-regulated trials, generally within the scope of 21 CFR Part 11.

March-In Rights

March-in rights are the authority under 35 U.S.C. § 203 letting a federal funding agency require the holder of a patent on a federally funded “subject invention” to grant additional licenses to a responsible third party -- or grant one itself -- when the holder isn't achieving practical application, isn't meeting unmet health/safety needs, isn't satisfying regulation-specified public-use requirements, or hasn't met the Section 204 U.S.-manufacturing agreement. Title is not transferred or revoked; only additional licensing is compelled, and only at the funding agency's discretion after a petition and agency review.

Patent Eligibility Restoration Act (PERA)

The Patent Eligibility Restoration Act (PERA) is proposed U.S. federal legislation — not current law — that would rewrite 35 U.S.C. § 101 to replace the judge-made "abstract idea" and "law of nature" exceptions with a shorter, closed list of statutory exclusions. It has been introduced, in varying forms, across the 116th, 118th, and 119th Congresses without being enacted. The current version, S. 1546 (119th Congress, 2025–2026), was reintroduced on May 1, 2025 by Senators Thom Tillis (R-NC) and Chris Coons (D-DE) and Representatives Kevin Kiley (R-CA) and Scott Peters (D-CA). The Senate Judiciary Subcommittee on Intellectual Property held a hearing on the bill on October 8, 2025; as of this writing it has not been marked up by the full committee, passed by either chamber, or signed into law. A page that treats PERA as settled law would be factually wrong — its defining characteristic, for research-administration purposes, is that it is a live legislative proposal responding to an unresolved doctrinal problem, not a rule anyone can rely on yet.<h2>The problem PERA is written to address</h2>Under current § 101 doctrine, the Supreme Court's Mayo Collaborative Services v. Prometheus Laboratories (2012) and Alice Corp. v. CLS Bank International (2014) decisions established a two-step framework (often called the "Alice/Mayo test" or, in USPTO examination guidance, "Step 2A/Step 2B") that lets an examiner or court invalidate a claim as directed to an unpatentable "abstract idea," "law of nature," or "natural phenomenon" even though those categories appear nowhere in the patent statute itself — they are judicial exceptions layered on top of § 101's text. See CASRAI's <a href='/guides/35-usc-101-patentable-subject-matter'>35 U.S.C. § 101: Patentable Subject Matter and the Alice/Mayo Eligibility Test</a> for the current test as it actually operates today. Critics across the patent bar, technology-transfer offices, and biotech/software industry groups argue the resulting case law is inconsistent and hard to predict at the claim-drafting stage, disproportionately affecting diagnostic methods, software and AI-related inventions, and certain life-sciences discoveries — exactly the categories a university technology transfer office most often needs to protect before licensing.<h2>What PERA proposes to change</h2>Rather than amending the Alice/Mayo case-law test directly, PERA's approach is to eliminate judicially-created exceptions from § 101 entirely and substitute a short, enumerated list of statutory exclusions from eligibility (categories such as claims to an unmodified human gene as it exists in the human body, or to a mathematical formula standing alone, are the kind of exclusion prior versions of the bill have specified) while otherwise stating that a claimed invention is eligible if it falls within one of the statute's existing categories (process, machine, manufacture, or composition of matter) and is not excluded. Sponsors describe the goal as restoring eligibility for practical, real-world applications in fields like AI, biotechnology, and diagnostics without reopening genuinely abstract claims to patenting. Because PERA has been revised between reintroductions, the exact exclusion list and definitions in the live S. 1546 text should be checked directly against <a href='https://www.congress.gov/bill/119th-congress/senate-bill/1546/text' rel='noopener'>the bill text on congress.gov</a> rather than assumed to match an earlier version.<h2>Why this matters for university tech transfer specifically</h2>A technology transfer office evaluating whether to patent a faculty invention has to make a § 101 eligibility judgment long before litigation is ever a possibility — at invention-disclosure triage, at the provisional-filing decision, and again when licensing counsel diligence the claims. Diagnostic-method inventions (a correlation between a biomarker and a disease state) and software/AI inventions (a novel algorithm or model architecture) are the two categories most exposed to Alice/Mayo rejections today, which in turn affects a TTO's practical calculus on whether patenting is worth the cost relative to protecting the same invention as a trade secret or relying on a first-mover/know-how advantage instead. PERA, if enacted, would not retroactively revive an invention a TTO already declined to patent under current doctrine — patentability is assessed as of filing — but it would change the eligibility calculus for inventions disclosed and filed after any effective date, and could affect prosecution strategy for pending applications depending on the bill's final transition provisions. None of that is triggered by introduction or a committee hearing; only enactment would change what is patentable.

FDA FOIA Request

A written request filed under 5 U.S.C. § 552 and FDA's implementing regulation, 21 CFR Part 20, submitted to FDA's Division of Freedom of Information asking the agency to release records it holds but has not proactively published — most commonly the narrative text of a Form FDA-483, the fuller Establishment Inspection Report, warning letters, or IND/NDA/BLA correspondence not already in a public FDA database.

Accelerated Approval

Accelerated Approval is an FDA regulatory pathway that lets the agency approve a drug or biologic for a serious or life-threatening condition on the basis of an effect on a surrogate endpoint, or an intermediate clinical endpoint, that is reasonably likely to predict the product's actual clinical benefit -- rather than waiting for a completed trial to show that benefit directly. It is authorized under 21 CFR Part 314 Subpart H (drugs, 21 CFR 314.500-314.560) and 21 CFR Part 601 Subpart E (biologics, 21 CFR 601.40-601.46). Approval is conditional: the sponsor must conduct a post-approval confirmatory trial to verify the predicted clinical benefit, and, under the Food and Drug Omnibus Reform Act of 2022 (FDORA, part of the Consolidated Appropriations Act, 2023), FDA can now require that confirmatory trial be underway -- not merely committed to -- at the time of approval or shortly after. If the confirmatory trial fails to verify clinical benefit, or other evidence shows the product isn't safe or effective, FDA can withdraw the approval through an expedited withdrawal procedure that FDORA also created.

35 U.S.C. § 154 (Patent Term)

35 U.S.C. § 154 is the U.S. Patent Act provision that (a) defines the substantive right a patent grants -- the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States, or importing it into the United States (and, for a process patent, the right to exclude others from using, offering for sale, or selling products made by that process) -- and states the length of that grant, and (b) authorizes patent term adjustment (PTA), which lengthens a patent's term to compensate for certain USPTO examination delays. A fact pattern is governed by § 154 whenever the question is how long an issued utility or plant patent's exclusionary term runs, or whether USPTO delay during prosecution entitles the applicant to extra term -- as distinct from patent eligibility (35 U.S.C. § 101), novelty (§ 102), the specification requirements (§ 112), or the presumption of validity in litigation (§ 282), each governed by its own provision.

SBIR/STTR Data Rights

The specific FAR/DFARS data-rights clause package (FAR 52.227-20 for civilian agencies, DFARS 252.227-7018 for DoD) that attaches automatically to SBIR/STTR-funded contracts and grants, giving the small-business or STTR awardee exclusive control over the technical data and computer software it generates under the award. During a 20-year protection period running from the date of award (per SBA's SBIR/STTR Policy Directive and, for DoD, DFARS 252.227-7018 effective January 17, 2025), the government may use that data only for internal government purposes and cannot release or disclose it to a third party -- including a competing contractor bidding on follow-on work -- without the awardee's permission. This is a distinct protection from patent rights: it applies to the data/software deliverables themselves, not the underlying invention, and does not require a patent to be filed at all.

Prescription Drug User Fee Act (PDUFA)

The Prescription Drug User Fee Act (PDUFA) is the 1992 U.S. federal law authorizing FDA to collect user fees from companies that submit certain human drug and biologic applications for review, or that are named as sponsors of certain approved prescription drug products. In exchange for these fees, FDA commits to specific performance goals -- most visibly, review-time targets such as the 10-month goal for a Standard Review application and the 6-month goal for a Priority Review application -- set out in a negotiated agreement between FDA and industry that Congress reauthorizes roughly every five years. PDUFA is the funding and accountability mechanism underlying FDA's human drug review program; it is distinct from the individual expedited-review pathways (Priority Review, Breakthrough Therapy, Fast Track, Accelerated Approval) that operate within the review process it funds.

Special Category Data (GDPR Article 9)

Personal data that GDPR Article 9(1) singles out for heightened protection because of its sensitivity — data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, plus genetic data, biometric data used to uniquely identify a person, health data, and data concerning sex life or sexual orientation. Processing any of these categories is prohibited by default; a research controller needs both an Article 6 lawful basis and a separate Article 9(2) condition before touching the data at all, and for most academic and clinical research that second condition is Article 9(2)(j), the research/archiving/statistics derogation.

NSF Merit Review Panel

An NSF merit review panel is the group of external subject-matter experts (or, for ad hoc/mail review, individual experts working independently) that the National Science Foundation convenes under PAPPG Chapter III to evaluate a proposal against the two NSB-mandated criteria, Intellectual Merit and Broader Impacts, producing individual Excellent-to-Poor ratings and written reviews that an NSF program officer weighs, alongside program-level considerations and Division Director concurrence, when recommending a funding decision.

ISO 14155 (Clinical Investigation of Medical Devices for Human Subjects — GCP)

ISO 14155:2020, ‘Clinical investigation of medical devices for human subjects — Good clinical practice,’ is the ISO standard defining GCP requirements — protocol design, informed consent, investigator qualification, sponsor monitoring, adverse-event/device-deficiency reporting, and reporting — for clinical investigations of medical devices in human subjects. It is the device-industry counterpart to ICH E6 for drug and biologic trials.

Evaluation Agreement

An evaluation agreement (sometimes called an evaluation license) is a short-term, narrowly-scoped contract that a university or research institution's technology transfer office (TTO) uses to let a prospective licensee test a specific technology — a device, material, dataset, or piece of software — before either party commits to a full commercial license negotiation. What makes an agreement an evaluation agreement, rather than something else, is the combination of: (1) a limited internal-use-only purpose (testing, benchmarking, or feasibility assessment — not manufacturing, sale, sublicensing, or use in a marketed product); (2) a short, fixed term (commonly 90 days to one year, sometimes renewable once); (3) non-exclusivity as the default, since the institution is not yet committing the technology to any one party; and (4) little or no financial consideration, since the point is to let the evaluator decide whether the technology is worth licensing at all, not to monetize use during the trial itself. Many evaluation agreements also include, or are paired with, confidentiality terms and a right of first negotiation or option period for a subsequent full license.

For-Cause Audit

A for-cause audit (or for-cause inspection) is a compliance review triggered by a specific, identified finding, complaint, safety signal, or concern -- as distinguished from a routine, scheduled, or directed audit conducted on a periodic or pre-planned basis regardless of any known issue. The defining test is the presence of a triggering event: a monitoring visit report flagging a serious deviation, an adverse-event or safety-reporting concern, a whistleblower complaint, evidence of possible data integrity problems, or a pattern of findings from a prior routine audit. Two related but distinct uses of the term appear in clinical research: (1) an FDA Bioresearch Monitoring (BIMO) for-cause inspection, opened by the agency's field-investigation function in response to a specific complaint, required report, or safety signal, and which may be unannounced; and (2) a sponsor-, CRO-, or IRB-initiated for-cause audit of a trial site, investigator, or vendor, opened internally in response to a monitoring red flag or reported concern rather than as part of the organization's standard audit schedule.

Clinical Trial Agreement (CTA)

A Clinical Trial Agreement (CTA) is the legally binding contract between a study sponsor (or a Contract Research Organization acting for the sponsor) and the institution/site conducting the trial (and, typically, the Principal Investigator as a party or signatory) that sets the business and legal terms under which the trial will be performed at that site. A document qualifies as a CTA -- as distinct from the protocol, the informed consent form (ICF), or a data/material-transfer agreement -- when it governs the commercial and risk-allocation terms of the relationship rather than the scientific conduct of the study itself: per-subject and milestone budget and payment schedule, indemnification and insurance (including coverage for trial-related subject injury), intellectual property ownership (background vs. foreground), publication and disclosure rights, data ownership and confidentiality, regulatory-compliance representations, and termination and record-retention terms. The protocol defines what will be done scientifically; the ICF discloses risks and obtains a subject's voluntary participation; the CTA is the separate contract that lets the institution and sponsor actually transact -- get paid, allocate liability, and agree who owns and can publish what comes out of the trial.

IND Annual Report

A comprehensive, once-a-year progress summary that a sponsor holding an active Investigational New Drug (IND) application must submit to FDA under 21 CFR 312.33, due within 60 days of the anniversary date the IND went into effect. It covers every study conducted under the IND during the preceding year (status, enrollment, and completion), a summary of IND Safety Reports and subject deaths/dropouts, preclinical findings, manufacturing or microbiological changes, any Investigator's Brochure revisions, Phase 1 protocol modifications, the sponsor's investigational plan for the coming year, and foreign marketing developments. It continues annually for as long as the IND remains active, independent of whether any individual study is enrolling.

Letter of Credit Drawdown

A letter of credit drawdown is the cash-management method under which a recipient institution draws federal grant funds from a Treasury-administered payment system — most commonly the <a href='https://pms.psc.gov' target='_blank' rel='noopener noreferrer'>HHS Payment Management System (PMS)</a>, but also agency-specific systems used by NSF, USAID, and others — only in the amount needed to cover actual, imminent disbursements, rather than receiving a lump-sum advance at the start of the award. It qualifies as an instance of this method when three conditions hold: (1) the institution holds standing drawdown authority against a Treasury-linked account tied to a specific award or pooled by awarding agency, not a one-time advance payment; (2) each individual drawdown request is sized to actual, immediate cash need rather than banked ahead of spending; and (3) the timing is governed by <a href='https://www.ecfr.gov/current/title-2/subtitle-A/chapter-II/part-200/subpart-D/section-200.305' target='_blank' rel='noopener noreferrer'>2 CFR §200.305</a>, the Uniform Guidance payment section, which requires non-State recipients to minimize the time elapsing between the transfer of funds from the federal awarding agency and the recipient's actual disbursement of those funds, regardless of whether the transfer happens by electronic funds transfer or another means. This distinguishes drawdown from a <a href='/dictionary/term/financial-report-grant'>periodic reimbursement</a> method, where the institution spends its own cash first and is paid back afterward (subject to a 30-calendar-day agency payment window under the same section), and from a single upfront advance payment covering an entire budget period.

Continuing Review (IRB)

Continuing review is the periodic re-review an IRB conducts of previously approved, ongoing research to decide whether approval should continue. Under 45 CFR 46.109(e), an IRB must conduct continuing review of research requiring review by the convened IRB at intervals appropriate to the degree of risk, and not less than once per year, except for the limited categories the revised Common Rule exempts from continuing review entirely under 46.109(f) (research eligible for expedited review, research receiving limited IRB review under certain exemptions, and research that has closed to enrollment and moved solely into data analysis or long-term follow-up using standard-of-care procedures). FDA's parallel provision, 21 CFR 56.109(f), requires continuing review of FDA-regulated research at intervals appropriate to the degree of risk and not less than annually, and does not carry the same 2018 Common Rule exceptions. The operative distinction for a study posing greater than minimal risk: continuing review of that research cannot be conducted through the expedited procedure, because expedited review (whether at initial approval or at a continuing-review interval) is only available for research that is no more than minimal risk. A greater-than-minimal-risk study must therefore go before the full convened IRB, with a quorum present and a majority vote, at every continuing-review interval for as long as the study remains open to enrollment or active intervention -- not just at initial approval.

IACUC Semiannual Program Review and Facility Inspection

The PHS-Policy-mandated recurring self-governance duties every Institutional Animal Care and Use Committee (IACUC) must perform on its own institution: reviewing the entire animal care and use program at least once every six months against the Guide for the Care and Use of Laboratory Animals, inspecting all of the institution's animal facilities on that same six-month cycle, and preparing and submitting a signed written report of the review and inspection to the Institutional Official that classifies any deficiencies as significant or minor and sets a correction plan and schedule.

21 CFR 312.60 (General Responsibilities of Investigators)

21 CFR 312.60 is the FDA regulation establishing that an investigator conducting an IND-regulated clinical investigation is responsible for: conducting the study according to the signed investigator statement (Form FDA-1572) and the investigational plan/protocol; protecting the rights, safety, and welfare of subjects under the investigator's care; and controlling drugs under investigation, including obtaining informed consent under 21 CFR Part 50 and complying with IRB requirements under 21 CFR Part 56.

Pharmacovigilance System Master File (PSMF)

The Pharmacovigilance System Master File (PSMF) is the single, maintained regulatory document in which an EU marketing-authorisation holder (MAH) describes its ENTIRE pharmacovigilance system -- not one product's safety data, but the organisational structure, processes, and quality system the MAH uses to detect, assess, and manage the safety of all the medicinal products it covers under that system. Required under GVP Module II (itself issued under the EU's 2010 pharmacovigilance legislation and Directive 2001/83/EC as amended), the PSMF must be kept permanently up to date and made available to EU national competent authorities and the European Medicines Agency (EMA) on request. A document is a PSMF, as opposed to some other pharmacovigilance record, if it (a) is maintained by or on behalf of a specific MAH, (b) describes the pharmacovigilance system as a whole -- covering organisational structure, the Qualified Person Responsible for Pharmacovigilance (QPPV) and their responsibilities, data sources, IT systems, and the quality system that supports the whole -- rather than a single case, study, or product, and (c) has a PSMF location and reference number that the MAH's marketing-authorisation dossiers reference back to, with QPPV and PSMF-location contact details held in the EMA database described in Article 57 of Regulation (EC) No 726/2004.

Maintenance of Effort (MOE)

Maintenance of Effort (MOE) is a condition attached to certain federal (and some state) grant programs requiring a recipient to sustain its own non-federal financial or programmatic effort in a defined area at or above a documented baseline level -- typically the prior year's expenditure, or an average of recent years -- as a continuing condition of eligibility for the federal award, independent of whether the federal funds themselves are spent correctly. Unlike a one-time eligibility test, MOE is assessed on a recurring basis (usually annually) by comparing current-year non-federal spending or effort against the baseline; falling short constitutes an MOE violation even if every dollar of the federal award was used appropriately.

TMF Reference Model

The TMF Reference Model is a harmonized, industry-developed taxonomy for organizing Trial Master File (TMF) content into a predictable three-tier hierarchy of Zones, Sections, and Artifacts (with a fourth, more granular Sub-Artifact tier), each artifact carrying a unique ID, a written purpose/definition, and expected trial-phase metadata. A TMF or eTMF is properly described as 'built on' or 'mapped to' the TMF Reference Model when its filing structure and document types trace back to this defined Zone/Section/Artifact scheme rather than an organization's own bespoke folder taxonomy -- it is a classification standard layered on top of the general TMF/eTMF concept, not a synonym for it.

21 CFR Part 314 (Applications for FDA Approval to Market a New Drug)

21 CFR Part 314, "Applications for FDA Approval to Market a New Drug," is the FDA regulation establishing the entire New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) framework: the content and format an application must have (Subpart B, chiefly 314.50), the abbreviated pathway for generics relying on bioequivalence to an already-approved drug (Subpart C), FDA's review process including the filing decision, approval standard, and Complete Response Letter mechanism (Subpart D, 314.101/314.105/314.110), administrative hearing procedures (Subpart E), confidentiality provisions (Subpart G), accelerated approval based on a surrogate endpoint (Subpart H), and approval without human efficacy studies when unethical or infeasible, the "Animal Rule" (Subpart I). It governs a drug from the point a sponsor seeks marketing approval onward, picking up where 21 CFR Part 312 (Investigational New Drug) leaves off at the end of clinical investigation. Two individual Part 314 sections have their own dedicated CASRAI entries: 314.70 (post-approval changes) and 314.80 (postmarketing adverse event reporting), both within Subpart B.

Delegation of Authority (DoA) Log

A Delegation of Authority (DoA) Log is the site-level record, maintained for each clinical trial at each investigator site, that documents which specific trial-related tasks the Principal Investigator (PI) has authorized named study-team members to perform, together with each person's qualifications, their signature or initials, and the exact date range during which that authorization was in effect. It answers one question for anyone reviewing the trial afterward — a monitor, an auditor, or an FDA inspector: was the person who performed this specific task actually authorized to perform it, on the date they performed it? A document set qualifies as a compliant DoA log when it names every individual (co-investigator, sub-investigator, clinical research coordinator, research nurse, research pharmacist, or other delegated staff) who performed a trial-related procedure or made a trial-related judgment; lists the specific tasks delegated to that person, not a generic job title; is signed or initialed by both the delegate and the PI; states the start date (and end date, once applicable) of each delegation; and is kept current as staff join, leave, or take on new responsibilities throughout the trial. Under ICH E6(R2) Section 4.1.5, the investigator must maintain a list of appropriately qualified persons to whom significant trial-related duties have been delegated; the DoA log is the standard operational instrument sites use to satisfy that requirement and to demonstrate it during inspection.

Investigator Site File (ISF)

A document or record belongs in an Investigator Site File (ISF) if it demonstrates something only the trial site itself can attest to under ICH E6(R2)'s essential-documents framework -- delegation of authority, site-specific IRB/IEC oversight, staff qualifications, signed informed consent, and site-level investigational-product accountability -- created and maintained by the site itself (not the sponsor or CRO) throughout the trial and kept available for monitoring and inspection.

FDA BIMO (Bioresearch Monitoring) Program

FDA's Bioresearch Monitoring (BIMO) Program is the umbrella FDA inspection and data-audit program covering clinical investigators, sponsors/monitors/CROs, IRBs, nonclinical (GLP) laboratories, in vivo bioequivalence facilities, and several narrower tracks (RDRC, PADE, REMS reporting). It exists to verify the quality and integrity of data submitted in support of FDA product approvals and to protect the rights, safety, and welfare of human subjects and animals involved in the underlying research. BIMO inspections can be routine/surveillance, directed data audits, for-cause, or compliance follow-up, and each closed inspection resolves to one of three classifications: No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI).

Stevenson-Wydler Technology Innovation Act

A 1980 federal statute (Public Law 96-480, codified at 15 U.S.C. Chapter 63, Sections 3701 et seq.) that made technology transfer an explicit mission of every federal laboratory, requiring labs to actively work to transfer federally developed technology to state and local governments and the private sector -- as distinct from Bayh-Dole, enacted the same year, which governs patent title for inventions made by universities, nonprofits, and small businesses under federal funding agreements, not the labs' own technology-transfer obligations.

Supplanting

Supplanting is the use of federal grant funds to replace non-federal funds a recipient would otherwise have spent on the same activity, position, or service, rather than using the federal award to add new or expanded effort. It is the prohibited counterpart to the "supplement, not supplant" condition attached to many federal grant programs, and is assessed by comparing the funded level of activity against a documented non-federal spending baseline.

NIH Prior Approval

A post-award change on an NIH grant or cooperative agreement requires NIH prior approval when it falls into one of the categories the NIH Grants Policy Statement (NIH GPS) Section 8.1.2 designates as requiring the awarding Institute or Center's written sign-off before the recipient implements it -- rather than a change the recipient may make unilaterally and simply report after the fact. The request must be submitted by the institution's Authorized Organization Representative/Signing Official (not the PD/PI directly) through the eRA Commons Prior Approval module, or by email to the assigned Grants Management Specialist where the module does not yet cover a given request type, and NIH's practice is to expect submission at least 30 days before the proposed change and to target a response within 30 days of a complete request. Acting on one of these changes without approval is not merely a paperwork lapse: it converts an otherwise defensible administrative decision into a potential audit finding or disallowed cost.

Final Invention Statement & Certification

The Final Invention Statement and Certification (HHS Form 568) is the grant-closeout document by which a federal award recipient certifies, to the funding agency, either a complete list of every subject invention conceived or first actually reduced to practice under the award, or an affirmative statement that no subject invention was made. It is a closeout-stage compliance filing required by NIH and other Public Health Service (PHS) awarding components under the Bayh-Dole Act's standard patent rights clause (37 CFR 401.14), submitted through the Interagency Edison (iEdison) system, and is distinct from the earlier, ongoing obligation to disclose each individual subject invention to the funding agency as it is made.

F&A Waiver

An F&A waiver (indirect cost rate waiver) is an institution's agreement to recover indirect costs on a specific award at less than its full federally negotiated F&A rate -- ranging from a partial reduction to a full waiver to 0%. It is an exception applied award-by-award, not a change to the institution's underlying Negotiated Indirect Cost Rate Agreement (NICRA), which continues to state the institution's full rate for every other award. A waiver is distinct from the de minimis rate (a flat substitute for organizations that have never negotiated a rate at all) and from a sponsor's own published rate cap, though a sponsor cap is the single most common reason institutions grant one.

Risk-Based Quality Management (RBQM)

Risk-Based Quality Management (RBQM) is the quality-by-design framework ICH E6(R2) introduced in its Section 5.0 (2016) and ICH E6(R3) generalized further: sponsors identify and prioritize risks to critical-to-quality trial data and processes starting at protocol design (E6(R2) Section 5.0.1), set predefined quality tolerance limits (QTLs, Section 5.0.4) for a small number of trial-critical parameters, and use centralized statistical monitoring and risk-proportionate on-site/remote monitoring (Section 5.18.3) to detect and correct deviations. RBQM is the overarching quality-management framework; risk-based monitoring (RBM) is one operational technique within it, not a synonym for it.

Clinical Trials Office (CTO)

A Clinical Trials Office (CTO) is the institutional unit -- typically housed within an academic medical center, hospital, or university health science center -- that provides centralized administrative, regulatory, and financial support to investigators conducting clinical trials at that institution. A unit qualifies as a CTO when it performs some combination of budget development and sponsor rate negotiation, clinical trial agreement (CTA) review and negotiation, regulatory-submission support (IRB liaison, FDA correspondence support), coverage-analysis and Medicare Clinical Trial Policy (NCD 310.1) billing-compliance review, and study feasibility/start-up coordination specifically for interventional or observational human-subjects trials -- as distinct from a general Sponsored Programs Office (which administers the institution's full grants and contracts portfolio across all disciplines) and distinct from a Contract Research Organization (an external commercial vendor a sponsor hires to run trial operations, not an internal institutional support office).

Cost Transfer

A cost transfer is the reassignment of an expense already posted to one sponsored project ledger to a different sponsored project (or from a non-sponsored account onto a sponsored one) after the original transaction has occurred. It is distinct from an initial charge decision made at the time an expense is incurred: a cost transfer is always a correction or reclassification made after the fact, moving a real, previously-recorded cost rather than authorizing a new one. Under the allowability and allocability standards at 2 CFR 200.403 and 200.405, every transferred cost must independently satisfy the same tests an original charge would -- necessary, reasonable, allocable to the receiving award in proportion to the benefit it provides, and consistently treated -- a transfer does not get a lower bar just because the underlying expense was legitimate somewhere. Most research institutions require transfers to be processed within a defined window, commonly 90 calendar days from the date the original charge posted, submitted with documentation specific enough that an independent reviewer, such as an auditor, could understand how the error occurred and confirm the new charge is correct -- a generic note that a transfer corrects "a posting error" or moves a cost "to the correct project" does not meet that bar on its own.

Biosafety Level 5 (BSL-5)

There is no “Biosafety Level 5” (BSL-5) in the biosafety containment framework used in the United States. The CDC/NIH publication Biosafety in Microbiological and Biomedical Laboratories (BMBL, 6th edition, 2020) — the primary US reference for laboratory biosafety practice, and the framework incorporated by reference into the NIH Guidelines and the Federal Select Agent Program — defines exactly four cumulative containment levels, BSL-1 through BSL-4. BSL-4 is explicitly the maximum standard containment level: it is reserved for agents that pose a high risk of life-threatening disease, have no routinely available vaccine or treatment, and carry a realistic risk of aerosol transmission (for example Ebola, Marburg, and Variola/smallpox virus). No recognized national or international biosafety framework — including the frameworks referenced by WHO or by other countries’ biosafety authorities — defines a fifth, more stringent numbered tier above BSL-4. A search for “BSL-5” or “Biosafety Level 5” almost always reflects one of three things: (1) a misremembering or misreading of BSL-4 as if the numbering continued further; (2) informal or journalistic usage describing an especially dangerous, BSL-4-level pathogen as needing “level 5” containment for emphasis, with no formal designation behind the phrase; or (3) conflation of BSL-4’s two distinct primary-containment approaches — cabinet laboratories and suit laboratories — or of facility-specific “enhanced” protocols layered on top of baseline BSL-4 for a small number of especially high-consequence agents, as if these were a separate, higher-numbered level rather than variations within BSL-4 itself.

ICH Q10 (Pharmaceutical Quality System)

ICH Q10 (Pharmaceutical Quality System) is the ICH Quality-series guideline that defines a model pharmaceutical quality system (PQS) spanning a product's entire life cycle -- pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. A quality system meets ICH Q10 when it (1) sits on top of applicable Good Manufacturing Practice (GMP/ICH Q7) requirements and incorporates ISO 9001 quality-management-system principles, (2) applies the risk-based tools of ICH Q9 (Quality Risk Management) to prioritize and scope quality decisions, (3) uses the science- and risk-based product/process understanding built during development under ICH Q8 (Pharmaceutical Development), and (4) operates four specific management enablers -- a Process Performance and Product Quality Monitoring System, a Corrective and Preventive Action (CAPA) system, a Change Management System, and Management Review -- under documented senior-management responsibility and a stated commitment to continual improvement.

Select Agent List

The Select Agent List is the HHS/USDA-maintained roster (42 CFR Part 73, 7 CFR Part 331, 9 CFR Part 121) of specific biological agents and toxins determined to pose a severe threat to human, animal, or plant health. Any entity possessing, using, or transferring a listed agent above regulatory exclusion thresholds must register with the Federal Select Agent Program (jointly run by CDC and USDA/APHIS), designate a Responsible Official, and ensure every individual with access clears an FBI Security Risk Assessment; a smaller Tier 1 subset carries additional security and suitability-monitoring requirements.

Declaration of Helsinki

The Declaration of Helsinki is the World Medical Association's statement of ethical principles for medical research involving human participants, first adopted in 1964 (Helsinki) and revised at WMA General Assemblies through the most recent revision, adopted October 19, 2024. It is the operative ethical reference a physician-investigator, sponsor, or ethics committee cites specifically for physician-conducted medical research -- distinct from the Nuremberg Code (a fixed 1947 tribunal judgment) and the Belmont Report (a US-specific 1979 national-commission document underlying the Common Rule) -- and it is the ethical source ICH E6 Good Clinical Practice cites as the origin of its own principles. A study or protocol is judged against the Declaration when the question is whether independent ethics-committee review occurred, informed consent was genuinely obtained, any placebo/no-treatment control arm was ethically justified, and results-transparency obligations were met.

Source Documentation (Source Documents / Source Data)

Source documentation is the body of original records -- medical charts, laboratory reports, imaging studies, pharmacy dispensing logs, subject diaries, correspondence, and automated instrument printouts -- in which clinical findings, observations, or other trial-related activities are first captured, at the point and time they occur. The information those records contain is source data; the records themselves are source documents. A record only counts as a source document for a given data point if it is where that data point was originally recorded -- a transcription onto a separate worksheet or data-collection tool is not itself a source document unless no earlier original record exists. Per ICH E6(R2) Section 1.51, source data is 'all information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial'; Section 1.52 defines source documents as the original documents, data, and records containing that information. To be inspection-ready and support reconstruction of the trial, source documentation must satisfy the ALCOA-C principles: Attributable (identifies who recorded it and when), Legible, Contemporaneous (recorded at the time of the observation, not backfilled), Original (the first record, or a verified certified copy), Accurate, and Complete.

CAPA (Corrective and Preventive Action)

CAPA (Corrective and Preventive Action) is the formal quality-system process an organization uses to investigate a finding -- an audit observation, a protocol deviation, an FDA Form 483 observation, or any other nonconformity -- determine its root cause, implement a correction and corrective action to eliminate that cause, take preventive action to stop the same or a similar problem recurring elsewhere in the system, and verify afterward that those actions actually worked.

ANZCTR (Australian New Zealand Clinical Trials Registry)

The Australian New Zealand Clinical Trials Registry (ANZCTR) is the primary online registry for clinical trials conducted in Australia and New Zealand, distinguished from clinical trial registration generally by being the specific bi-national system, housed and managed by the NHMRC Clinical Trials Centre at the University of Sydney since 2005, that assigns every registered study a unique ACTRN (Australian Clinical Trial Registration Number) and was, in 2007, one of the first three registries the World Health Organization recognized as a Primary Registry under its International Clinical Trials Registry Platform (WHO ICTRP).

Medical Device Amendments of 1976

The Medical Device Amendments of 1976 (Pub. L. 94-295) is the U.S. federal statute, signed by President Gerald Ford on May 28, 1976, that amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to create the modern medical device regulatory framework. Before 1976, FDA had essentially no premarket authority over devices -- only the FD&C Act's general adulteration and misbranding provisions applied, the same standard used for drugs since 1938 but poorly suited to the mechanical, electrical, and implantable nature of devices. The Amendments added Section 513 to the FD&C Act, establishing a risk-based, three-tier classification system (Class I, II, III) and, for the first time, two premarket regulatory pathways keyed to that classification: premarket notification (what the statute's own section number gave us as the now-familiar '510(k)') and premarket approval (PMA) for the highest-risk devices. Devices already legally on the U.S. market when the law took effect were not retroactively required to prove safety and effectiveness from scratch; they were classified based on their existing marketing history, and later devices could establish 510(k) eligibility by claiming 'substantial equivalence' to one of these pre-1976 devices or to a device subsequently cleared through that same route -- the origin of the 'predicate device' concept that still anchors the 510(k) pathway today.

IND Exemption (21 CFR 312.2(b))

The regulatory determination, made by a sponsor under 21 CFR 312.2(b), that a clinical investigation of a drug already lawfully marketed in the United States does not require an Investigational New Drug (IND) application because the study meets all five conditions in the rule: it is not intended to support a new indication or a significant labeling/advertising change, it does not significantly increase the risk (or decrease the acceptability of risk) associated with the drug's approved use, it is conducted in compliance with IRB review (21 CFR Part 56) and informed consent (21 CFR Part 50) requirements, it is not intended to promote the drug for an unapproved use, and it does not involve a route of administration, dosage level, patient population, or other factor that significantly increases the risks associated with the drug's approved use. All conditions must be met simultaneously; failing any one of them means the study needs a full IND regardless of how the others resolve.

21 CFR 314.70 (Changes to an Approved NDA or ANDA)

21 CFR 314.70 is the FDA regulation ("Supplements and other changes to an approved NDA," applied to ANDAs via 21 CFR 314.97) that requires the holder of an approved New Drug Application or Abbreviated New Drug Application to classify every post-approval change to the product, its manufacturing, or its labeling into one of four reporting tracks based on the change’s potential to adversely affect identity, strength, quality, purity, or potency: a Prior Approval Supplement (PAS) for major changes, requiring FDA approval before distribution of product made using the change; a Changes Being Effected in 30 Days supplement (CBE-30) for moderate-risk changes, permitting distribution 30 days after FDA receives the supplement absent an FDA objection; a Changes Being Effected in 0 Days supplement (CBE-0) for a narrower, FDA-designated set of lower-risk changes (most notably certain safety labeling updates), permitting distribution immediately upon FDA’s receipt; and the Annual Report track for minor changes, which are simply documented in the applicant’s next annual report rather than submitted as a standalone supplement. The applicable category is determined by the nature of the specific change, not by applicant discretion.

ePRO (Electronic Patient-Reported Outcomes)

ePRO is the electronic capture of a Patient-Reported Outcome (PRO) directly from a clinical trial participant -- via a provisioned or patient-owned (BYOD) device, app, wearable, or web portal -- without amendment or interpretation by site staff. A data point qualifies as ePRO only when three conditions hold together: (1) the underlying instrument is a validated PRO measure with a defined concept of interest and context of use; (2) the response is entered by the patient at the point of report, not transcribed later by a coordinator or clinician; and (3) the capture system produces a timestamped, attributable, auditable electronic record sufficient to serve as source data for FDA inspection. It is distinguished from Clinician-Reported Outcome (ClinRO) data entered into the trial's eCRF by a site investigator, and from a paper PRO diary that a coordinator later keys into an EDC system -- both of those break the direct-from-patient chain that defines a PRO in the first place.

Medical Device Reporting (MDR)

Medical Device Reporting (MDR) is FDA's mandatory adverse-event reporting system under 21 CFR Part 803, requiring device manufacturers, importers, and device user facilities (hospitals, nursing homes, outpatient facilities) to notify FDA when they become aware that a device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause death or serious injury if the malfunction recurred. It is distinct from the EU's 'MDR' (Regulation (EU) 2017/745, the Medical Device Regulation governing premarket CE marking and market access) -- the two share only an acronym, not a regulatory function.

IND Safety Report

A written or electronic notification that a sponsor holding an active Investigational New Drug (IND) application must submit to FDA, and to every participating investigator, under 21 CFR 312.32, whenever the sponsor determines there is reasonable possibility that the investigational drug caused a serious and unexpected adverse event (i.e., the event qualifies as a suspected unexpected serious adverse reaction, or SUSAR). It is distinct from routine investigator-to-sponsor adverse event reporting, from the IND annual report, and from post-marketing adverse-event reporting under 21 CFR 314.80, which applies only after a drug is approved.

Standard Operating Procedure (SOP)

In a research context, a Standard Operating Procedure (SOP) is a written, controlled, step-by-step instruction for performing a specific recurring task the same way every time it is performed, regardless of who performs it -- distinct from a protocol, which specifies what a particular study will do, and from a policy, which states an institution's general position or requirement. A document counts as a research SOP only if it is: (1) task- or process-specific rather than study-specific (e.g. "how this laboratory calibrates a balance" or "how this site receives and stores investigational product," not "what Study ABC-123 will test"); (2) formally approved and version-controlled, with an identifiable author, approver, effective date, and version/revision history; (3) written in enough procedural detail that a trained staff member unfamiliar with that specific instance of the task could follow it and produce a consistent, auditable result; and (4) actually followed and enforced in practice, with deviations documented -- an unused or unenforced document is not functioning as an SOP even if it is labeled one.

DoD Indirect Cost Rate: ONR/DCAA Process

For institutions whose cognizant federal agency for indirect costs is the Department of Defense (assigned via the Office of Naval Research (ONR) under 2 CFR 200 Appendix III), the standard NICRA negotiation process contains one distinct extra step not present for HHS-cognizant institutions: rather than the cognizant agency's own cost-allocation staff reviewing the university's indirect cost rate proposal in-house, ONR contracts that technical review out to the Defense Contract Audit Agency (DCAA), which independently audits the proposal under DCAA Contract Audit Manual (DCAAM) Chapter 13 -- the chapter specifically covering audits at educational institutions, nonprofit organizations, and FFRDCs -- and returns an audit report to ONR, which ONR then uses as the basis for negotiating the final F&A rate with the institution. The resulting agreement is still an ordinary NICRA under 2 CFR 200 Appendix III; the difference is confined to who performs the underlying audit before negotiation, not to a separate rate instrument or rate structure.

Indirect Cost Rate Proposal

An indirect cost rate proposal is the documentation package an institution of higher education compiles and submits to its cognizant federal agency for indirect costs, under 2 CFR Part 200 Appendix III, to support negotiation of an indirect (F&A) cost rate. It identifies and assigns indirect costs to defined cost pools, selects an allocation base for each pool (or, for small institutions using the simplified method, a single base for total indirect costs), calculates proposed rates, and includes a signed Certificate of Indirect (F&A) Costs. The proposal is the institution's submitted request; the resulting signed document the cognizant agency issues after negotiation is the Indirect Cost Rate Agreement (NICRA), a distinct artifact.

Condition Code 30

Condition Code 30 is the two-digit value ("30 – Qualifying Clinical Trial") entered in the condition codes field of an institutional Medicare claim (UB-04 / CMS-1450, or the equivalent field on the electronic 837I transaction) to flag that the claim includes items or services furnished in connection with a qualifying clinical trial under Medicare's Clinical Trial Policy (National Coverage Determination 310.1). A claim requires Condition Code 30 when the trial meets NCD 310.1's qualifying criteria (falls within a Medicare benefit category, has therapeutic intent, and satisfies one of the NCD's deeming criteria — including NIH, FDA IND, or VA/DOD/CDC/AHRQ/CMS-funded/-supported studies) and the provider is billing Medicare for routine patient-care costs alongside the trial. It is reported on ALL clinical-trial-related institutional claims from a qualifying study, whether or not every line item on that particular claim is trial-related, and is submitted together with ICD-10 diagnosis code Z00.6 (encounter for examination for normal comparison and control in clinical research) and the trial's eight-digit National Clinical Trial (NCT) number — reported as UB-04 value code D4, or in loop 2300, REF02 (REF01 = P4) on the 837I. It functions purely as a claims-processing flag: it does not itself create coverage, it tells the Medicare Administrative Contractor (MAC) which coverage rules to apply to the claim.

SF-424 (Application for Federal Assistance)

The SF-424, "Application for Federal Assistance," is the standard cover-sheet form used to open nearly every application for federal grant or cooperative-agreement funding submitted through Grants.gov. A submission qualifies as using "the SF-424" when it supplies the form's core identifying and administrative data — applicant legal name and Unique Entity Identifier (UEI), type of applicant, funding opportunity number, congressional districts, project title, proposed period of performance, requested federal and non-federal funding amounts, and the Authorized Organization Representative's certification — as the umbrella cover page bundled with program-specific forms in a single Grants.gov Workspace submission package. The base SF-424 (OMB Number 4040-0004) is one member of a wider "SF-424 family": SF-424A (Budget Information for Non-Construction Programs, OMB 4040-0006) and SF-424B (Assurances for Non-Construction Programs) are commonly paired with it, SF-424C/D cover construction programs, and a distinct variant, SF-424 R&R ("Research and Related"), is used by NIH, NSF, and other research-funding agencies in place of the base non-research SF-424. A document is NOT "the SF-424" merely because it is a federal grant application — the term refers specifically to this standardized cover form, not to the full application package, the budget narrative, or agency-specific supplemental forms bundled alongside it.

NIDA GCP Training

NIDA GCP Training refers to the Good Clinical Practice training course developed and administered by NIDA's Center for the Clinical Trials Network (CCTN), the coordinating body for the National Institute on Drug Abuse's Clinical Trials Network (CTN) -- a network of research sites and community treatment programs that conducts multisite trials on substance use disorder treatments. The course is not a separate regulatory standard: its content is built on the same underlying framework as ICH E6 Good Clinical Practice and applicable U.S. Code of Federal Regulations (CFR) provisions for human subjects research, but it is packaged, delivered, and administered specifically by NIDA/CCTN rather than by a third-party provider such as the CITI Program. A record is a genuine instance of 'NIDA GCP Training' when the completion certificate was issued through NIDA's own training platform (gcp.nidatraining.org) rather than through a different GCP course that merely also references ICH GCP.

Protocol Amendment

A protocol amendment is a written, sponsor-initiated description of a change to, or formal clarification of, an already IRB/IEC-approved research protocol. Under ICH E6(R2) Section 1.60, that is the formal definition. An amendment is planned and prospective: it must be submitted to and reviewed by the IRB/IEC (and, for FDA-regulated drug trials, separately reported to FDA under 21 CFR 312.30) and receive documented approval before the changed procedures take effect, with two narrow exceptions -- a change made to eliminate an immediate hazard to subjects, and a change that is purely logistical or administrative (e.g., a monitor's phone number) and does not affect subject safety, rights, welfare, or the scientific integrity of the study. This prospective-approval requirement is what separates an amendment from a <a href='/dictionary/term/protocol-deviation'>protocol deviation</a>, which is an unplanned departure discovered and documented after the fact.

FDA Form 3926

FDA Form 3926, officially the "Individual Patient Expanded Access Investigational New Drug Application," is the streamlined form a treating physician uses to request FDA authorization for a single named patient to receive an investigational drug -- or an approved drug whose availability is restricted by a Risk Evaluation and Mitigation Strategy (REMS) -- outside a clinical trial, under the individual-patient category of FDA's expanded access ("compassionate use") pathway codified at 21 CFR Part 312, Subpart I. A request counts as a Form 3926 submission when: (1) the treating physician (not the manufacturer) files it with the relevant FDA review division, or in a genuine emergency initiates the request by phone/other rapid means and completes the form afterward; (2) the manufacturer/sponsor has agreed, generally via a Letter of Authorization, to supply the product for this specific patient; (3) the physician has documented the patient's brief clinical history, prior therapy, and treatment plan (dose, route, schedule, duration, monitoring) in the form's required sections; and (4) FDA has not objected within the applicable waiting period. Form 3926 is FDA's purpose-built, physician-oriented alternative to filing a full commercial IND application on Form FDA 1571 -- it is not used for multi-patient or sponsor-initiated expanded access categories, and it is not part of the separate Right to Try Act pathway.

RTSM (Randomization and Trial Supply Management)

A system counts as RTSM (Randomization and Trial Supply Management) -- also called IRT (Interactive Response Technology) -- if, within a single platform used by trial sites, it performs at least one of: (1) subject randomization to a treatment arm per the protocol's randomization scheme at enrollment, with blind maintenance and an auditable emergency-unblinding path where the trial is blinded; or (2) trial-supply management -- real-time kit- or dose-level inventory tracking and automatic resupply triggering to sites or depots. Most production RTSM/IRT platforms do both together. A platform that only captures clinical data (an EDC) or only manages site financial, regulatory, and monitoring workflow (a CTMS) is not RTSM/IRT, even though all three are routinely used side by side, and sometimes integrated, on the same trial.

Institutional Biosafety Committee (IBC)

A standing institutional committee, registered with the NIH Office of Science Policy under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, that reviews, approves, and provides ongoing oversight of research involving recombinant or synthetic nucleic acid molecules before such research may begin.

ICH Q9 (Quality Risk Management)

ICH Q9 (Quality Risk Management) is the ICH guideline establishing a systematic process — risk assessment, risk control, risk communication, and risk review — for evaluating, controlling, and communicating risks to pharmaceutical quality across a product's lifecycle. A quality decision follows ICH Q9 when it (1) is grounded in scientific and clinical knowledge ultimately linked to patient protection, (2) applies effort and documentation proportionate to the level of risk involved, and (3) uses a structured method — such as FMEA, FMECA, or HACCP — rather than an ad hoc or purely subjective judgment.

Protocol Deviation

A protocol deviation is any unplanned departure -- by the investigator, study staff, or a subject -- from the procedures, visit schedule, eligibility criteria, or other requirements set out in the IRB/IEC-approved clinical trial protocol, made without prior sponsor agreement and prior IRB/IEC approval. It is distinct from a protocol amendment, which is a formal, prospectively reviewed and approved change to the protocol itself. Deviations are typically classified by severity -- commonly as minor/administrative versus important (also called major or significant) -- based on whether they affect subject rights, safety, or well-being, or the completeness, accuracy, or reliability of study data.

University Intellectual Property (IP) Policy

A university intellectual property (IP) policy is the formal, institution-wide governing document -- adopted by a board of trustees or regents -- that establishes ownership of IP created by faculty, staff, and students using university resources, the obligation to disclose inventions, how resulting revenue is shared with inventors, and how those rules differ for federally sponsored, industry-sponsored, and unsponsored research.

SAM.gov (System for Award Management)

SAM.gov is the U.S. federal government's official, GSA-operated registration and data system for organizations and individuals doing business with the federal government, including recipients of federal financial assistance. An organization is not eligible to receive a federal grant, cooperative agreement, or contract until it has an active SAM.gov entity registration and a valid Unique Entity Identifier (UEI) -- registration is a precondition for award, not a paperwork step that can be completed afterward, and it must be renewed at least every 12 months to stay active.

Collaborative Research Agreement (CRA)

A Collaborative Research Agreement (CRA) is the umbrella contract that governs a joint research project between two or more independent parties -- typically universities, non-profit research institutes, hospitals, and/or companies -- none of which is a federal laboratory acting under statutory authority. A CRA is the instance of this instrument whenever the document (regardless of its exact title, which varies by institution -- 'Collaborative Research Agreement,' 'Joint Research Agreement,' 'Research Collaboration Agreement,' or 'Consortium Agreement' for 3+ parties) sets out, for a defined project and term: (1) a scope of work and each party's respective research contributions (personnel, facilities, funding, data, or existing background IP); (2) ownership and licensing of resulting (foreground) IP, including how jointly-made inventions are handled; (3) publication rights, including any sponsor/partner review period before a paper is submitted; and (4) confidentiality obligations covering information shared in the course of the collaboration. It is the parent agreement under which narrower, single-purpose instruments -- a Material Transfer Agreement (MTA) for a specific biological or physical material, a Confidential Disclosure Agreement (CDA/NDA) for pre-agreement or ancillary confidentiality, or a Data Use Agreement (DUA) for a specific dataset -- are frequently executed as subordinate or referenced agreements for one particular exchange within the larger project.

Indirect Cost Rate Agreement (NICRA)

An Indirect Cost Rate Agreement -- commonly called a NICRA (Negotiated Indirect Cost Rate Agreement) -- is the formal document issued by an organization's cognizant federal agency under 2 CFR 200.414 and its supporting appendices, setting out the specific indirect cost (F&A) rate(s), the distribution base each rate applies to, the rate type (provisional, predetermined, fixed, or final), and the period for which each rate is authorized for use on federal awards.

Preclinical Development

Preclinical development (or nonclinical development) is the drug/biologic development stage between candidate selection and the filing of an Investigational New Drug (IND) application, during which a sponsor generates the animal and in vitro pharmacology, toxicology, and pharmacokinetic (ADME) data — chiefly under Good Laboratory Practice, 21 CFR Part 58, for pivotal safety studies — needed to establish a reasonable basis for testing the candidate safely in humans, alongside early formulation and manufacturing (CMC) work. It does not involve human participants and is therefore distinct from a clinical trial; the common phrase “preclinical trials” is a misnomer — the correct terms are preclinical or nonclinical studies.

Chemistry, Manufacturing, and Controls (CMC)

A regulatory submission qualifies as containing CMC information when it documents, for a specific drug substance and/or drug product, the identity, composition, and manufacturing process used to produce it; the in-process controls and specifications (analytical test methods and acceptance criteria) used to confirm its strength, quality, and purity at each stage; and the stability data supporting the proposed container closure system and shelf life. In an eCTD-formatted submission to FDA or another ICH-aligned regulator, this material is filed as Module 3 (Quality) -- CMC is the informal, universally-used shorthand for that module's content, not a separate submission or a formal ICH-defined term itself. A document that describes only the clinical protocol, nonclinical toxicology, or regulatory administrative forms, with no data on how the product is made, tested, or controlled, does not constitute CMC information regardless of how complete it is on those other dimensions.

EU Clinical Trials Regulation (CTR) & CTIS

A clinical trial is governed by the EU Clinical Trials Regulation (Regulation (EU) No 536/2014, the "CTR") -- and therefore must be authorised and registered through the EU's Clinical Trials Information System (CTIS) -- when it (1) is an interventional trial (not a purely observational/non-interventional study), (2) tests a medicinal product for human use (not a medical device, which falls under the MDR/IVDR instead), and (3) includes at least one trial site in an EU/EEA member state. Since CTIS became the sole authorisation and registration route on 31 January 2025 -- completing a three-year transition away from the prior Clinical Trials Directive 2001/20/EC and the EudraCT/EU Clinical Trials Register it used -- this applies whether the trial runs in a single member state or spans multiple countries via one application, one Reporting Member State (RMS), and any number of other Member States Concerned (MSC).

Plant Variety Protection Act (PVPA)

The Plant Variety Protection Act (PVPA), 7 U.S.C. §§ 2321-2582, is a U.S. federal law, enacted in 1970, that gives plant breeders a certificate-based intellectual-property right in a new, distinct plant variety. It is administered not by the USPTO but by the Plant Variety Protection Office (PVPO), part of USDA's Agricultural Marketing Service. A PVP certificate covers a specific reproducible variety -- as bred, not an underlying gene, trait, or breeding method -- that is new, distinct from existing varieties, and genetically uniform and stable across generations. Originally limited to sexually reproduced (grown from seed) and tuber-propagated varieties, the Agricultural Improvement Act of 2018 (the 2018 Farm Bill) extended PVPA eligibility to asexually reproduced varieties as well, creating overlap with the older plant-patent system for the first time.

Conflict of Interest in Human Subjects Research

A conflict of interest in human subjects research exists when an investigator's, institution's, or IRB member's financial or personal interest could compromise -- or reasonably appear to compromise -- the design, conduct, oversight, or reporting of a study involving human participants. Unlike the general research-COI concept, review here is tied directly to the IRB approval decision: federal guidance and institutional policy require that a significant financial conflict be evaluated and, where warranted, managed under a documented plan before the IRB may approve the protocol, and require any IRB member with a conflicting interest in a specific protocol to recuse from reviewing or voting on it.

21 CFR 314.80 (Postmarketing Reporting of Adverse Drug Experiences)

The FDA regulation (21 CFR Part 314, Subpart B) requiring holders of an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), and nonapplicant manufacturers/packers/distributors named on the drug's label, to surveil for, evaluate, and report postmarketing adverse drug experiences to FDA. It defines what makes an event "serious" (death, life-threatening, hospitalization, persistent disability, congenital anomaly, or an important medical event requiring intervention) and "unexpected" (not described in the drug's current approved labeling), and sets three reporting tracks: 15-day Alert reports for events that are both serious and unexpected, quarterly periodic reports for the first 3 years post-approval, and annual reports thereafter. It is the regulatory mechanism that populates the FDA Adverse Event Reporting System (FAERS) with mandatory manufacturer reports, distinct from FAERS's voluntary MedWatch stream and from pre-market IND safety reporting under 21 CFR 312.32.

OIG Work Plan

An OIG Work Plan is the forward-looking list an agency's Office of Inspector General maintains of audits, evaluations, and inspections it has planned or has underway for the coming period. Unlike an <a href='https://casrai.org/dictionary/term/oig-reports'>OIG report</a>, which documents a completed piece of work and its findings, a Work Plan entry is a statement of intent -- it names a program area, population, or compliance topic the OIG has decided to examine, before the examination has produced any findings. For research administrators, the Work Plan is the single clearest public signal of where a funding agency's oversight attention is headed next, which is why sponsored-programs and compliance offices routinely cross-check active Work Plan items against their own institution's award portfolio.

21 CFR Part 54 (Financial Disclosure by Clinical Investigators)

21 CFR Part 54 is the FDA regulation requiring sponsors of a covered clinical study to obtain, and FDA to evaluate, information about certain financial interests and arrangements held by the clinical investigators who conducted the study. It applies to any 'covered clinical study' -- a study in humans that a marketing applicant or FDA relies on to establish a product's effectiveness (including a study demonstrating equivalence to an approved product), or a study in which a single investigator's data makes a significant contribution to the demonstration of safety -- submitted in support of an NDA, ANDA, BLA, or a device marketing application (PMA or certain 510(k)s). Rather than banning financially interested investigators from participating, Part 54 requires the sponsor to certify (via FDA Form 3454) that no covered investigator has a disclosable financial interest, or to disclose (via FDA Form 3455) any that exist, so FDA can factor that information into its evaluation of the study's reliability. Sections 54.5 and 54.6 -- FDA's authority to act on disclosed interests and the sponsor's recordkeeping obligation -- are part of Part 54 itself but are not addressed by either form.

FDA Form 3455 (Disclosure: Financial Interests and Arrangements of Clinical Investigators)

FDA Form 3455 ('Disclosure: Financial Interests and Arrangements of Clinical Investigators') is the form a marketing-application sponsor files with FDA when its financial-interest review, conducted under 21 CFR Part 54, finds that one or more clinical investigators (or a subinvestigator, spouse, or dependent child) participating in a covered clinical study has a disclosable financial interest or arrangement -- e.g. compensation tied to study outcome, equity in the sponsor exceeding the regulatory thresholds, a proprietary interest in the tested product, or significant payments beyond direct study costs. Rather than certifying the interests' absence (the role of the counterpart form, FDA Form 3454), Form 3455 requires the sponsor to disclose the interest completely and accurately -- its nature and, where applicable, its value -- and, per 21 CFR 54.4(a)(3), describe what steps, if any, were taken to minimize its potential to bias the study's design, conduct, or reporting. It is submitted with the marketing application the covered study supports.

Electronic Batch Record (EBR)

An Electronic Batch Record (EBR) is the electronic-system equivalent of a paper batch record in GMP-regulated manufacturing: the record documenting, for one specific manufactured batch, that each step of the validated Master Production Record was performed -- by whom or by which qualified automated equipment, when, with what materials and quantities, and with what in-process results -- retained in a system meeting 21 CFR Part 11 controls (validation, independent audit trail, access control, attributable electronic signatures) because it is the electronic record being used to satisfy the GMP predicate requirement at 21 CFR 211.188. A record only functions as an EBR, rather than a digitized image of a paper record, if the generating system itself is validated and Part-11-compliant.

Real-World Evidence (RWE)

Real-World Evidence (RWE) is clinical evidence about the usage, benefits, or risks of a medical product derived from the analysis of Real-World Data (RWD) -- data relating to patient health status and/or care delivery that is routinely collected outside the controlled setting of a randomized controlled trial (RCT). RWD sources include electronic health records (EHRs), medical claims and billing data, product and disease registries, and data from digital health technologies or patient-generated sources. RWE becomes regulatory-grade evidence only after the underlying RWD has been assessed as fit for use -- relevant, reliable, and sufficiently complete for the specific question being asked -- and the study design (e.g., pragmatic trial, prospective registry study, or retrospective database analysis) adequately addresses confounding and bias, since RWE studies typically lack the randomization and blinding that isolate causal effect in a traditional RCT.

ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients)

ICH Q7 ("Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients") is the International Council for Harmonisation's harmonized GMP guideline governing the manufacture of active pharmaceutical ingredients (APIs) -- from starting materials through the finished API -- as distinct from finished-dosage-form manufacturing (governed by 21 CFR 210/211 or EudraLex Volume 4 Part I). FDA adopted it as guidance (originally "Q7A," effective September 25, 2001, later recodified to Q7); it also forms the basis of EudraLex Volume 4, Part II in the EU.

Fair Information Practice Principles (FIPPs)

Fair Information Practice Principles (FIPPs) are a U.S.-originated framework of privacy norms governing how organizations collect, use, disclose, and secure personal information. First articulated in the 1973 HEW report Records, Computers, and the Rights of Citizens, they underpin the Privacy Act of 1974 and were later reflected in the OECD's 1980 Guidelines on the Protection of Privacy. A dataset-handling or systems practice qualifies as FIPPs-aligned when it addresses, at minimum: transparency/notice about what personal data is collected and why; purpose specification and use limitation (data used only for stated, compatible purposes); data minimization (collecting no more than necessary); individual participation (the ability to access, correct, or contest one's own records); data quality and integrity; security safeguards; and accountability for compliance. There is no single canonical numbered list — the original HEW report set out five principles, the Privacy Act of 1974 codified eight statutory safeguards, and later agency restatements (for example the U.S. Department of Homeland Security's widely cited 2008 formulation) group them into eight principles: Transparency, Individual Participation, Purpose Specification, Data Minimization, Use Limitation, Data Quality and Integrity, Security, and Accountability and Auditing. FIPPs is a governance framework, not itself a statute — it becomes binding only where a specific law (such as the Privacy Act of 1974 for federal agency records, or a sector law like the Family Educational Rights and Privacy Act) incorporates it.

Human Research Participant (Human Subject)

A human research participant (the regulatory term is "human subject") is a living individual about whom an investigator conducting research either obtains information or biospecimens through intervention or interaction, or obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens (45 CFR 46.102(e)). "Subject" is the term used in the Common Rule and IRB paperwork; "participant" is the term preferred by APA style and many journals for manuscript prose. Both refer to the same regulatory category of person.

Non-Interventional Study

A non-interventional study is a clinical study of a medicinal product in which treatment assignment is not decided in advance by a protocol, prescribing and enrollment decisions are kept separate, and no diagnostic or monitoring procedures beyond normal clinical practice are imposed. Under EU Regulation (EU) No 536/2014, Article 2(2)(4), it is defined directly as any clinical study that is not a clinical trial. The classification determines whether a study needs prior competent-authority/ethics approval under the EU Clinical Trials Regulation, whether it triggers an FDA IND, and which registration/reporting regime applies.

Investigational Device

A device is an "investigational device" under FDA's IDE regulation (21 CFR 812.3(g)) when it is "the object of an investigation" -- being studied in a clinical investigation to generate safety or effectiveness data for a use FDA has not already cleared or approved, rather than being used strictly within its existing cleared/approved labeling. Whether the study needs a full IDE application and FDA approval, or only abbreviated requirements, depends on whether the device is classified significant risk (SR) or nonsignificant risk (NSR) under 21 CFR 812.3(m).

Consolidated Screening List (CSL)

A single, merged database published by the US Department of Commerce (trade.gov) that consolidates the restricted- and denied-party lists maintained separately by the Departments of Commerce (BIS: Denied Persons List, Entity List, Unverified List, Military End-User List), State (AECA Debarred List, Nonproliferation Sanctions list), and Treasury (OFAC's Specially Designated Nationals List and related sanctions lists). Institutions screen a party's name against the CSL once to check for a match on any contributing list, then trace a hit back to the underlying regulation (EAR, ITAR, or an OFAC sanctions program) it falls under. Source lists are updated daily.

ClinicalTrials.gov

ClinicalTrials.gov is the NLM-operated (NIH, with FDA) public registry and results database for clinical studies, distinguished from clinical trial registration generally by being the specific U.S. system launched in 2000 (FDAMA Sec. 113) whose mandatory-registration and results-reporting requirements were established by the FDAAA 801 final rule (effective 18 January 2017), and which assigns every registered study a unique NCT identifier.

Grants.gov Registration

The prerequisite entity-registration process an organization -- university, nonprofit, or small business -- must complete before it can submit an application through Grants.gov, the federal government's shared portal for discretionary federal grant opportunities. Registration is built on a SAM.gov entity record and a Unique Entity Identifier (UEI), not on Grants.gov itself; Grants.gov authenticates against SAM.gov rather than maintaining a separate applicant database.

OFAC List (SDN List)

The "OFAC list" ordinarily refers to the Specially Designated Nationals and Blocked Persons List (SDN List) maintained by the US Department of the Treasury's Office of Foreign Assets Control (OFAC). OFAC administers and enforces economic and trade sanctions based on US foreign policy and national security goals, targeting foreign countries, regimes, terrorists, international narcotics traffickers, weapons-of-mass-destruction proliferators, and other threats. The SDN List names individuals, companies, research institutions, non-profits, vessels, and aircraft with which US persons -- including US universities and their employees -- are generally prohibited from dealing at all: their property and interests in property that come within US jurisdiction are "blocked" (frozen), and virtually all transactions between them and a US person are prohibited absent a specific OFAC license or applicable general license. OFAC also maintains a broader Consolidated Sanctions List (which folds in several narrower sectoral and program-specific lists) and country-based comprehensive sanctions programs (for example, on Cuba, Iran, North Korea, Syria, and the Russia-related programs); an entity or person can be sanctioned by inclusion in one of those programs without appearing on the SDN List specifically. For research institutions, "checking the OFAC list" is shorthand for restricted-party screening: running a prospective international collaborator, visiting scholar, subrecipient, vendor, or payment counterparty through OFAC's Sanctions List Search tool (which uses fuzzy-name matching) before entering into the relationship or releasing funds or controlled items.

Independent Review Committee (IRC)

An Independent Review Committee (IRC) — also called a Blinded Independent Central Review (BICR) in oncology trials — is a panel of qualified, external reviewers (typically radiologists or other specialists) who re-assess protocol-specified efficacy endpoint data, most commonly medical imaging, according to a predefined charter and standardized criteria (e.g., RECIST for tumor response). Reviewers work independently of the trial sponsor, investigators, and local site assessors, and are blinded to treatment assignment and to the local site's own read, to produce a bias-minimized, reproducible determination of endpoints such as objective response rate (ORR), progression-free survival (PFS), or time to progression (TTP). FDA guidance on cancer drug approval and on clinical trial imaging endpoints recommends or requires an IRC/BICR specifically when a trial is not fully blinded and endpoint assessment could otherwise be influenced by knowledge of treatment assignment.

National Research Act of 1974

The National Research Act (Public Law 93-348) is the U.S. federal statute, signed into law by President Nixon on July 12, 1974, that created the modern legal framework for protecting human subjects in research. It established the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research and charged it with identifying the basic ethical principles that should govern human-subjects research; that mandate is what produced the Belmont Report in 1979. Separately, the Act amended the Public Health Service Act to require that any institution receiving federal funding for biomedical or behavioral research involving human subjects establish an Institutional Review Board (IRB) to review and approve such research before it begins -- the statutory origin of mandatory IRB review, later codified in regulation at 45 CFR 46 (the Common Rule). A statute qualifies as "the National Research Act" in this sense only if it is Public Law 93-348 itself (or a provision directly traceable to it); the Belmont Report and the Common Rule are downstream products the Act required or made possible, not the Act itself.

IRB Number (IRB ID)

The unique identifier an Institutional Review Board assigns to a single approved research protocol at the time of initial submission, used to track and reference that specific study throughout its review lifecycle (approval, amendment, continuing review, closure) and to cite in manuscripts, consent forms, and funder reports — distinct from the institution's OHRP IRB Registration Number (identifies the review board itself) or Federalwide Assurance (FWA) number (identifies the institution as a whole).

Clinical Study

A clinical study is the umbrella term ClinicalTrials.gov and the U.S. National Library of Medicine (NLM, part of NIH) use for any research study involving human volunteers (participants) that is intended to add to medical knowledge. Under this definition, every clinical study is one of two subtypes: an interventional study — commonly called a clinical trial — in which participants are prospectively assigned, according to a protocol, to receive a specific intervention (a drug, device, procedure, or behavioral change) so its effect can be evaluated; or an observational study, in which participants are assessed for health-related outcomes or characteristics as they occur naturally, without the investigator assigning any intervention. "Clinical study" is therefore broader than "clinical trial": every clinical trial is a clinical study, but not every clinical study is a clinical trial. This is a separate axis of classification from NIH's own narrower, funding-and-policy-consequential test for whether a specific study is an "NIH-defined clinical trial" (prospective assignment to an intervention to evaluate its effect on a health-related biomedical or behavioral outcome) — a study can be a clinical trial in the general ClinicalTrials.gov sense while the NIH four-question test is what actually determines registration, reporting, and funding-opportunity obligations for NIH-funded work.

Electronic Medical Record (EMR)

An electronic medical record (EMR) is the digital equivalent of a single healthcare provider's paper chart: a patient's medical and treatment history as captured, stored, and used within one clinical practice or healthcare organization. An artifact is an EMR (rather than an EHR) when its data model, access controls, and interoperability are scoped to a single organization's internal clinical workflow, not designed for structured exchange with external providers, payers, or research systems -- even if the underlying software vendor also sells EHR-branded products elsewhere.

Vulnerable Populations in Research

A research participant or class of participants that 45 CFR 46 (the Common Rule) subjects to additional, IRB-enforced protections beyond ordinary informed-consent review: either because they fall into one of three subparts with dedicated, codified requirements (Subpart B — pregnant women, human fetuses, and neonates; Subpart C — prisoners; Subpart D — children), or because the IRB determines under §46.111(b) that they are otherwise likely to be vulnerable to coercion or undue influence (e.g., individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons) and documents the additional safeguards included to protect their rights and welfare.

Non-Practicing Entity (NPE)

An entity that owns one or more issued or pending patents but does not manufacture, sell, or otherwise commercially practice the invention itself, and instead generates value from the patent through licensing, litigation/demand-letter assertion, or both. "Non-practicing" describes the entity's relationship to the patent, not the patent's validity -- individual inventors, universities and research institutions, pre-commercialization startups, failed operating companies holding residual portfolios, and dedicated patent-acquisition/licensing firms are all NPEs in this technical sense, even though only a narrower subset of them (the FTC's "patent assertion entity," or PAE, category, and the pejorative "patent troll" label) draw the negative connotation the term is often assumed to carry.

Investigator-Initiated Study (IIS)

An investigator-initiated study (IIS), also called an investigator-initiated trial (IIT), is a clinical trial that an individual investigator -- not a pharmaceutical or device company -- designs, initiates, and holds primary regulatory responsibility for conducting. The distinguishing test is not whether an academic clinician is involved (nearly every clinical trial has one), but who originates the protocol and holds the regulatory authorization to conduct it: the Investigational New Drug (IND) application for a US drug/biologic trial, or the Investigational Device Exemption (IDE) for a device trial. Under 21 CFR 312.3, an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered, is a "sponsor-investigator" -- a single person who simultaneously carries the regulatory obligations FDA assigns to a sponsor (21 CFR 312 Subpart D, sections 312.50-312.59) and those assigned to an investigator (sections 312.60-312.69). 21 CFR 812.3 defines the equivalent role for device studies conducted under an IDE. This is what distinguishes an IIS from a physician serving only as a participating-site principal investigator in an industry-sponsored multi-site trial, where a company holds the IND/IDE and remains sponsor of record.

Humanitarian Use Device (HUD)

A device qualifies as a Humanitarian Use Device (HUD) when it is intended to treat or diagnose a disease or condition that affects, or is manifested in, not more than 8,000 individuals in the United States per year (FD&C Act Section 520(m); 21 CFR Part 814, Subpart H). For a diagnostic device, the threshold is applied to the number of people who would be subject to diagnosis by the device, not to the prevalence of the disease itself. HUD designation, granted by FDA's Office of Orphan Products Development, is the required first step before a sponsor may submit a Humanitarian Device Exemption (HDE) application -- a marketing authorization that permits FDA approval based on a finding of probable benefit outweighing risk, rather than the reasonable assurance of effectiveness a standard Premarket Approval (PMA) requires.

FDA (Food and Drug Administration)

The U.S. Food and Drug Administration (FDA) is the federal agency within the Department of Health and Human Services (HHS) responsible for protecting public health by regulating the safety and effectiveness of human and veterinary drugs, biological products, and medical devices, along with the U.S. food supply, tobacco products, and cosmetics. In a research context, FDA is the authority that reviews and authorizes Investigational New Drug (IND, 21 CFR Part 312) and Investigational Device Exemption (IDE, 21 CFR Part 812) applications before a human clinical investigation of an unapproved drug, biologic, or device may proceed, and it inspects trial sites, sponsors, IRBs, and manufacturing facilities for compliance with its regulations. FDA is organized into center-level components with jurisdiction over different product categories -- principally CDER (drugs), CBER (biologics), and CDRH (devices) for research purposes -- plus a field-inspection arm, the Office of Inspections and Investigations (OII, renamed from the Office of Regulatory Affairs in an October 2024 reorganization).

OMB Compliance Supplement

The OMB Compliance Supplement is the annual publication, issued by the US Office of Management and Budget and codified as 2 CFR Part 200, Appendix XI, that gives independent auditors the compliance requirements and suggested audit procedures to test, program by program, when conducting a Single Audit of a non-federal entity under 2 CFR 200 Subpart F.

Australian Code for the Responsible Conduct of Research

Australia's foundational research-integrity governance document (the "2018 Code"), jointly issued by the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC), and Universities Australia in June 2018, replacing the more prescriptive, rules-based 2007 Code. It is a principles-based document setting out eight principles of responsible research conduct (honesty, rigour, transparency, fairness, respect, recognition of the rights of Indigenous peoples to be engaged in research that affects or is of significance to them, accountability, and promotion of responsible research practices) plus 29 specific responsibilities — 13 for institutions (R1–R13) and 16 for researchers (R14–R29). Unlike the National Statement on Ethical Conduct in Human Research, which governs the ethical review of studies involving human participants specifically, the Code covers research-integrity conduct broadly across all disciplines: authorship, data management and retention, supervision, publication and dissemination, peer review, conflicts of interest, and how institutions must manage and investigate potential breaches.

Trademark

A word, phrase, symbol, design, or combination of these that identifies and distinguishes the source of goods or services in commerce (a mark used with goods is a trademark; the identical protection used with services is a service mark). Trademark rights arise automatically from actual use of the mark in commerce, under the Lanham Act (15 U.S.C. § 1051 et seq.); federal registration with the USPTO is not required to have enforceable rights but converts geographically-limited common-law rights into a nationwide, publicly recorded claim. Unlike a patent (protects an invention), a copyright (protects a creative work), or a trade secret (protects confidential information via secrecy), a trademark protects only the identifier itself, and lasts indefinitely as long as the mark stays in active use and any registration is maintained.

Software License Agreement

A software license agreement, in a university technology-transfer context, is the contract a TTO uses to grant an outside company or party rights to use, modify, and/or distribute software the university itself developed — the university acting as licensor of its own copyright (and occasionally an associated patent), not as a licensee of someone else's commercial software. Because software is protected primarily by copyright rather than patent (computer programs are "literary works" under 17 U.S.C. § 101, added by the Computer Software Copyright Act of 1980), the agreement's exclusivity controls the specific codebase and its expression, not the underlying idea or method (17 U.S.C. § 102(b)) — a materially different scope of exclusivity than a patent license conveys. Typical negotiated terms include exclusive vs. non-exclusive scope, field-of-use and territory restrictions, royalty/fee structure (upfront fees, running royalties, minimums, or equity), source code delivery/escrow, maintenance and support obligations, ownership of derivative works, sublicensing and audit rights, termination, and — for federally funded software — flow-down of the government's 2 CFR § 200.315 use rights.

Electronic Data Capture (EDC)

Electronic Data Capture (EDC) is the general category of software systems that collect clinical or research study data directly in electronic form -- via electronic case report forms (eCRFs) -- at the point of collection, in place of paper-based data collection. A system counts as EDC when it provides study-specific eCRFs, direct point-of-collection data entry, field-level validation and query management, and an audit trail sufficient to make the electronic record the study's data of record. EDC is the site-facing data-entry layer within the broader discipline of clinical data management; a full Clinical Data Management System (CDMS) is the broader term covering EDC plus surrounding query-management, coding, and database-lock workflow. EDC is distinct from a Clinical Trial Management System (CTMS), which manages trial operations rather than the research data itself. Both non-profit/academic platforms (e.g., REDCap) and commercial, enterprise-scale platforms (e.g., Medidata Rave EDC, Oracle Clinical One) fall within the EDC category.

Clinical Trials Unit (CTU)

A unit is a Clinical Trials Unit (CTU) when it is a centralized institutional infrastructure -- organizationally part of the same academic medical center, hospital, or university as the investigators it serves, not a separately contracted external entity -- that provides shared, reusable operational services (regulatory support, data management, monitoring, biostatistics, and/or budgeting) to more than one investigator or study across the institution, so no individual Principal Investigator has to build that infrastructure from scratch for a single trial. Investigators engage a CTU internally, through a service agreement, cost-recovery charge, or institutional mandate for certain trial types -- not through a Clinical Trial Agreement the way an external sponsor engages a Contract Research Organization (CRO).

Fly America Act

The requirement, under 49 U.S.C. § 40118 and its implementing Federal Travel Regulation (41 CFR part 301-10, subpart B), that air transportation paid for with U.S. government funds -- including federal grants and cooperative agreements -- be provided by a U.S. flag air carrier, unless a specific, narrowly defined exception applies (an Open Skies bilateral/multilateral agreement, documented necessity, or a defined travel-time/connection threshold).

Biosafety Level 3 (BSL-3)

The CDC/NIH BMBL laboratory-containment tier assigned to a protocol when the biological agent(s) involved can cause serious or potentially lethal disease through inhalation of infectious aerosols, but for which a licensed vaccine or effective treatment is routinely available. An instance of BSL-3 combines controlled/restricted access, sustained directional inward airflow through a double-door entry, HEPA-filtered exhaust, biosafety-cabinet use for all open agent manipulation, and respiratory protection where indicated, with the level itself formally assigned through an Institutional Biosafety Committee (IBC) risk assessment before laboratory work begins.

Software Patent

A software patent is a utility patent under 35 U.S.C. § 101 whose claims are directed to a computer-implemented invention — an algorithm, data-processing method, or system whose novelty lies substantially in what a computer program does. There is no separate statutory category for software; instead, software claims are tested against the same judicially created "abstract idea" exception to § 101 that applies to every utility patent, using the two-step framework the Supreme Court set out in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012), and applied directly to computer-implemented claims in Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014): (1) is the claim, as a whole, "directed to" an abstract idea, and if so, (2) do the claim elements, individually or in combination, supply an "inventive concept" that amounts to "significantly more" than the abstract idea itself? Generic computer hardware performing a well-known process does not supply that inventive concept. Because software claims reach Step One's abstract-idea inquiry far more often than claims in most other technology areas, and because Step Two sets a genuinely demanding bar, software patents are markedly harder to obtain and to defend against post-grant invalidity challenges than most other utility patents.

OHRP (Office for Human Research Protections)

OHRP is the HHS office that oversees institutional compliance with the Common Rule (45 CFR 46) for HHS-conducted or HHS-supported human-subjects research. It administers the Federalwide Assurance (FWA) program institutions file to commit to Common Rule compliance, registers the IRBs designated under those assurances, and conducts compliance oversight -- not-for-cause evaluations and for-cause investigations -- of institutions and IRBs, issuing determination letters and, where warranted, corrective-action or FWA-restriction remedies. OHRP's jurisdiction is the institution's assurance and its IRB's registration and conduct, not direct review or approval of individual study protocols.

Good Pharmacovigilance Practices (GVP)

Good Pharmacovigilance Practices (GVP) is the European Medicines Agency's formal, numbered set of guidelines (GVP Modules I-XVI, with Modules XI-XIV void) governing how EU marketing-authorisation holders, national competent authorities, and the EMA itself must detect, assess, and prevent adverse effects and other medicine-related problems across an authorised medicine's lifecycle. Issued under Article 108a of Directive 2001/83/EC as amended, GVP requires an EEA-resident Qualified Person Responsible for Pharmacovigilance (QPPV), a maintained Pharmacovigilance System Master File (PSMF), and EudraVigilance-routed safety reporting. GVP incorporates but is not identical to the internationally harmonised ICH E2 guideline series (E2A/E2B/E2C(R2)/E2D): ICH E2 sets the global base definitions and formats several GVP modules cite directly, while GVP adds EU-specific structures (QPPV, PSMF, EudraVigilance, GVP-specific inspection) that ICH E2 does not itself require.

CFIUS (Committee on Foreign Investment in US)

CFIUS (the Committee on Foreign Investment in the United States) is the US federal interagency committee, chaired by the Secretary of the Treasury and acting under Section 721 of the Defense Production Act of 1950 (as amended by FIRRMA in 2018) and its implementing regulations at 31 CFR Part 800, that reviews “covered transactions” — foreign acquisitions of control of a US business, and, since FIRRMA, certain non-controlling foreign investments granting governance or information rights in a critical-technology, critical-infrastructure, or sensitive-personal-data US business (a “TID US business”) — for national security risk.

Patentability of Biological Subject Matter

Whether a claimed invention involving a living organism, cell, or genetic/biological material is patent-eligible subject matter under 35 U.S.C. § 101 turns on one question: has a human being changed it into something with markedly different characteristics from what exists in nature, or is the claim, in substance, directed to the product or law of nature itself, merely isolated, purified, or observed? "Manufacture" and "composition of matter" in Section 101 reach human-made, human-altered living organisms — the fact that something is alive is not, by itself, a bar to patenting (Diamond v. Chakrabarty, 447 U.S. 303 (1980)). But those same terms do not reach a naturally occurring nucleic-acid sequence merely separated from its surrounding genetic material, because isolating something nature already made is not an act of invention (Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)). A synthetic construct that does not occur in nature — such as complementary DNA (cDNA), which omits the non-coding intron sequences present in the genomic original — remains patent-eligible even under Myriad, because a lab technician creates something structurally new when cDNA is synthesized.

Certificate of Confidentiality (CoC)

A Certificate of Confidentiality (CoC) is a federal legal protection, under Section 301(d) of the Public Health Service Act (42 U.S.C. 241(d)) as amended by the 21st Century Cures Act, that shields a researcher from being legally compelled -- by subpoena, court order, or similar legal, administrative, or legislative demand -- to disclose names or other identifying information about research participants. For NIH-funded research collecting or using identifiable, sensitive information, a CoC has attached automatically, as a standing term of the award, since October 1, 2017 (NOT-OD-17-109), replacing the prior application-based system under which investigators had to request a certificate for each project. A CoC does not de-identify or otherwise secure the underlying data -- it is a legal shield against compelled disclosure through legal process, not a data-security or data-masking control, and it does not protect against every disclosure (recognized exceptions include participant consent, certain legally mandated reporting, and DHHS or FDA regulatory access).

Data Breach Response Plan

A data breach response plan for research data is a documented, pre-established procedure -- distinct from a generic enterprise IT incident response plan -- specifying how an institution or research team will detect, contain, assess the impact of, and report a security incident involving research data, with particular attention to data subject to a specific regulatory, contractual, or funder obligation: HIPAA-covered protected health information (PHI), data obtained under a signed Data Use Agreement or a controlled-access repository's data use certification (e.g., NIH's dbGaP), export-controlled technical data (EAR/ITAR), or identifiable human-subjects data subject to IRB oversight. What distinguishes it from a general IT incident response plan is not the detection/containment mechanics -- those follow the same ISO/IEC 27001 Annex A.5.24-A.5.28 discipline any organization uses -- but an explicit notification-routing step naming, for each data type, which additional party (an IRB, a funding agency, a repository's Data Access Committee, an export control office) must be notified, and on what timeline, on top of whatever an institution's central IT security office already does for any security incident.

Utility Patent

A utility patent is a patent granted under 35 U.S.C. § 101 for a new and useful process, machine, article of manufacture, or composition of matter, or a new and useful improvement of one of those four categories -- it protects how an invention works or functions, not its ornamental appearance (design patent, 35 U.S.C. § 171) or its status as a newly-created asexually-reproduced plant variety (plant patent, 35 U.S.C. § 161). It is the default patent category: an application is a utility application unless expressly filed as design or plant. Something qualifies as a utility patent if its claims are directed to one of the four § 101 categories and it separately satisfies novelty, non-obviousness, utility, and enablement during USPTO examination.

Designated Institutional Official (DIO)

The individual appointed by an ACGME-accredited Sponsoring Institution's Governing Body who holds institution-wide authority and responsibility for the oversight and administration of every graduate medical education (GME) program the institution sponsors, and who is accountable to the Accreditation Council for Graduate Medical Education (ACGME) for the institution's compliance with its Institutional, Common, and specialty-specific Program Requirements -- distinct from the "Institutional Official" role used in federal human-subjects and financial-conflict-of-interest compliance.

FDA Form 1572 (Statement of Investigator)

FDA Form 1572 ("Statement of Investigator") is the signed document by which an individual becomes an "investigator" of record on an FDA-regulated drug or biologic trial conducted under an Investigational New Drug (IND) application. Under 21 CFR 312.53, a sponsor may not permit an investigator to begin participating in the study until this form -- along with the investigator's curriculum vitae and financial disclosure information -- is completed and signed. The investigator's signature affirms they are qualified to conduct the study and constitutes a written commitment to comply with FDA's clinical-investigation regulations, including protocol adherence, IRB oversight, informed consent, adverse-event reporting, and recordkeeping. Only the person who meets the 21 CFR 312.3 definition of "investigator" -- the responsible leader of the site's study team, commonly the principal investigator -- signs the form; subinvestigators are listed on it but do not sign their own.

Biosafety Level 4 (BSL-4)

The CDC/NIH BMBL's maximum laboratory-containment tier, assigned when a protocol involves biological agent(s) that pose a high risk of life-threatening disease, for which no vaccine or treatment is routinely available, and for which aerosol transmission (or an unpredictable transmission risk tied to a known aerosol-transmissible agent) is a realistic exposure route. An instance of BSL-4 combines a dedicated, physically isolated facility; either a positive-pressure supplied-air suit or a Class III biosafety-cabinet line for all agent manipulation; redundant, dedicated, HEPA-filtered air supply and exhaust; and a mandatory personnel decontamination shower on exit -- with the level itself formally assigned through an Institutional Biosafety Committee (IBC) risk assessment, and, for most BSL-4 agents, additional oversight under the Federal Select Agent Program, before laboratory work may begin.

Biosafety Level 2 (BSL-2)

The CDC/NIH BMBL laboratory-containment tier assigned to a protocol when the biological agent(s) involved pose a moderate hazard to personnel and the environment, are generally treatable or preventable, and are transmitted primarily by direct/mucous-membrane contact, ingestion, or percutaneous exposure rather than by infectious aerosol. An instance of BSL-2 combines restricted laboratory access, biohazard signage, a certified biosafety cabinet for any aerosol- or splash-generating procedure, and standard PPE, with the level itself formally assigned through an Institutional Biosafety Committee (IBC) risk assessment before laboratory work begins.

Data Ownership

The allocation of legal title to and decision-making control over a research dataset. Because raw data is rarely copyrightable and no single U.S. statute assigns default ownership of research data, the operative answer in practice comes from a combination of institutional policy, the funder's terms and conditions, the Data Management Plan, and any executed data sharing/use agreement -- not from a single ownership doctrine. Distinguish from data stewardship/custodianship, which describes accountability for a dataset's day-to-day management regardless of who holds title.

HIPAA Accounting of Disclosures

A disclosure of protected health information (PHI) is subject to the HIPAA accounting-of-disclosures requirement at 45 CFR §164.528 when a covered entity makes it without the individual's authorization and it does not fall into one of the Privacy Rule's enumerated exempt categories (treatment/payment/health care operations, disclosures to the individual, incidental disclosures, authorized disclosures under §164.508, facility-directory/care-related disclosures, national-security/law-enforcement disclosures, limited-data-set disclosures under §164.514(e), or disclosures made before the covered entity's Privacy Rule compliance date). An individual has the right to request — and the covered entity must provide within 60 days, extendable once by 30 — a written accounting of every disclosure meeting that definition made in the six years preceding the request.

CTCAE (Common Terminology Criteria for Adverse Events)

The Common Terminology Criteria for Adverse Events (CTCAE) is NCI/CTEP's standardized terminology and 5-point severity-grading scale (Grade 1-5) for adverse events in clinical trials. An event is graded under CTCAE when a study team assigns it the grade whose published, term-specific criteria it meets in the version specified by the protocol -- from Grade 1 (mild; observation only) to Grade 5 (death related to the event) -- not an ad hoc severity judgment. CTCAE grades severity only; it is distinct from whether an event separately meets regulatory 'serious adverse event' (SAE) criteria or is causally related to the study intervention.

Regulatory Affairs

Regulatory affairs, in a research-institution context, is the function -- an office, unit, or role -- responsible for identifying which regulatory frameworks apply to a given study (human-subjects protections, FDA drug/biologic/device rules, biosafety and recombinant-DNA oversight, controlled-substance handling, export control, and comparable frameworks outside the US), preparing and maintaining the submissions those frameworks require (e.g., an Investigational New Drug (IND) application under 21 CFR Part 312, or an Investigational Device Exemption (IDE) under 21 CFR Part 812), and keeping the study's regulatory record current for the life of the project. It is distinct from Institutional Review Board (IRB) review, which evaluates a study's ethics and human-subjects protections, and from Good Clinical Practice (GCP) conduct, which governs how a trial is run day to day -- regulatory affairs is the function that determines which of those requirements attach to a study in the first place and manages the paper trail with the regulator.

Open Innovation Networks

An open innovation network is a multi-party, ongoing arrangement in which a university (typically through its technology transfer office) intentionally sources and shares R&D and intellectual property across organizational boundaries, per Henry Chesbrough's open innovation framework (2003) -- rather than relying solely on internally generated, exclusively-held R&D. Three elements distinguish it from an ordinary bilateral deal: (1) multiple external parties (not a single sponsor), (2) a standing, often membership-based structure rather than a one-off transaction, and (3) non-exclusive or shared IP access as the default rather than one party holding exclusive rights. Common forms at research universities include NSF-style Industry-University Cooperative Research Centers (IUCRC), university innovation hubs and accelerators, open-source hardware/software collaborations, and pre-competitive research consortia.

NIH Salary Cap

The NIH salary cap is the maximum annual rate of institutional base salary that NIH (and other HHS agencies applying the same limitation, including CDC, AHRQ, and SAMHSA) will reimburse against a grant, cooperative agreement, or contract. It is not a limit on what an institution may pay an investigator — it is a limit on what federal grant funds may reimburse. The cap is set by statute at the rate for Executive Level II of the Federal Executive Pay Schedule and, since FY2026, can change more than once within a fiscal year: for awards issued October 1, 2025 through December 31, 2025, the cap is $225,700; for awards issued January 1, 2026 through September 30, 2026, it is $228,000 (per Guide Notice NOT-OD-26-034, effective date corrected by NOT-OD-26-038). For a 9-month academic-year appointment, the proportional equivalent of the $228,000 rate is approximately $171,000. Since FY2025 (NOT-OD-25-025), the cap applies to both direct salaries of individuals working on NIH projects and indirect salaries (executive salaries in uncapped cost pools) — not direct salary alone, as was the case FY1990–FY2024. Any portion of an investigator's institutional base salary above the applicable cap, for the percentage of effort charged to an NIH award, cannot be charged to that award — the institution must either cost-share the excess from non-federal funds or reduce the effort percentage charged to stay within the capped amount.

OIG Reports

An OIG report is any audit, evaluation, investigation, or periodic report published by a federal agency's Office of Inspector General (OIG) -- an independent oversight unit created under the Inspector General Act of 1978 -- documenting findings, recommendations, questioned costs, or enforcement referrals concerning that agency's own programs, operations, grantees, or contractors.

Inspection Readiness

Inspection readiness is the continuously maintained state of an institution's or clinical trial site's preparedness to undergo a regulatory inspection -- an FDA Bioresearch Monitoring (BIMO) inspection, a GMP or GLP inspection, or a sponsor/CRO audit -- at any time, rather than a set of tasks performed reactively once a specific visit is scheduled. Operationally, a site is "inspection ready" when its essential documents and regulatory binder (or Trial Master File) are organized and current as a matter of routine, staff know their assigned roles for an inspection visit, internal quality reviews or mock audits are conducted on a recurring schedule (not only pre-visit), and open corrective and preventive action (CAPA) items are being tracked and closed continuously. A site that only assembles its files, briefs its staff, and closes outstanding issues after receiving notice of an inspection is "preparing" for that one visit -- it is not inspection ready in the operational sense, because the same gaps would exist if FDA showed up unannounced.

Animal Welfare Act (AWA)

The primary US federal law (7 U.S.C. §2131 et seq., originally enacted 1966 as the Laboratory Animal Welfare Act, Pub. L. 89-544) that sets minimum standards for the humane care, handling, and treatment of certain warm-blooded animals used in research, teaching, testing, exhibition, and transport, enforced by USDA APHIS under the Animal Welfare Regulations (9 CFR Parts 1-3). It excludes rats and mice bred for research, birds bred for research, and cold-blooded animals from its definition of "animal," and — together with PHS Policy — is one of two legal bases requiring a research institution to convene an IACUC.

REDCap (Research Electronic Data Capture)

REDCap (Research Electronic Data Capture) is a secure, metadata-driven, web-based software platform for building surveys and case-report-form databases for research, originated at Vanderbilt University in 2004. An instance only counts as REDCap if it runs the actual Vanderbilt-distributed software, licensed at no cost to non-profit institutions through the REDCap Consortium and installed/administered by that partner institution -- there is no direct commercial purchase path or self-service individual signup. Typical uses include participant surveys, longitudinal case report forms, and multi-site clinical data capture, frequently chosen specifically because the platform supports HIPAA, FDA 21 CFR Part 11, FISMA, and GDPR compliance controls at the institutional level.

National Statement on Ethical Conduct in Human Research

Australia's core ethics-governance document for research involving human participants, jointly developed and issued by the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC), and Universities Australia under the National Health and Medical Research Council Act 1992. Every Human Research Ethics Committee (HREC) in Australia applies it when reviewing a proposed study; it is organised around four core values (research merit and integrity, justice, beneficence, respect) plus topic-specific chapters, and functions as Australia's counterpart to the US Common Rule/Belmont Report and Canada's TCPS2. The current operative edition is the 2025 update (released 1 April 2025, effective from 23 June 2026), which revised Section 4; the prior 2023 update (effective 1 January 2024) revised Chapter 2.1 and Section 5.

HIPAA (Health Insurance Portability Act)

Something is properly described as "HIPAA" (rather than another privacy regime) when it derives from the Health Insurance Portability and Accountability Act of 1996 (Pub. L. 104-191) or the federal regulations HHS issued under its Title II Administrative Simplification authority -- principally the Privacy Rule (45 CFR Part 160 and Subparts A/E of Part 164), the Security Rule (45 CFR Part 160 and Subparts A/C of Part 164), and the Breach Notification Rule (45 CFR Part 164, Subpart D, added via the HITECH Act of 2009). These rules apply only to a 'covered entity' (a health plan, health care clearinghouse, or health care provider that transmits health information electronically in connection with a standard transaction) or its business associates, and only to 'protected health information' (PHI) -- individually identifiable health information, as defined at 45 CFR 160.103, held or transmitted by one of those entities. HIPAA is a distinct federal regime from the Common Rule (45 CFR 46), which governs the ethics of human-subjects research (IRB review, informed consent) rather than the privacy/security of health data; the two frequently apply to the same study but are evaluated against different criteria by different offices.

Cost Accounting Standards (CAS)

A cost accounting practice at a US institution of higher education is governed by the Cost Accounting Standards (CAS) when the institution has received $50 million or more in federal awards subject to 2 CFR Part 200 Subpart E in its most recently completed fiscal year, triggering compliance with CAS 501, 502, 505, and 506 (48 CFR 9905.501/.502/.505/.506) as incorporated via 2 CFR 200.419 and Appendix III. The operative test is consistency, not any single accounting method: the same institution must use the same cost-accounting practice when it estimates a cost in a proposal, when it accumulates that cost in its books, and when it reports that cost on an award, and it must apply the same direct-vs-indirect classification to like costs in like circumstances institution-wide. An institution below the $50 million threshold is not CAS-governed in this sense, even though it still must satisfy the separate, universally applicable cost-principle tests of allowability, allocability, and reasonableness.

Data Safety Monitoring Board (DSMB)

An independent group of clinical, statistical, and (where relevant) bioethics experts, external to a trial's investigators and sponsor, that periodically reviews accumulating -- typically unblinded -- safety and efficacy data from an ongoing clinical trial at pre-specified intervals, and recommends to the sponsor whether the trial should continue, be modified, or stop, for safety, demonstrated efficacy, or futility. Generally required by NIH policy for multi-site trials with substantial participant risk, most notably Phase III trials. Distinct from bodies that review a protocol before it opens (a Scientific Review Committee), advise on organizational strategy (a Scientific Advisory Board), or conduct human-subjects ethics review (an IRB) -- a DSMB's function begins only once a trial is enrolling and is confined to ongoing data monitoring.

Conflict of Interest (COI) in Research

A conflict of interest (COI) exists whenever a researcher's, reviewer's, official's, or institution's outside financial or personal interests could reasonably be seen to compromise, or actually do compromise, objective and unbiased conduct, review, or oversight of research. The test is whether a reasonable person could conclude the secondary interest created a risk of undue influence over the primary interest -- not whether bias in fact occurred. COI is distinct from research misconduct: an undisclosed or unmanaged conflict is treated as a violation, but the underlying interest itself is not, by default, evidence of wrongdoing.

Prior Art

Prior art is any evidence — a patent, a published patent application, a journal article, a conference presentation or poster, a thesis, a product already on sale, or a device already in public use — showing that a claimed invention, or something that would render it obvious, was already publicly known or otherwise available before the patent application's effective filing date (or, for an application claiming priority from an earlier filing, the priority date). Under 35 U.S.C. 102(a)(1), prior art includes material the inventor made public themselves, not only material originating from someone else. Under 102(a)(2), an earlier-filed U.S. patent application naming a different inventor also counts as prior art as of its filing date once it later publishes or issues — so-called "secret prior art" — even though it was not publicly visible at the time. A reference or event functions as prior art only if it discloses the claimed invention outright (defeating novelty under 35 U.S.C. 102) or, in combination with other references, would have made the invention obvious to a person having ordinary skill in the art (defeating non-obviousness under 35 U.S.C. 103).

Risk-Based Monitoring (RBM)

Risk-based monitoring (RBM) is a clinical trial monitoring methodology, formally incorporated into ICH E6(R2)/(R3) Good Clinical Practice and described in FDA's 2013 guidance for industry, in which a sponsor allocates monitoring resources -- the mix of centralized, remote, and on-site activities, and the extent of source data verification (SDV) -- according to a documented, protocol-specific risk assessment of what is most likely to affect participant safety and the reliability of trial results. It replaces the older default of fixed-frequency on-site visits with 100% SDV at every site, regardless of actual risk, with a monitoring plan that is proportionate to identified risk and revisited as the trial progresses.

Continued Process Verification (CPV)

Continued Process Verification (CPV) is Stage 3 of the FDA's three-stage process validation lifecycle, set out in the FDA's January 2011 guidance "Process Validation: General Principles and Practices." It is an ongoing program -- required under 21 CFR 211.180(e) -- of collecting and statistically trending process and product data during routine commercial production to confirm the manufacturing process remains in a validated "state of control" after Stage 1 (Process Design) established the process and Stage 2 (Process Qualification) demonstrated it was capable of reproducible commercial manufacturing. A single Process Performance Qualification run is Stage 2, not CPV -- CPV is the continuing program that follows it for the life of the product.

ICH E6(R3) (Good Clinical Practice Guideline Revision)

ICH E6(R3) is the current, staged-adoption revision of ICH's core Good Clinical Practice guideline, replacing E6(R2) (2016). It comprises overarching Principles plus Annex 1 (traditional interventional trials -- ICH Step 4 6 January 2025; EU/UK/Switzerland effective 23 July 2025; FDA final guidance 8 September 2025, non-binding) and Annex 2 (non-traditional/decentralized trial designs -- ICH Step 4 3 June 2026; EU effective 15 January 2027; FDA has not yet issued Annex 2 guidance). Substantively it shifts to a risk-proportionate, quality-by-design approach, adds explicit technology/electronic-systems and decentralized-trial provisions, and restructures investigator/sponsor responsibilities around the Principles rather than as a standalone checklist.

Adverse Event (AE)

Any untoward medical occurrence in a subject administered a pharmaceutical or investigational product, whether or not it is considered related to that product — the causality-neutral base definition set by ICH E2A, from which the narrower Serious Adverse Event (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR) categories are derived.

Laboratory Safety (OSHA Chemical Hygiene Plan)

A written, laboratory-specific compliance program required under OSHA's Laboratory Standard (29 CFR 1910.1450) whenever hazardous chemicals are used in a laboratory on a non-production basis; it sets out procedures, engineering/administrative controls, PPE, training, exposure monitoring, and a designated Chemical Hygiene Officer, and is distinct from biosafety programs governing biological agents.

NIH Public Access Policy

A specific NIH funding-compliance requirement — not a general "open access" commitment — under which any peer-reviewed journal article arising in whole or in part from NIH funds must have its Author Accepted Manuscript submitted to PubMed Central (PMC) upon acceptance for publication. For articles accepted for publication on or after July 1, 2025, the manuscript must be made publicly available in PMC immediately, with zero embargo, at the article's official date of publication; articles accepted before that date remain governed by the prior policy's 12-month embargo. Compliance is tracked through a PMCID that grant recipients must cite in progress reports and in any subsequent application or progress report referencing that publication.

ICH (International Council for Harmonisation)

The international standard-setting body — a Swiss non-profit association of drug regulatory authorities and pharmaceutical-industry associations — that develops and maintains the harmonised technical guidelines, grouped into Quality (Q), Safety (S), Efficacy (E), and Multidisciplinary (M) series, used to register medicines for human use across its member jurisdictions; ICH E6 Good Clinical Practice is one specific guideline it publishes, not a synonym for the organization itself.

Investigational Medicinal Product Dossier (IMPD)

The Investigational Medicinal Product Dossier (IMPD) is the EU/UK clinical-trial-application document presenting the quality (chemistry, manufacturing, controls), nonclinical, and clinical data on a specific medicinal product being used in a clinical trial -- submitted under Regulation (EU) No 536/2014, Annex I, Section G (via CTIS) or, in the UK, to the MHRA under SI 2004/1031. It documents the product; it is not the product itself (see Investigational Medicinal Product). A full IMPD follows the ICH CTD Module 3/4/5 format; a simplified IMPD -- referencing a current Summary of Product Characteristics (SmPC) instead -- is permitted for an already-authorised product used within its marketing authorisation, a previously-assessed unmodified product, or most placebos.

FDA Form 483

An FDA Form 483 is a written list of "inspectional observations" that an FDA investigator hands to a firm's or site's management at the conclusion of an on-site inspection, whenever the investigator judges that observed conditions or practices may violate the Food, Drug, and Cosmetic (FD&C) Act or related FDA regulations. A Form 483 is not a final Agency determination of a violation and does not itself carry legal force — FDA's own guidance is explicit that inspectional observations "do not represent a final Agency determination regarding compliance." The form is used across every type of FDA-regulated inspection — drug and biologic cGMP facilities, medical device manufacturers, food facilities, nonclinical (GLP) testing laboratories, and Bioresearch Monitoring (BIMO) inspections of clinical trial sites, sponsors, and IRBs — wherever an FDA investigator identifies conditions serious enough to document as an observation.

Human Tissue Act (UK)

The Human Tissue Act 2004 is the UK statute (England, Wales, and Northern Ireland) governing the removal, storage, and use of human tissue from both the living and the deceased for defined "scheduled purposes," including research into disorders or the functioning of the human body. It makes "appropriate consent" the legal precondition for these activities and establishes the Human Tissue Authority (HTA) to license and inspect the organisations -- including research tissue banks -- that store human tissue for research.

Belmont Report

The Belmont Report is the 1979 statement titled "Ethical Principles and Guidelines for the Protection of Human Subjects of Research," issued by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (created by the National Research Act of 1974 in response to the Tuskegee Syphilis Study). It establishes three basic ethical principles for human-subjects research -- Respect for Persons, Beneficence, and Justice -- each linked to a specific application (informed consent, risk/benefit assessment, and equitable selection of subjects, respectively). It is not itself a regulation, but its principles were subsequently codified into binding federal regulation at 45 CFR 46 (the Common Rule) and remain the ethical basis every U.S. IRB applies when reviewing human-subjects research.

De-identification

De-identification is the process of removing or altering direct and indirect identifiers in a dataset so that a specific individual cannot reasonably be identified from it, either alone or combined with other information a realistic recipient could obtain. It is a general concept operationalized differently across frameworks — HIPAA defines two concrete de-identification methods that remove data from the Privacy Rule's scope entirely, while the GDPR distinguishes reversible pseudonymisation (still personal data) from full anonymisation (outside GDPR's scope) and never uses the term "de-identification" itself. Whether a given approach is adequate always depends on the residual risk of re-identification, not simply which fields were removed.

21 CFR Part 11: Electronic Records & Signatures

21 CFR Part 11 is FDA's regulation establishing the criteria under which an electronic record or electronic signature is considered trustworthy, reliable, and equivalent to a paper record or handwritten signature, for any record an FDA predicate rule (e.g., Good Clinical Practice, Good Manufacturing Practice, Good Laboratory Practice) already requires a regulated organization to create, modify, maintain, archive, retrieve, or transmit. It does not create new record-keeping obligations on its own -- and, per FDA's 2003 scope-and-application guidance, its full electronic-record controls apply only when the record is maintained electronically in place of paper to satisfy that predicate requirement.

Investigational Medicinal Product (IMP)

An Investigational Medicinal Product (IMP) is the EU and UK clinical-trials regulatory term (Regulation (EU) No 536/2014, Article 2(2)(5); the UK's Medicines for Human Use (Clinical Trials) Regulations 2004, SI 2004/1031, as amended) for a medicinal product -- a drug, biologic, or placebo -- that is being tested or used as a reference in a clinical trial, including an already-authorised product used, formulated, or packaged differently than its approved marketing authorisation, used for an indication it isn't approved for, or used to gain further information about an approved use. It is functionally equivalent to, but not the same regulatory term as, the US FDA's "investigational new drug" (21 CFR 312.3) or the ICH E6 GCP-harmonised umbrella term "investigational product" (E6(R2) §1.33).

HIPAA in Clinical Research

A research activity falls under 'HIPAA in clinical research' when a HIPAA covered entity (or its business associate) creates, uses, or discloses protected health information (PHI) in connection with a systematic investigation designed to develop or contribute to generalizable knowledge (45 CFR 164.501). Because research is not treatment, payment, or health care operations, the Privacy Rule's general TPO permissions do not apply -- a covered entity may use or disclose PHI for research only through one of the pathways the Rule specifically authorizes: (1) a subject-signed Authorization meeting the core-element and required-statement standards of 45 CFR 164.508; (2) an IRB- or Privacy Board-granted waiver or alteration of Authorization under 45 CFR 164.512(i), documented against the Rule's minimal-risk criteria; (3) disclosure as a Limited Data Set under a Data Use Agreement (45 CFR 164.514(e)); (4) de-identification under the Safe Harbor or Expert Determination method (45 CFR 164.514(a)-(b)), which removes the data from HIPAA's scope entirely; or (5) narrower exceptions for reviews preparatory to research and for research on a decedent's information (both at 45 CFR 164.512(i)(1)). HIPAA governs this data-privacy layer only -- it is a separate federal regulatory regime from the Common Rule (45 CFR 46) and FDA human-subjects regulations that govern the ethical conduct of the research itself (IRB review, informed consent to participate). A single study involving PHI at a covered entity typically must satisfy both regimes concurrently, through separate, though often procedurally combined, analyses and documents.

Good Laboratory Practice (GLP)

Good Laboratory Practice (GLP) is the FDA quality-system regulation (21 CFR Part 58) governing how nonclinical (preclinical) laboratory safety studies — chiefly animal toxicology and safety-pharmacology studies — are planned, conducted, monitored, recorded, and reported when submitted to support an IND, NDA, BLA, or other FDA research or marketing application; internationally, the OECD Principles of GLP serve the same function under the Mutual Acceptance of Data (MAD) system.

Biosafety Level (BSL)

The graded laboratory-containment classification -- BSL-1 through BSL-4 -- assigned under the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) framework, combining a biological agent's Risk Group with the specific laboratory practices, personal protective equipment, and facility engineering controls a given protocol requires. For research involving recombinant or synthetic nucleic acid molecules, the BSL is formally assigned through an Institutional Biosafety Committee (IBC) risk assessment under the NIH Guidelines before any lab work may begin.

Pseudonymisation

Under GDPR Article 4(5), pseudonymisation is the processing of personal data so that it can no longer be attributed to a specific data subject without additional information, provided that additional information is kept separately and is protected by technical and organisational measures ensuring non-attribution. Pseudonymised data remains personal data under GDPR (Recital 26) because re-identification stays technically possible with the separately-held key — unlike anonymised data, where re-identification is not reasonably possible and GDPR no longer applies. GDPR Article 89(1) names pseudonymisation directly as an accepted safeguard for processing personal data for scientific/historical research, archiving in the public interest, or statistical purposes, supporting research-specific derogations from certain data subject rights.

Clinical Research Coordinator (CRC)

A Clinical Research Coordinator (CRC) is the site-based professional who manages the day-to-day conduct of a clinical trial at a single investigational site under the delegation and direction of the Principal Investigator (PI) -- screening and consenting participants, scheduling and conducting study visits, entering data into case report forms, and maintaining source documents and regulatory files in compliance with the protocol, Good Clinical Practice (GCP), and applicable regulations. A CRC is employed by the investigational site itself (a hospital, academic medical center, or dedicated trial site), not by the trial sponsor or a contract research organization (CRO) -- this employer/authority distinction is what separates a CRC from a Clinical Research Associate (CRA), who is sponsor/CRO-employed and independently monitors a portfolio of sites, including verifying the CRC's own source data, rather than executing day-to-day site operations.

Federalwide Assurance (FWA)

A Federalwide Assurance (FWA) is a written, time-limited agreement an institution files with HHS's Office for Human Research Protections (OHRP) committing the institution -- not any single study -- to comply with the Common Rule (45 CFR 46) for the nonexempt human-subjects research it conducts or supports through funding from HHS or any other U.S. federal department or agency that has adopted the Common Rule and relies on OHRP's FWA. It is signed by an institutional Signatory Official, names a Human Protections Administrator, and must designate at least one IRB already registered with OHRP to perform the review the FWA commits the institution to.

FERPA (Family Educational Rights and Privacy Act)

FERPA (20 U.S.C. § 1232g; 34 CFR Part 99) is the U.S. federal law giving eligible students privacy rights over their education records and restricting a federally funded institution from disclosing personally identifiable information from those records without consent; a research project is subject to FERPA whenever it accesses, uses, or receives education records the institution already maintains — as distinct from new data collected directly from consenting participants — and the institution may disclose those records only under a recognized exception (school official, studies exception, de-identified/coded data, or directory information) or with the eligible student's written consent.

Bayh-Dole Act

The Bayh-Dole Act (Public Law 96-517, enacted December 12, 1980, codified at 35 U.S.C. §§ 200–212) is the federal statute allowing universities, nonprofit institutions, and small businesses to retain title to inventions made under federal funding agreements -- grants, cooperative agreements, or contracts -- in exchange for disclosing the invention to the funding agency, electing within a set window whether to keep title, filing a patent application, and accepting the government's retained rights, including a nonexclusive government-use license, march-in rights (35 U.S.C. § 203), and a U.S. manufacturing preference on exclusive licenses (35 U.S.C. § 204). It applies only to a 'subject invention' conceived or first reduced to practice under a qualifying federal award held by an eligible recipient; it does not apply to inventions made without federal funding.

Trade Secret

Information that (1) derives independent economic value from not being generally known or readily ascertainable by others who could profit from it, and (2) is subject to reasonable efforts by its owner to maintain its secrecy, per the two-element definition shared by the federal Defend Trade Secrets Act (18 U.S.C. § 1839(3)) and the state-law Uniform Trade Secrets Act. Unlike a patent, a trade secret is never registered or examined by a government office and carries no fixed term: it lasts exactly as long as both elements continue to hold, and ends the moment either fails.

Clinical Outcome Assessment (COA)

A measure that describes or reflects how a clinical trial participant feels, functions, or survives, captured via a clinician's report (ClinRO), the patient's own report (PRO), a non-clinician observer's report (ObsRO), or a standardized performance task (PerfO) — used, per FDA's COA framework, as a direct measure of clinical benefit rather than a substitute (as a biomarker-based surrogate endpoint is).

Contract Research Organization (CRO)

An organization counts as a Contract Research Organization (CRO) for a given clinical trial when a sponsor has contracted it, under a written agreement (per ICH E6(R2) Section 5.2 and, for FDA-regulated trials, 21 CFR 312.52), to assume one or more specific trial-related duties and functions -- such as site management, monitoring, data management, biostatistics, pharmacovigilance, or regulatory submissions -- on the sponsor's behalf. The sponsor retains ultimate responsibility for trial data quality and integrity regardless of which functions are transferred, and must actively oversee the CRO's performance of those functions, including any further subcontracted work.

Clinical Research Associate (CRA)

A Clinical Research Associate (CRA) is the industry job title for the professional who performs the ICH E6(R2)-defined clinical trial "monitor" function on behalf of a trial sponsor or a contract research organization (CRO): overseeing an investigational site's conduct, verifying source data against case report forms, confirming protocol and Good Clinical Practice (GCP) compliance, and reporting site-visit findings back to the sponsor. CRAs are employed by the sponsor or a CRO -- not by the investigational site itself -- and typically travel to a portfolio of assigned sites across the life of a trial.

Clinical Research Assistant

An entry- to early-career, site-based clinical trial support role that assists study staff with participant scheduling, data entry, specimen handling, and documentation under supervision -- without independent authority to monitor site compliance, review regulatory documents, or verify source data, which distinguishes it from a Clinical Research Associate (CRA).

TCPS2 (Tri-Council Policy Statement)

TCPS2 is the joint policy of Canada's three federal research funding agencies (CIHR, NSERC, SSHRC) that sets the ethical principles and requirements Research Ethics Boards (REBs) apply when reviewing research involving human participants, their data, or their biological materials, and compliance with it is a condition of institutional eligibility for Tri-Agency funding.

Scientific Advisory Board (SAB)

An external, independent panel of subject-matter experts convened by a company, research institution, foundation, or funded program to advise leadership on scientific direction and strategy — which programs, indications, or research questions to prioritize, and how the organization's science compares with the field. An SAB is advisory only: it has no governing, regulatory, or fiduciary authority, no independent power to approve, halt, or modify a specific study or protocol, and its recommendations are non-binding.

Creative Commons License

A standardized, pre-written public copyright license published by Creative Commons that a rights holder attaches to a work to grant reusers specified permissions (attribution, share-alike, noncommercial, no-derivatives, in any standard combination) in advance, without individual negotiation. CC0 is a related public-domain dedication, not technically a license.

Patent Prosecution

Patent prosecution is the administrative process of pursuing a patent grant from a patent office (the USPTO in the US, or a foreign equivalent such as the EPO) -- drafting and filing the application, responding in writing to the examiner's office actions, amending claims, and carrying the application through to allowance and issuance. It is distinct from patent litigation, which enforces or challenges a granted patent's validity in court after the fact.

Scientific Review Committee (SRC)

An institutional committee — distinct from the IRB — that reviews a research protocol’s scientific merit and feasibility (originality, study design, statistical plan, and accrual feasibility) before or alongside IRB ethical review. Most commonly a formal requirement at NCI-designated cancer centers, where it forms part of the NCI-mandated Protocol Review and Monitoring System governing cancer clinical trial protocols.

RightsLink

RightsLink is the automated permission-clearance and licensing platform operated by the Copyright Clearance Center (CCC), embedded on the article or book-chapter page it covers as a "Get Rights and Content" / "Request Permissions" control. A given reuse falls under RightsLink when the underlying content is traditionally copyrighted (all rights reserved, or held by the publisher under a copyright transfer agreement) and the reader needs the rightsholder's affirmative permission before reusing it beyond fair use/fair dealing -- e.g., republishing a figure, including an excerpt in a coursepack, or translating a chapter. Clicking the control routes the request through CCC's hosted workflow, which returns either a generated price and license, a no-fee license for many standard academic uses, or escalates to the publisher's rights department for non-standard requests.

Debarment and suspension verification (SAM.gov)

Verifying, before a subaward or covered federal contract, that the other party and its principals are not debarred, suspended, or excluded from federal funds. Required by 2 CFR 200.214 and 2 CFR Part 180 via a SAM.gov Exclusions search, a signed certification, or a contract clause under 2 CFR 180.300.

Cost Accounting Standards Disclosure Statement (DS-2)

A formal document, tied to 2 CFR 200.419 and reproduced as Appendix III to 2 CFR Part 200, in which an institution of higher education (IHE) describes how it accounts for costs charged to federally sponsored awards -- how it distinguishes direct costs from Facilities & Administrative (F&A/indirect) costs, and how it treats items such as depreciation, leave, and deferred compensation. Any IHE receiving an aggregate total of $50 million or more in federal awards subject to Subpart E of the Uniform Guidance during its most recently completed fiscal year is subject to the Cost Accounting Standards Board's standards CAS 501, 502, 505, and 506 (48 CFR 9905.501, .502, .505, .506) -- consistency in estimating/accumulating/reporting costs, consistency in allocating costs incurred for the same purpose, accounting for unallowable costs, and cost accounting period, respectively. Before 1 October 2024, crossing that same $50 million threshold also created a standalone obligation to file a DS-2 with the institution's cognizant federal agency for indirect costs (usually HHS or the Department of Defense's Office of Naval Research, assigned by whichever agency provides the majority of the institution's federal funding). OMB's April 2024 revision to the Uniform Guidance, effective for awards made on or after 1 October 2024, removed the standalone DS-2 filing requirement from the regulatory text -- the underlying obligation to comply with CAS 501/502/505/506 at the $50 million threshold was not removed, only the separate mandate to submit a dedicated disclosure form documenting it. In practice, many institutions still maintain a DS-2-format document as their internal cost-accounting governance record and as the basis for F&A rate negotiations, even though a fresh regulatory filing is no longer independently required.

NISO Access and License Indicators (ALI)

NISO RP-22: machine-readable metadata (free_to_read, license_ref) letting systems determine an article's access status and reuse terms without parsing prose.

Clinical Trial Registration

The act of submitting a clinical trial's identifying and design information — sponsor, condition studied, intervention, key eligibility criteria, and primary/secondary outcome measures — to a recognized public clinical-trial registry (ClinicalTrials.gov or any other WHO ICTRP primary registry) so the trial's existence and design are publicly discoverable independent of whether or how its results are ultimately published. Registration identifies the trial before or during its conduct; posting the trial's results to the same registry after completion is a separate, later obligation (results reporting), not part of registration itself.

Prospective Clinical Trial Registration

Registration of a clinical trial in a public, WHO-recognized registry (for example ClinicalTrials.gov or another WHO ICTRP primary registry) at or before the date of first participant consent for enrollment — ICMJE's operative date is when the registry record was submitted, not when it was posted publicly. Registration submitted after enrollment has already begun is retrospective, not prospective, regardless of how far before manuscript submission it occurs.

Exempt human subjects research

Human subjects research that an institution's IRB or another authorized reviewer — never the investigator personally — has formally determined falls within one of the eight categories listed at 45 CFR 46.104(d) of the U.S. Common Rule, and has accordingly been relieved from the initial full-board or expedited review pathway and from ongoing continuing review. 'Exempt' describes the outcome of a review decision, not an absence of review: a study is not exempt merely because an investigator judges it low-risk, anonymous, or otherwise harmless. It becomes exempt only once someone with institutional authority has checked the protocol against the specific regulatory category and recorded that determination, typically through the IRB office rather than a convened committee meeting. Four of the eight categories — (d)(2), (d)(3), (d)(7), and (d)(8) — additionally require a 'limited IRB review' of privacy, confidentiality, or broad-consent safeguards before the exemption applies, so even exempt research can pass through IRB scrutiny once; it is only relieved of the continuing, ongoing review that non-exempt research remains subject to.

Ethics approval statement

A statement within a manuscript — typically in the Methods or a dedicated ethics-declarations section — asserting that a study involving human participants, human data or tissue, or animals received prior approval from a named, independent ethics review body, and identifying that body, an approval or protocol reference number, and the date of approval (or documenting an applicable exemption or waiver), sufficient for an editor or reader to verify that ethical oversight preceded the research rather than merely occurred at some point.

OPEN Government Data Act

A federal agency data asset falls under the OPEN Government Data Act's open-by-default requirement when it was created by, collected by, or is under the control, direction, or maintenance of a federal agency, and its public release as machine-readable data in an open format under an open licence is not otherwise restricted by law (e.g., privacy, national security, confidentiality, or other statutory non-disclosure provisions). Agencies may weigh a cost-benefit analysis before converting an asset to an open format, but the statutory default is publication, not withholding.

ICH GCP (Good Clinical Practice)

ICH GCP is the ICH-issued international standard (current core revision: E6(R3), finalized 6 January 2025) for the ethical and scientific conduct, recording, and reporting of interventional clinical trials involving human subjects, incorporated into FDA, EMA, MHRA, PMDA, and Health Canada regulatory frameworks.

Conflict of interest disclosure

The institutional process by which investigators report significant financial interests, fiduciary relationships, and other competing interests that could directly and significantly affect the design, conduct, or reporting of their research, enabling the institution to assess and manage, reduce, or eliminate identified conflicts.

Data processor

A natural or legal person, public authority, agency or other body that processes personal data on behalf of the controller, as defined in Article 4(8) of the GDPR, only on documented instructions from the controller and bound by a written contract meeting Article 28 requirements.

Data controller

The natural or legal person, public authority, agency or other body that, alone or jointly with others, determines the purposes and means of the processing of personal data, as defined in Article 4(7) of the GDPR.

Privacy by design

The obligation under Article 25 of the GDPR for a controller to implement appropriate technical and organisational measures at the time of determination of the means of processing and at the time of processing itself in order to implement data-protection principles effectively and integrate the necessary safeguards into the processing.

Data Protection Impact Assessment (DPIA)

A documented assessment required under Article 35 of the GDPR where a type of processing is likely to result in a high risk to the rights and freedoms of natural persons, describing the processing, assessing necessity, proportionality, and risks, and identifying mitigating measures.

Right to erasure

The right under Article 17 of the GDPR for a data subject to obtain from the controller the erasure of personal data concerning them without undue delay where one of the grounds in Article 17(1) applies and no exception in Article 17(3) operates.

Data subject rights (GDPR)

The collective set of rights conferred on identifiable individuals by Chapter III of the GDPR (Articles 12-22), including the rights to be informed, of access, to rectification, to erasure, to restriction of processing, to data portability, to object, and not to be subject to solely automated decision-making with legal or similarly significant effects.

Withdrawal of consent

The exercise by a research participant of the right to revoke their consent to ongoing participation in research, after which the investigator must cease prospective collection of data or biospecimens from that participant and apply the protocol-specified handling of data already collected.

Dynamic consent

A consent model implemented via a secure digital platform that enables participants to grant, modify, or withdraw consent for specific research uses over time and to receive ongoing communication about studies that use their data or samples.

Broad consent

A regulatory consent option introduced by the 2018 revised Common Rule at §46.116(d) by which a subject consents prospectively to the storage, maintenance, and secondary research use of identifiable private information or identifiable biospecimens for future unspecified studies, subject to the elements enumerated in that paragraph.

Informed consent

The voluntary agreement of a prospective research participant, or their legally authorised representative, to take part in a specific research activity, given after disclosure of the information required by the applicable regulation and free from coercion or undue influence.

HIPAA Privacy Rule

The US federal regulation at 45 CFR Parts 160 and 164 Subparts A and E that establishes national standards for the protection of individually identifiable health information held or transmitted by covered entities and their business associates, requiring authorisation, a waiver, or another permitted basis for any use or disclosure for research.

GDPR (General Data Protection Regulation)

The European Union regulation that governs the processing of personal data of individuals in the EU, requiring a lawful basis for processing, transparency to data subjects, data-minimisation, security, and accountability, with extraterritorial application where data subjects in the EU are targeted or monitored.

Confidentiality agreement (NDA)

A contract by which one or more parties agree to keep specified non-public information in confidence and to use it only for a defined purpose for a defined period, typically as a precursor to scientific discussions or contract negotiations.

Data Sharing Agreement (DSA)

A contract between two or more parties that governs the bidirectional or multilateral exchange of data, allocating responsibilities for data quality, security, lawful basis, sub-processor use, and any controller-to-controller or joint-controller obligations.

Data Use Agreement (DUA)

A contractual instrument required before a recipient may access an identifiable, restricted, or limited dataset that defines permitted uses, security obligations, re-disclosure prohibitions, destruction requirements, and breach-notification duties.

Material Transfer Agreement (MTA)

A bilateral contract governing the transfer of tangible research materials between two institutions that defines permitted uses, ownership of the original material and derivatives, publication rights, liability, and onward-transfer restrictions.

Common Rule (45 CFR 46)

The US federal policy for the protection of human subjects codified at 45 CFR Part 46 Subpart A and adopted by twenty federal departments and agencies, which applies to all non-exempt human-subjects research conducted or supported by those agencies.

IACUC (Institutional Animal Care and Use Committee)

An institutionally appointed committee constituted under the US Animal Welfare Act regulations and the PHS Policy on Humane Care and Use of Laboratory Animals that reviews and approves all proposed activities involving vertebrate animals before such activities may begin.

REC (Research Ethics Committee)

A UK or EU committee constituted to provide an independent ethical opinion on a research proposal involving human participants, their tissue, or their identifiable data before the research may lawfully commence.

IRB (Institutional Review Board)

An institutionally designated committee constituted under 45 CFR 46.107 that reviews, approves, requires modification of, or disapproves research involving human subjects before any such research may be initiated at the institution. Depending on risk level, review proceeds through one of three pathways -- exempt, expedited, or full board -- and, for FDA-regulated research, the IRB also operates under the parallel 21 CFR Part 56 regulation.

Reuse license

A set of terms and conditions that facilitates the reuse of published information.

Publishing agreement

A legal contract between publisher and author(s) to publish written material by the author(s). This may involve a single written work, or a series of works.

Publication permission

The circumstances under which copyright material may be used and where permission must be sought from the copyright holder.

Press embargo

A request by a source that the information or news provided by that source not be published until a certain date or certain conditions have been met.

Licence

In scholarly publishing, the legal terms under which a work — an article, dataset, preprint, or other output — may be reused, redistributed, or built upon, typically expressed as a Creative Commons licence attached at the point of publication or deposit.